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JA Bstract
A 6stract
Nicotine-mediated activation of nicotinic acetylcholine receptors (nAChRs) located in 
the prefirontal cortex (PFC) has been associated with the augmentation of attention and working 
memory. Whilst studies have implicated a7 and 02* nAChRs in nicotine-elicited cognitive 
enhancement, the cellular mechanisms underlying these effects have yet to be elucidated. The 
aim of this project was to characterise the cellular mechanisms by which presynaptic a7 and 02* 
nAChRs mediate excitatory amino acid (EAA) release from rat PFC.
The first part of this project established the suitability of PFC P2 synaptosomes and 
[3H]D-aspartate for measuring presynaptic mechanisms of EAA release, as well as confirming 
the presence of a7 and (32* nAChRs in the PFC. Initial experiments showed that nicotine could 
evoke EAA release via both a7 and (32* nAChRs, this was confirmed following the 
characterisation of selective nAChR subtype agonists, (R)-N-(l-azabicyclo[2.2.2]oct-3-yl)(5-(2- 
pyridyl)thiophene-2-carboxamide) (compound A) and 5-iodo-A-85380. Having established that 
compound A and 5-iodo-A-85380 evoke EAA release via a7 and (32* nAChRs, respectively; 
investigations into the cellular mechanisms mediating this release were carried out. Whilst 
higher concentrations of KC1 application revealed that EAA release can be mediated by EAA 
transporter reversal and a Ca2+-dependent mechanism, EAA release mediated by a7 or (32* 
nAChRs was entirely Ca2+-dependent.
The use of voltage-operated Ca2+ channel (VOCC) inhibitors and modulators of 
intracellular Ca2+ stores determined that a7 and (32* nAChR-mediated EAA release was elicited 
via distinct pathways. Whilst (32* nAChR-mediated responses were dependent upon VOCC 
activation, a7 nAChR-mediated responses required Ca2+-induced Ca2+ release (CICR) with no 
VOCC involvement. To establish whether this distinct coupling of a7 and 02* nAChRs was a 
widespread phenomenon, a l  and 02* nAChR subtype selective tools were used to alter Ca2+ 
levels in PC 12 cells. As seen at the presynaptic terminal, a7 and 02* nAChRs were coupled to 
VOCCs and CICR, respectively.
The segregation of these two nAChR subtypes to separate Ca2+ pathways may constitute 
a method by which they regulate different neuronal events. Intracellular Ca2+ stores have 
recently been implicated in synaptic plasticity, and may provide a mechanism by which a l  
nAChRs mediate their effects on cognition. One possible pathway that can translate presynaptic 
Ca2+ release into synaptic plasticity is the extracellular regulated kinase cascade. The use of 
inhibitors and western blotting revealed that this pathway was activated in PFC synaptosomes 
following a l  nAChR activation and was essential for a l  nAChR-mediated EAA release, 
consistent with a possible role for this receptor in nicotine-evoked synaptic plasticity in the 
PFC.
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BAPTA l,2-bis-(o-Aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid,
tetraacetoxymethyl ester
Bmax maximal concentration of binding sites
BSA bovine serum albumin
°C degrees Celsius
CICR Ca2+-induced Ca2+ release
Compound A (R)-N-(l-Azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) 
CNS central nervous system
CPM counts per minute
DHpE dihydro-P-erythroidine
EC50 agonist concentration which evokes a half-maximal response
EDTA ethylenediaminetetraacetic acid
EGTA ethyleneglycol- bis-(p-aminoethylether)-N,N,N’,N’- tetreaacetic acid
ER endoplasmic reticulum
ERK extracellular signal-regulated kinase
(m)EPSC (miniature) excitatory post-synaptic current
(m)EPSP (miniature) excitatory post-synaptic potential
g gram
GFAP glial fibrillary acidic protein
HEPES N-[2-hydroxyethyl]piperazine-N’-[2-ethane sulfonic acid]
HPLC high performance liquid chromatography
5-I-A-85380 5-Iodo-A-85380 dihydrochloride
IC50 ligand concentration which reduces radioligand binding or functional response
to half-maximal
IP3 inositol 1,4,5-triphosphate







MAPK mitogen-activated protein kinase





nAChR nicotinic acetylcholine receptor
NGF nerve growth factor
NMD A N-methyl-D-aspartate
PBS phosphate buffered saline
PFC preffontal cortex
rpm revolutions per minute
RyR ryanodine receptor
s second
SDS sodium dodecyl sulphate
TEMED tetramethylethylenediamine
Tris 2-amino-2-(hydroxymethyl)-1,3 -propanediol
VGluT vesicular glutamate transporter
VOCC voltage operated calcium channel
w/v weight/volume
6Rea ( io ns
(Vu6Cications
In <R§fereecCjournals
Dickinson JA., Hanrott KE., Mok MH., Kew JN., Wonnacott S., (2007). Differential coupling 
of alpha7 and non-alpha7 nicotinic acetylcholine receptors to calcium-induced calcium release 
and voltage-operated calcium channels in PC 12 cells. Journal o f Neurochemistry. 100(4): 1089- 
96.
Wonnacott S., Barik J., Dickinson JA., Jones IW., (2006). Nicotinic receptors modulate 
transmitter cross talk in the CNS: nicotinic modulation of transmitters. Journal of Molecular 
Neuroscience. 30(1-2): 137-40.
In (Preparation
Dickinson JA., Kew JN., Naim AC., Wonnacott S., (2007). Presynaptic mechanisms 
underlying a7 nAChR-mediated excitatory amino acid release from rat prefrontal cortex nerve 
terminals.
Willcox AJ., Dickinson JA., Jones IW., Wonnacott S., (2007). Co-localisation of functional 
presynaptic a7 nicotinic acetylcholine receptors with VGluT isoforms in the rat anterior 
prefrontal cortex.
Oral Communications
Dickinson JA., Hanrott KE., Kew JNC., Wonnacott S., (2005). a l  nicotinic acetylcholine 
receptors promote ryanodine-sensitive Ca2+-induced Ca2+ release in PC 12 cells. British 
Pharmacological Winter Meeting 026P.
Poster Communications
Dickinson JA., Jones IW., Kew JNC., Wonnacott S., (2006). a l  nicotinic acetylcholine 
receptor (nAChR) activation promotes Ca2+-induced Ca2+ release (CICR) and extracellular
-  v i  -
-Publications
regulated kinasel/2 (ERK1/2) phosphorylation. Federation European Neuroscience Forum 
Abstracts A044.4.
Dickinson JA., Kew JNC., Roberts C., Weil A., Wonnacott S., (2005). Investigation of the 
mechanism of action of a7 nicotinic acetylcholine receptor agonist-mediated [3H]D-aspartate 
release from rat prefrontal cortex synaptosomes Society for Neuroscience. 35; 961.18.
Dickinson JA., Willcox AJ., Jones IW., Kew JNC., Wonnacott S., (2005). a7 and non- a7 
Nicotinic Acetylcholine Receptor Modulation of [3H]D-Aspartate Release from Rat Prefrontal 
Cortex Synaptosomes British Neuroscience Association 18; 29.10.
Dickinson JA., Jones IW., Kew JNC., Roberts C., Wonnacott S., (2004). Modulation of 
glutamatergic transmission by a7 nicotinic acetylcholine receptors within the prefrontal cortex 
British Pharmacological Society Summer Meeting; 072P.
(Ta6fe o f  Contents






Table of Contents viii
Chapter One: Introduction
1.1 Smoking Memories 1
1.2 The Prefrontal Cortex 3
1.2.1 The PFC: anatomical location and definition 3
1.2.2 The PFC: connections with the rest of the brain 4
1.2.3 The PFC as the executive centre of the brain: a role for nicotine? 5
1.3 The nicotinic acetylcholine receptor 10
1.3.1 Structural characteristics and gating of nAChRs 10
1.3.2 Classification and distribution of nAChRs 13
1.3.3 nAChRs, the PFC and cognition 19
1.4 Ca2+ and signalling 25
1.4.1 Ca2+homeostasis 25
1.4.2 Ca2+ permeability of nAChRs 27
1.4.3 VOCCs and nAChRs 29
1.4.4 Intracellular stores and nAChRs 31
1.4.4.1 Presynaptic Ca2+-induced Ca2+ release and nAChRs 36
1.5 Extracellular Signal-Regulated Kinase 39
1.5.1 ERK1/2: activation and synaptic plasticity 39
1.5.2 nAChRs, ERK1/2 and synaptic plasticity 41
1.6 L-Glutamate 43
1.6.1 Glutamate as neurotransmitter 43
1.6.2 Nicotine, glutamate and the PFC 44
1.6.3 Glutamate release 46
1.6.4 Synaptosomes: D-aspartate as a surrogate for L-glutamate 49
1.7 Aims 52




(Ta6fe o f  Contents
Buffers 56
Methods 57
2.4.1 Prefrontal Cortex Dissection 57
2.4.2 Synaptosome Preparation 57
2.4.2.1 P2 Synaptosome Preparation 57
2.4.2.1 Percoll™ Purified Synaptosomes 58
2.4.3 [3H]Amino acid uptake into PFC synaptosomes 58
2.4.4 [3H]Amino acid uptake into a presynaptic vesicle fraction 59
2.4.5 [3H]Amino acid release from PFC synaptosomes -  superfusion 60
2.4.6 Preparation of P2 membranes for [l25I]aBgt binding 63
2.4.6.1 [125I]aBgt saturation and competition binding 63
2.4.7 Cell Culture 64
2.4.8 In situ radioligand binding to nAChR in PC 12 cell line 64
2.4.9 Calcium Fluorimetry 65
2.4.10 Microscopy 65
2.4.10.1 Transmission electron microscopy of synaptosomes 65
2.4.10.2 Immunolabbeling of synaptosomes 65
2.4.10.3 Immunolabelling of PC12 cells 66
2.4.10.4 aBgt-488 labelling of PC12 cells 66
2.4.10.5 Confocal microscopy 66
2.4.1 Western blotting 67
2.4.11.1 Sample Preparation 67
2.4.11.2 Western Blotting 68
Chapter Three: Characterisation o f nJ^Ch^mecCiatecC excitatory amino acicf reCease 
from <PFC synaptosomes.
3.1 Introduction 69
3.1.1 Aims of this chapter 69
3.2 Results 70
3.2.1 a7 nAChR levels in the rat PFC 70
3.2.2 Characterisation of P2 vs. Percoll™-purified PFC synaptosomes 71
3.2.2.1 P2 vs. Percoll™ synaptosomes: morphology 71
3.2.2.2 P2 vs. Percoll™ synaptosomes: neurochemical markers 72
3.2.2.3 P2 vs. Percoll™ synaptosomes: KCl-evoked [3H]D-aspartate release 75
3.2.3 D-Aspartate vs. L-Glutamate: Uptake into PFC P2 synaptosomes and vesicles 76
3.2.4 D-Aspartate vs. L-Glutamate: KC1- and nicotine-evoked release from PFC P2
synaptosomes 80
3.2.5 Pharmacological characterisation of nAChR-evoked [3H]D-aspartate release 83
3.2.5.1 Nicotine 83
3.2.5.2 Compound A 84
- k -
‘I'aBfe o f  Contents
3.2.53 PNU 120596 87
3.2.5.4 5-Iodo-A-85380 88
3.2.6 KCl-evoked [3H]D-aspartate release 91
3.3 Discussion 92
3.3.1 Summary 92
3.3.2. nAChRs in the PFC 92
3.3.3 P2 versus Percoll™ purified PFC synaptosomes 95
3.3.4 D-aspartate as a surrogate for L-glutamate 97
3.3.5 nAChR subtype-mediated [3H]D-aspartate release from PFC synaptosomes 98
Chapter Tour: nAChTjtnediatecC p'KJo-aspartate reCease from (PTC synaptosomes: 
ceCCuCar mechanisms.
4.1 Introduction 103
4.1.1 Aims of this chapter 103
4.2 Results 105
4.2.1 Ca2+ dependency of [3H]D-aspartate release 105
4.2.2 Effect of VOCC inhibitors on [3H]D-aspartate release 107
4.2.3 Effect of modulators of intracellular Ca2+ on [3H]D-aspartate release 113
4.2.4 Identification of ryanodine receptor isoforms in PFC synaptosomes 115
4.2.5 Effect of MEK1 inhibitors on [3H]D-aspartate release 116
4.2.6 Ability of presynaptic nAChRs to mediate ERK1/2 phosphorylation 118
4.3 Discussion 121
4.3.1 Summary 121
4.3.2. Ca2+-dependent and EAAT reversal mediated [3H]D-aspartate release from PFC
synaptosomes. 122
4.3.3 Mechanisms of Ca2+-dependent [3H]D-aspartate release 123
4.3.4 a7 and (32* nAChRs segregate to disparate Ca2+ pathways -  physiological significance?
128
4.3.6 al, but not P2* nAChR are coupled to are coupled ERK1/2: a role in synaptic 
plasticity? 130
Chapter Tive: nfLChTjmecfiatecf increases in intraceCCuCar Ca?+ in (PC12 cells.
5.1 Introduction 133
5.1.1 Aims of this chapter 133
5.1.2. The PC12 cell line 133
5.1.3 PC 12 cell line and nAChRs 134
5.1.4 PC 12 cell line and voltage operated Ca2+ channels 135
5.1.5 PC 12 cell line and intracellular Ca2+ stores 136
5.1.6 Ca2+ measurements in cell lines 13 6
5.2 Results 138
5.2.1 Determination of nAChR subtypes expressed in PC12 cells 138
-JC-
(Ta6ft’ of Contents
5.2.2 a7 and non-a7 nAChR-mediated increases in intracellular Ca2+ in PC12 cells 139
5.2.3 a7- and non-a7 nAChR-evoked increases in Ca2+studies with subtype selective agonists
142
5.2.4 Routes of Ca2+influx following a7-or non-a7 nAChR stimulation 148




5.3.2 nAChR expression in the PC 12 cell line 158
5.3.3 a.1 and non-a7 nAChR-mediated increases in intracellular Ca2+ 159
5.3.4 Pathways of al  and non-a7 nAChR-mediated increases in intracellular Ca2+ 161
5.3.5 a l  and (32* nAChRs segregate to disparate Ca2+ pathways: physiological significance?
165
Chapter SvQ FinaCConcCusions an(C Future (Perspectives.
6.1 Conclusions 167
6.2 Future Perspectives 169
(References 174
-  Chapter One -
Introduction
1.1 Smoking Memories -1 -
1.2 THe PrefrontaCCortex  -3-
1.3 The Nicotinic JLcetyfcfioCine Receptor -9-
1.4 Cakium andSignaling -25-





Smoking tobacco is, without a shadow of doubt, bad for you. As o f 2007 it is the
second greatest cause o f death worldwide and, if the current levels o f smoking are upheld, it will
be responsible for ten 
million deaths each year 
by 2020 (WHO; 2007). 
Cigarette tobacco
contains over 4000 
chemicals, with the most 
well known being 
nicotine. Nicotine is 
responsible for the 
psychoaddictive 
properties o f tobacco 
through its actions at 
neuronal nicotinic
acetylcholine receptors (nAChRs, discussed in Section 1.3). Whilst tobacco smoke contains a 
variety o f carcinogenic and toxic compounds, administration o f nicotine is regarded as relatively 
safe (Greenland et al., 1998).
Despite the health risks associated with smoking it is important to acknowledge the
plethora o f reports outlining the beneficial effects o f tobacco. O f particular relevance to the
work presented in this thesis is the enhancement o f cognitive function; a term used to embrace a 
range o f processes broadly defined as the information-handling component o f behaviour (Sacco 
et al., 2004), following tobacco consumption. This advantageous aspect o f tobacco has been 
recognised since the 17th century with the publication o f Dr Giles Everard’s book: Panacea; or 
The Universal Medicine, Being a Discovery o f the Wonderfull Vertues o f Tobacco Taken in a 
Pipe, with its Operation and Use both in Physick and Chyrugery (1659), in which the author 
states ‘...to  /trengthen the memory the /m oke is excellent taken by the no/rils, for it is properly 
belonging to the brain...’ (McGehee and Role, 1996).
The propensity o f tobacco to alter cognitive output has been attributed to nicotine 
(Levin, 2002). As discussed in Section 1.2.3 the ability o f nicotine, acting at nAChRs, to
enhance learning and memory is evident from multiple studies in numerous models, including
zebrafish, rodents and non-human primates, whilst in humans nicotine has been shown to ease 
the cognitive dysfunction associated with Alzheimer’s disease, attention deficit hyperactivity 
disorder, obsessive compulsive disorder, Tourettes syndrome and schizophrenia.
(To6acco Industry
W e will hunt out th e se  global 
m a ss  killers, w e will sm oke 
them  out, w here ever they  
hide & bring them  to justice
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C JfM xW l i  1: Introduction
Of specific interest to this thesis is the ability of nicotine to enhance both attention and 
working memory (Levin et al., 2006), two forms of cognition that are associated with the 
anterior region of the brain, the prefrontal cortex (PFC; Jones, 2002; Section 1.2). The cognitive 
functions of the PFC are thought to be regulated by dopaminergic and glutamatergic 
innervations, originating from the ventral tegmental area/hippocampus, amygdala and thalamic 
nuclei, respectively. Presynaptic nAChRs have been shown to facilitate release of multiple 
neurotransmitters, including dopamine and glutamate (Wonnacott, 1997); as such it has been 
postulated that nicotine mediates its cognitive-enhancing properties via neurotransmitter 
modulation in the PFC.
C fC ^PF B K  t: Introduction
1.2 ‘The <PrefrontaCCortex
The PFC has been described as the ‘executive centre’ of the brain (Jones, 2002), 
providing a locus for multiple cognitive processes, including attention and memory, which are 
enhanced by nicotine. Here we describe:
• 1.2.1 The PFC: anatomical localisation and definition
• 1.2.2 The PFC: connections with the rest of the brain
• 1.2.3 The PFC as the executive centre of the brain: a role for nicotine?
1.2.1 The (PFC anatomicaC(bcation and definition
The area now referred to as the PFC was first defined by Brodmann (1909/1994), with 
the primary criterion being the presence of cortex, rostral to motor and premotor areas with the 
inclusion of a granular layer IV. Defining an area solely by cytoarchitecture can be problematic, 
with many areas varying in the (a)granular pattern between species. Indeed an unequivocal 
definition of the PFC, centring on a single morphological or functional criterion has proved 
elusive; as such the presence of PFC within rodents has been questioned (Preuss, 1995; Uylings 
et al., 2003). However, using the seminal report of Rose and Woolsey (1947), that defined PFC 
as cortex in receipt of reciprocal connections from the mediodorsal thalamic nuclei combined 
with Uylings and van Eden’s (1990) criteria of multiple reciprocal thalamic connections it is 
possible to conclude that the rodent has a clearly defined PFC (see Uylings et al., 2003 and 
Dailey et al., 2004). Based on these connections and differing cytoarchitecture the rodent PFC 
can be divided into three distinct regions, each containing subdivisions (Vertes, 2006; Dailey et 
al., 2004; Fig 1.1). Unless stated all aspects described in this thesis refer to the rodent PFC; the 
human PFC is described in relation to cognition in Section 1.2.3.
• Medial PFC: containing the frontal 2 region (Fr2), the dorsal and ventral anterior 
cingulated cortices (ACd and ACv, respectively), the prelimbic cortex (PL) and 
inffalimbic and medial orbital cortices (IL and MO, respectively).
• Lateral PFC (also referred to as the orbital, or sulcal PFC): containing the lateral orbital 
cortex (LO), dorsal ventral and agranular insular cortices (Aid and AIv, respectively)
• Ventral PFC: containing the ventral orbital cortex (VO) and ventral lateral orbital 
cortex (VLO).
C H j^F V E ^l: Introduction
Motor cortex
A coronal section through the rat brain at 4.4 mm anterior to bregma, at the level of cut used 
for the experiments described herein, showing the PFC subregions. B lateral view of the 
PFC. Arrow indicates 4.4 mM anterior to Bregma, scale bar equals 2 mm. Fr2: frontal 
region 2; AC: anterior cingulated cortex; MO/VO: medial/ventral orbital cortices; LO: 
lateral orbital cortex; Al: agranular insular cortex; PL: prelimbic region; IL: infralimbic 
region; CC: corpus collosum. Adapted from Dailey et al., (2004) and Vertes, (2006).
1.2.2 ‘The (FFQ connections with tfte rest o f  tfie 6rain
To have a full understanding o f the functions attributed to the PFC it is first essential to 
know the connections this region has with other neuronal nuclei. By definition, all areas o f the 
PFC have reciprocal connections to the mediodorsal thalamic nuclei (Section 1.2.1). The lateral 
and medial PFC also have strong reciprocal links to the anteromedial thalamic nuclei, which are 
strongly innervated by both the hippocampus and the amygdala, showing just one example of 
regions that are both directly and indirectly connected to the PFC. The advent o f tracing 
experiments, combined with lesion studies, microdialysis and electrophysiological experiments 
has expanded the plethora o f known connections with the PFC, these data are summarised in Fig
1.2. In brief the PFC receives cholinergic (basal forebrain), dopaminergic (ventral tegmental 
area and to a lesser extent the substantia nigra), glutamatergic (cortico-cortical connections, 
hippocampus, amygdala and thalamic nuclei), noradrenaline (locus coeruleus) and serotonin 
(dorsal and median raphe nuclei) innervations as well as glutamatergic neurones and GABA 
intemeurones (Pamavelas, 1990). The PFC has reciprocal connections to all these regions and 
also directly innervates the hypothalamus, with the medial PFC also projecting into the spinal 
cord. It is perhaps not surprising the PFC has been previously described as ‘almost hopelessly 
complicated’ (Kolb and Gibb, 1990).
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Fig 1.2: Schematic of the primary reciprocal connections to the PFC
Regions of PFC with which connections are made is shown in central box. Data taken from: 
Groenewegen and Uylings, (2000); Heidbreder and Groenewegen, (2003); Uylings et al., 
(2003); Dailey et al., (2004) and Vertes, (2006).
1.2.3 The <FFC and executive functions: a rode fo r  nJUCh^ Rs?
Since the renowned incident o f Phineas Cage and a tamping iron in 1848 (Damasio, 
1994), the frontal cortex has been associated with higher cognitive functions and has 
consequently received much scientific attention. As figure 1.3 shows there is an increase in PFC 
size with increased scope for executive functions through the animal kingdom. Although the 
graph (Fig 1.3B) shows the relative PFC volumes for just a few species the slope o f the line 
(1.1) indicates that this relationship is partially skewed, with a greater proportion o f the primate 
(in particular the human) brain, being defined as PFC compared to that o f the rodent. These data 
are consistent with this region being involved in higher cognitive functions. The beneficial 
effects o f nicotine on cognitive functions have been examined in both humans and animal 
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Fig 1.3: Comparison of PFC versus whole brain volume for various species
A: Diagrams of cat, dog, rhesus monkey and human brain, showing the PFC shaded in grey, 
adapted from http://thebrain.mcgill.ca. B: PFC volume for five different species, plotted 
against respective brain volume. Data taken from Uylings and Van Eden, (1990) slope = 1.1; 
r2 = 0.99.
Jfumans
The PFC o f human brain contains multiple sub-regions and constitutes approximately 
30 % o f the entire cortex (Groenewegen and Uylings, 2000). Damage to this region has been 
shown to have a devastating effect on both attention and memory o f the subject, consistent with 
its role in executive functions (Miller et al., 2002). Neurotransmitter imbalances and subsequent 
changes in the cytoarchitecture o f this region have been associated with cognitive disorders (see 
Jones, 2002), strengthening the hypothesis that this region is key to cognition. These studies 
were substantiated by Coull et al., (1996) who confirmed, using PET, a clear contribution o f the 
PFC during rapid visual information processing (RVIP), which investigates both attention and 
working memory.
Smoking is well documented as enhancing cognition (see Levin et al., 2006). Studies 
into the beneficial effects o f nicotine on cognitive processes have been carried out sporadically 
since the early 1900s (Wesnes and Warburton, 1983a); however, it was not until later in the 
century that the development o f specific tasks allowed the investigation o f specific aspects o f 
cognition. The enhancement o f RVIP by increasing doses o f nicotine was first demonstrated in 
the early 1980s (Wesnes and Warburton, 1983b, 1984a, b; Edwards et al., 1985). Lawrence et 
al., (2002) subsequently revealed, using fMRI that this enhancement by nicotine was due to a 
specific increase in PFC activity. Whilst RVIP is the predominant measure o f human attention 
and working memory that has been clearly defined as activating the PFC there are multiple
- 6 -
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other paradigms. Indeed nicotine has been shown to enhance the stroop test (although there are 
paradoxical data, see below), paired-pulse inhibition as well as verbal and non-verbal learning 
(for review see Sacco et al., 2004).
The concept that nicotine may be beneficial to those suffering from cognitive deficits 
has been supported by the observation that the majority o f these subjects smoke. The incidence 
o f smoking within patients diagnosed with diseases characterised by cognitive disturbances such 
as schizophrenia, bipolar disorder and attention deficit hyperactivity disorder (ADHD) are 
significantly greater (up to three-fold in the case o f schizophrenia) than found in the general 
population (Williams and Ziedonis, 2004). Indeed schizophrenics are reportedly able to alleviate
the negative symptoms o f this disease by smoking (Ziedonis, 2004). There is also clear evidence
for the beneficial effect o f  nicotine on the P50 gating mechanism deficit present in
schizophrenic patients (Adler et al., 1993) strengthening the hypothesis that these patients are 
smoking as a form o f  self medication; indeed (a7) nAChR activation as a target for 
neuropsychiatric disease is currently being investigated by multiple pharmaceutical companies 
(Broad et al., 2007). Interestingly the incidence o f schizophrenia is also positively correlated 
with abnormalities on 15q 13-14, the site o f  the a7 nAChR gene (Freedman et al., 2001a, b).
to increase attention (using the 
continuous performance task) in 
non-smoking subjects, who did 
not show ADHD, historically 
the majority o f studies
investigating the effect o f  
nicotine on cognitive output 
have been carried out using 
smokers. Indeed there are have 




deprived smokers, or subjects 
with cognitive impairments. In 
their 2004 review o f  nicotine 
and cognitive performance Newhouse et al., discuss this phenomenon in terms o f cognitive 
performance prior to administration o f nicotine. The authors postulate that if the subject’s 
cognitive ability is not at its optimal level then nicotine will serve to improve performance (Fig
1.4). However, there is a peak to the subject’s cognitive ability, if  the subject is already







Start level End level
Start level End level
Nicotine Stim ulation
Fig 1.4: Theoretical model of the effect of nicotine on 
cognition
The model shows how the same dose of nicotine can either 
enhance (green) or decrease (red) cognitive performance 
depending upon starting cognitive ability. Adapted from 
Newhouse et al., (2004).
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performing at this level then nicotine will not be able to increase the levels of cognition further 
and may even produce a decrease in the cognitive output (Fig 1.4). This theory can be further 
extrapolated to analyse the response if the task is particularly hard, or by the same analogy if the 
task has been well learnt prior to testing. Whilst the former scenario would reveal a beneficial 
effect of nicotine administration the latter would not.
Whilst it would be hard to dispute the involvement of multiple brain regions in 
cognitive disorders such as schizophrenia (for example the hippocampus and amygdala, for 
review see Tamminga, 2006), there is a clear contribution of the PFC (Robbins, 2005). Recent 
reports focus on an imbalance of multiple neurotransmitters including glutamate and dopamine 
as the leading schizophrenia hypothesis (for review see Lyne et al., 2004), although the 
underlying cause remains unclear. nAChRs are capable of mediating neurotransmitter release in 
multiple regions, including the PFC, consistent with nicotine eliciting its beneficial effect via 
neurotransmitter modulation in this region.
Non-human
Despite the clear role for the PFC in multiple human disorders (see above) the majority 
of investigations into the effects of nicotine on working memory have been carried out using 
rodents. The behavioural mazes: radial-arm, water- and, to a lesser extent, elevated-T-, were 
originally designed to investigate aspects of spatial memory; however, it is now apparent they 
tap into multiple other forms of cognition, including working (short-term) memory (for review 
see Hodges, 1996). Studies using these behavioural mazes or novel object recognition tasks 
have provided suitable platforms for investigating working memory in rodents, with the 5- 
choice serial time task providing a paradigm for examining attention (Robbins, 2002).
Although the focus of this section is the importance of the PFC in cognition there are 
clearly other brain regions that play key roles (Robbins, 2000; Marshuetz and Smith, 2006). For 
example the hippocampus, which has strong reciprocal connections with the PFC (section 1.2.2; 
Fig 1.2; Vertes, 2006), has also been linked to role in memory, notably spatial memory. 
Multiple studies have investigated the hippocampal to PFC pathways (for review see Serge 
Laroche, 2000). Anterior-grade tracing experiments have shown the PFC to receive innervations 
from the CA1 and subiculum, but not the CA2 or CA3 regions of the hippocampus (Jay and 
Witter, 1991). In concordance with this Laroche et al., (1990) reported that stimulation of the 
CA1 region in vitro could lead to LTP formation within the inffalimbic region of the PFC, with 
subsequent investigation revealing this synaptic plasticity to be mediated by glutamatergic 
hippocampal inputs (Jay et al., 1992).
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Using the eight-arm radial maze and rats with either PFC or hippocampal lesions Chiba 
et al., (1994) directly assessed the contribution of PFC versus hippocampus in memory 
paradigms. In this study the authors concluded that PFC lesioned animals displayed a decrease 
of performance overall, whilst the hippocampal lesion resulted in a decrease in the spatial 
memory. These analyses have been furthered by Kesner and colleagues who, using lesion 
studies have confirmed the importance of the PFC for visual working memory (Ragozzino et al., 
2002) and suggest the hippocampus has a more prominent role in temporal memory (Jackson et 
al., 1998). Using an elegant design of combining a permanent lesion in either the PFC or 
hippocampus with a pharmacological inactivation in the other region, this group determined that 
both PFC and hippocampus process short-term spatial memory in parallel, serving as a 
compensatory mechanism for each other (Lee and Kesner, 2003). Interestingly this study 
showed that the hippocampus has a stronger role in the longer-term memory formation, 
consistent with the PFC being primarily involved in working memory (D'Esposito, 2007). This 
is further strengthened by the necessity of the PFC in retrieval memory, as shown in lesion 
studies (Botreau et al., 2004).
Both acute and chronic nicotine and nAChR subtype specific agonists enhance PFC- 
associated cognition in mice and rats. These experiments are discussed with respect to the 
subunits involved in section 1.3.4 after introducing the nAChR itself.
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1.3 Hie nicotinic acetyCcHoRne receptor
Nicotine is an agonist at the nicotinic acetylcholine receptor (nAChR). The nAChR 
was the first receptor to be recognised and named, as well as the earliest to be characterised 
using electrophysiology (Karlin, 2002). The focus o f this thesis is to determine the cellular 
mechanism by which specific presynaptic nAChRs subtypes modulate excitatory amino acid 
release from the PFC. Here we will describe:
• 1.3.1 The structural characteristics and gating of nAChRs
• 1.3.2 Classification and distribution of nAChRs
• 1.3.3 nAChRs, the PFC and cognition
1.3.1 StructuraCcharacteristics antf gating ofn ftChtRs
The nAChR family is the prototype receptor family in the cys-loop ligand-gated ion 
channel super-family. This super-family is so named because o f the presence o f a two 
disulphide-bonded cysteine residues on the extracellular amino-terminal that are separated by 13 
amino acids. The ion channels can be either 
anion (GABA- and glycine-activated) or cation 
(ACh- and 5HT-activated) permeable in 
vertebrates.
Although the nAChR structure has yet 
to be resolved using x-ray crystallography the 
structure is currently identified to 4 A resolution 
using electron microscopy (Unwin, 2005; Fig
1.5). This technique has the advantage of 
facilitating the imaging o f a protein in its native 
environment, therefore avoiding
denaturing/refolding (Unwin, 2003). This is o f 
particular importance for membrane proteins, 
such as the nAChR.
The majority o f investigations into the 
structure o f the nAChR were carried out on 
isolated receptors from electric rays and eels; both o f which provide an abundant source o f 
nAChRs, homologous to the muscle-type nAChR (section 1.3.2). The nAChR is a 290 kDa 
protein consisting o f a large extracellular domain, containing ligand-binding domains, a cation-
Fig 1.5: Structure of the nAChR
Cross-section through the nAChR at 4.6 A 
determined by electron microscopy, showing 
the ACh binding path (dotted line). Taken 
from Karlin, (2002), with permission.
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selective membrane spanning channel, and a relatively small intracellular segment, Fig 1.5-6. 
Each o f the five subunits forming the nAChR consists o f  500-600 amino acid residues with each 
subunit containing 4 transmembrane domains, with the second the lining the intrinsic ion 
channel pore (Fig 1.6)
M1 M 2M 3M 4
Fig 1.6: Schematics of the nAChR structure
A nAChR topology: each subunit contains 4 transmembrane domains (M l-4) and a large 
extracellular N-terminal that contains the ligand binding site. B Atomic model of the nAChR 
viewed from the extracellular side. Relative positions of the transmembrane domains are 
shown, with the M2 lining the ion channel. Adapted from Jensen et al., (2005).
The nAChR has a total length o f -1 7 0  A, o f which the inner pore, involving the M2 
helices (Fig 1.6) comprises -4 0  A (Unwin, 2003). These helices kink inwards through the pore 
(Fig 1.6-7). Approximately midway through the membrane these helices become so close as to 
form a block against ion movement due to the 
formation o f a ‘molecular gate’, created due to 
the close proximity (— 6 A) o f hydrophobic side 
chains (Jensen et al., 2005); Fig 1.7).
Studies to determine the nAChR 
structure have been greatly advanced by the 
discovery and subsequent structural analysis of 
the acetylcholine binding protein (AChBP) from 
the fresh water snail Lymnaea stagnalis (Smit et 
al., 2001). The crystal structure o f the AChBP, a 
210 amino acid glial-derived protein that 
modulates ACh transmission has been solved to
2.7 A (Brejc et al., 2002). Although the AChBP 
lacks the transmembrane and intracellular domains o f  nAChR its ACh binding site is
Thr244 Thr244
Ser 266 S e r266
Glu 262 Glu 262
Val 259 Val 259
Val 255 Val 255
Leu 251 Leu 251
Ser 248 Ser 248
Thr244 Thr 244
Glu 241 Glu 241
Asp 238 Asp 238
Fig 1.7: nAChR ion pore
Amino acid residues lining the nAChR ion 
channel, adapted from Jensen et al., (2005).
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homologous to that o f  the nAChR. Using this protein, which shares closest identity to the a7 
nAChR, structural analysis has shown an acetylcholine binding site at each o f the subunit 
interfaces, secluded from the extracellular space by the N-terminal domain. Further work with 
the muscle nAChR and heteromeric nAChRs has shown the binding site to be located between a  
-  y, (a  -  5) and a  -  p subunit (Section 1.3.2) interfaces, respectively.
The functional states o f  the nAChR can be best described by the Monod-Wyman- 
Changeux (MWC) model o f allosteric receptors (Monod et al., 1965; Fig 1.8). This model is 
based upon the theory that the receptor can exist in multiple, inter-convertible, conformations in 
the absence o f agonist. The presence o f agonist serves to stabilise these conformations/promote 
the likelihood o f receptor opening (Fig 1.8). Consistent with this model electrophysiological 
experiments both in muscle and Xenopus oocytes have shown that this receptor is capable o f 
mediating a current in the absence o f ligand (Jackson, 1986).
Fig 1.8: The MWC model
Showing the allosteric model of nAChR 
function. MWC model incorporates the 
resting (R), active (A) and both fast onset (I) 
and slow onset (D) desensitised states. 
Adapted from Changeux and Edelstein, 
(2005)._______________________________
Closed Open
Fig 1.9: The closed and open nAChR
Conformations of the closed (left) and open 
(right) channels, binding of acetylcholine 
caused rotation of the inner p-sheets of the 
a-subunit M2 domain. This widens the pore 
thereby removing the molecular gate. Figure 
modified from Unwin, (2003).
The muscle nAChR opens within 20 ps o f agonist application, and subsequent 
desensitisation occurs within 20 ms (Matsubara et al., 1992). This fast timescale presents a 
problem when investigating agonist-induced conformational changes. To overcome this 
quandary Unwin and colleagues devised an elegant experimental design, consisting o f  spraying 
agonist onto the nAChR and immediately freezing the receptor (Unwin, 2003). This technique 
revealed that upon agonist binding there are two conformational changes. Binding o f the 
endogenous agonist, acetylcholine results is a slight conformational change o f the binding 
domain, this in term causes the P-sheets o f the second transmembrane domain to twist by 15 °
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(Miyazawa et al., 2003). Prior to this twist cation flux is prevented due to the molecular gate 
(Fig 1.7; 1.9); the agonist-induced M2 twist serves to increase the intrinsic pore size by 3 A, 
subsequently allowing the flux of hydrated cations (Miyazawa et al., 2003; Fig 1.9).
1.3.2 Classification ancC(£istri6ution ofnJLChtRf
nAChRs are expressed throughout both the central and peripheral nervous system, as 
well as in muscle. To date 17 nAChR subunit genes have been identified in vertebrates. At the 
neuromuscular junction there are five nAChR subunits which form two distinct nAChRs. The 
expression of these muscle nAChR subunits is developmentally regulated, with the embryo 
containing the (a l)2ply8 nAChR and the adult expressing the (a l)2pls8 containing nAChR. 
Expression of these muscle nAChR subunits is altered following application of growth factors, 
but appears to be primarily regulated by electrical activity, as whilst the a 1, pi, 8 and y nAChR 
mRNAs can be detected at embryonic day 12 in the rat, e nAChR subunit mRNA can only be 
detected following innervation of the of the muscle (Kues et al., 1995). Replacement of the y 
subunit with e in the adult significantly alters single channel conductance and channel kinetics, 
with the presence of the y subunit causing a lower conductance compared to that in the presence 
of 6 (Camacho et al., 1993).
In neuronal tissues there is a greater array of nAChRs than at the neuromuscular 
junction with 12 nAChR subunits present: a2 -  alO and p2 -  p4. These nAChR subunits are 
termed as a subunits or p subunits based on their amino acid sequence. Affinity labelling of 
the electroplax in the presence or absence of cobratoxin identified the a subunit as containing 
the ACh binding site (Reiter et al., 1972). Karlin and associates (Kao et al., 1984; Kao and 
Karlin, 1986), subsequently revealed the affinity labelled residues to consist of a pair of adjacent 
cysteines (position 187 and 188 in the AChBP). These cysteines are the defining characteristic 
of a subunits, although subsequent analysis by Galzi et al., (1990) and Middleton and Cohen, 
(1991) revealed that four other residues on the a subunit are also labelled (Tyr 89, Trp 143, Tyr 
185 and Tyr 192). These amino acids are present in all a subunits with the exception of the a5 
subunit (see below). Whilst it was initially thought that the a subunits were primarily 
responsible for the binding of ACh it is now apparent the binding sites are located between the 
subunit interfaces, with the a subunit providing the binding pocket and the adjacent subunit (e or 
8 at the neuro-muscular junction, p in heteromeric or a in homomeric neuronal nAChRs) 
supplying complementary components (for review see Jensen et al., 2005).
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The nAChR subunits can be further subcategorised into three evo lu tio n ary  distinct 
families by there sequence similarities (Fig 1.10). The resulting subfamilies are consistent with
those produced by assessment of 
functional and pharmacological data (Le 
Novere et al., 2002a).
In contrast to the two nAChRs 
formed at the neuromuscular junction 
the larger population o f nAChRs present 
in neuronal tissue facilitated the 
formation o f a plethora o f possible 
neuronal nAChRs. The complexity o f 
neuronal nAChR subunit composition is 
furthered by the ability o f the these 
nAChRs to function as either a 
homomeric, aBgt-sensitive (a7 -  10) or 
heteromic aBgt-insensitive (a2 -  6 and 
P2 -  p4) nAChRs, based on then- 
evolutionary background (Corringer et al., 2000; Le Novere et al., 2002a; Fig 1.10).
Whilst nicotine activates all nAChRs it does so with differing affinities for different 
receptor subtypes. Two distinct nAChR populations can be identified by their affinity for 
nicotine, those that respond to nicotine with a high affinity (in the nanomolar range), and those 
that are activated with a low affinity for nicotine (Romano and Goldstein, 1980); the latter 
correspond to aBgt-sensitive nAChRs. In 1984 Clarke and colleagues reported differences in 
[3H]nicotine versus [125I]aBgt binding sites in rat brain using autoradiography. This group then 
went on to compare [3H]nicotine, [3H]ACh and [125I]aBgt binding sites and revealed that 
[3H]nicotine, [3H]ACh were similar in distribution and density, but [125I]aBgt binding was 
markedly different (Clarke et al., 1985). These two populations o f nAChR are discussed below.
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Fig 1.10:The vertebrate nAChR family tree
nAChR subunit families, showing the subunits that 
form homomeric and heteromeric neuronal nAChRs 
as well as nAChRs at the neuromuscular junction. 




The a l  -  9 nAChR subunits are the only nAChR subunits capable o f forming 
functional homomeric nAChRs in vitro (Fig 1.11), where they are characterised by their large 
Ca2+ flux (section 1.4.2) and sensitivity to aBgt. In contrast, the alO  nAChR subunit does not 
form a functional nAChR when expressed alone, but can form a heteromeric receptor in the 
presence o f a9 (Elgoyhen et al., 2001). Whilst the a l  nAChR subunit is distributed in multiple 
mammalian brain regions (Table 1.1) the a 8 nAChR subunit is present only in the avian nervous 
system and the a9 and alO  nAChR subunits have not been identified in the brain.
Although there is clear 
evidence that the a l  subunits form a 
homomeric nAChR (Drisdel and Green,
2000) this subunit also has been shown 
to form functional heteromeric nAChRs 
both in vivo and in vitro. Within the 
chick eye the a l  nAChR subunit forms 
heteromeric nAChRs with the a 8 
nAChR subunit (Keyser et al., 1993), 
but not the p3 nAChR subunit (Vailati et 
al., 2000). In vitro assays have shown 
that co-expression o f the a l  nAChR and 
P2 or (33 nAChR subunits produces a 
functional nAChR (Palma et al., 1999;
Khiroug et al., 2002). Whilst the 
heteromeric a7p2 receptors form 
channels with higher ACh affinity, and a 
slower desensitisation rate than the 
homomeric a l  nAChR (Khiroug et al.,
2002); the a7p3 receptors have a lower 
affinity for ACh and a faster 
desensitisation rate than a l  receptors, although it should be noted that this latter study was 
carried out using the L247Ta7f subunit (Palma et al., 1999). The concurrence o f a l  mRNA with
P2 mRNA has lead to speculation that these subunits may form a heteromeric nAChR in vivo
(Azam et al., 2003). Although there is some preliminary evidence for heteromeric a l*  nAChR
f This a l nAChR subunit has a leucine-threonine SNP within the M2 region that results in a decrease in 
desensitization rate (Revah et al., 1991).





Fig 1.11: nAChR subtypes
A: muscle type nAChRs B: Possible nAChR subunit 
combinations. White oval indicates acetylcholine 




within the mammalian peripheral nervous system (Cuevas and Berg, 1998; Virginio et al., 2002) 
these data could also be explained by the presence of different a7 subunit isoforms. Whilst 
investigations using human tissue have identified an a7 subunit isoform to contain a premature 
stop codon/a lack of ACh binding (Gault et al., 1998; Villiger et al., 2002). Severance et al., 
(2004) provided evidence for a functional rat a7 nAChR subunit splice variant. Within the CNS 
they reported this variant to be predominantly localised to the soma, or post-synaptic densities, 
with little presynaptic labelling, they also showed this protein to be present in the PNS. As 
reported for peripheral a7* nAChR responses this spice variant (a7-2) shows a slow 
desensitisation rate (Cuevas and Berg, 1998; Cuevas et al., 2000; Virginio et al., 2002; 
Severance et al., 2004).
cdBgt-insensitive (Heteromeric) nJlCH^
The a2 -  6  and p2 -  4 nAChR subunits comprising the nAChR family ID form 
heteromeric aBgt-insensitive nAChRs. In their seminal work in this area Whiting and Lindstrom 
used immunoprecipitation experiments to identify high nicotine-affmity nAChRs to be made up 
of a4 and (32 subunits (Whiting and Lindstrom, 1987; Whiting et al., 1991). The subsequent 
near total elimination of high-affinity [3H]nicotine binding sites in both the a4 (Marubio et al., 
1999) and P2 (Picciotto et al., 1995) nAChR subunit knock out mice confirmed these earlier 
findings. Although it is clear that the a4 and p2 nAChRs subunits encompass the vast majority 
of [3H]nicotine binding sites in the mammalian brain the stoichiometry of this nAChR in vivo 
remains elusive.
Functional studies with thalamic synaptosomes, showing a biphasic p2* nAChR- 
mediated response, that is not present in p2 nAChR subunit knock out mice suggests the 
presence of more than one stoichiometry (Marks et al., 1999; Picciotto et al., 2001; Butt et al.,
2002). It is more than likely though that there is more than one type of a4p2 nAChR. When 
expressed in Xenopus laevis oocytes these two nAChR subunits commonly form a pentameric 
receptor comprising two a4 subunits and three p2 subunits (Anand et al., 1991; Fig 1.11). 
However, the response produced following ACh application is biphasic, suggesting the 
formation of more than one nAChR stoichiometry (Buisson and Bertrand, 2001). When the a4  
and p2 nAChRs subunit mRNA are injected in either equal ratios or at a 9:1 a4:p2 ratios, the 
EC50 value of acetylcholine is -6 0  pM. This value is enhanced to - 2  jiM  when the ratio is 
altered to 1:9 a4:p2 (Zwart and Vijverberg, 1998). Nelson et al., (2003) have shown (a4)2(p2)3 
nAChRs are responsible for the high-affinity ACh-response with (a4)3(p2)2 nAChRs mediating 
the low-affinity ACh response. Interestingly these two a4p2 nAChRs also display differential 
sensitivity to p2* agonists and antagonists with both epibatidine and DHpE being more potent at
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the high affinity receptor (Moroni et al., 2006). This latter study also showed the EC5o values for 
the two a4|32 nAChRs to be identical to those previously reported in vivo (Butt et al., 2002).
Whilst a2, a3 and a4 nAChR subunits form nAChRs with either (32 or (34 subunits the 
a 6 nAChR subunit is more commonly found in vivo with an extra a  or (3 for example a3a6|34, 
a4a6p4 or a6p2p3 (Fucile, 1998; Gotti and Clementi, 2004; Fig 1.11). Set slightly apart from 
the other members o f this family are the a5 and p3 nAChR subunits. Although these subunits 
share homologies with the rest o f  the nAChR family III they lack the amino acids essential for 
the formation o f a ligand binding domain (Jensen et al., 2005). Therefore they can be treated as 
‘structural’ subunits that are equivalent to the neuromuscular p i nAChR subunit. The a5 and P3 
nAChR subunits can combine with other a, p combinations to increase the complexity o f  the 
nAChR and significantly alter the channel properties (Wang et al., 1996; Fig 1.11).
CeCCuCar distri6ution ofu flC h^
There is a large body o f evidence for the presence o f nAChR on multiple non-neuronal 
cell types, including lymphocytes, macrophages, dendritic cells, adipocytes, keratinocytes, 
endothelial cells, and epithelial cells o f  the intestine and lung (for review see Gahring and 
Rogers, 2005). There is also evidence for the presence o f a7 nAChRs on hippocampal 
astrocytes in culture (Sharma 
and Vijayaraghavan, 2001).
Here we discuss the cellular 
localisation o f nAChRs on 
neurones.
nAChRs can be located 
on cholinergic neurones where 
they function as autoreceptors to 
enhance acetylcholine release.
Whilst there is evidence for the 
involvement o f the P4 nAChR 
subunits on the cholinergic 
neurones o f the mouse interpeduncular nucleus (Grady et al., 2001), the nAChRs subtypes 
mediating this release in other regions has yet to be confirmed (Sher et al., 2004).
nAChRs are also located on non-cholinergic neurones (cholinoceptive cells), including 
glutamatergic (predominantly a l  nAChRs), dopaminergic, GABA-ergic, serotinergic and
S om atodendritic
/  Preterm inal
P reterm inalP resynap tic
P resynap tic
Fig 1.12: Cellular location of nAChRs
nAChRs are found at presynaptic, preterminal and 
somatodendritic locations. Modified from Wonnacott, (1997).
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noradrenergic neurones (Wonnacott, 1997). nAChRs can reside at several different locations on 
the neurone (Sher et al., 2004; Fig 1.12). There is evidence for the presence of a7 and 02* 
nAChRs on the post-synaptic membrane in cortex and hippocampus, where they can mediate 
fast synaptic transmission (Roerig et al., 1997; Alkondon et al., 1998). A large proportion of 
nAChRs appear to be located presynaptically, where they can modulate neurotransmitter 
release. In the frontal cortex nicotine has been shown in vivo to modulate acetylcholine release 
(Bruno et al., 2006), in vivo and in vitro dopamine release (Marshall et al., 1997; George et al., 
2000; Rao et al., 2003; Cao et al., 2005), in vitro (via a7 and 02*) glutamate release (Rousseau 
et al., 2005) as well as both noradrenaline and 5-HT in vitro (Anderson et al., 2000; Rao et al.,
2003) via 02*.
<Distri6ution o f n j l C h w i t h i n  the 6rain
The complementary techniques of radioligand binding, in situ hybridisation, RT-PCR 
and immunohistological analysis has allowed a reasonably thorough map of nAChR subunit 
mRNA and protein distribution in the brain to be produced (for review see Gotti and dementi,
2004). These finding, the majority of which have subsequently been confirmed using knock out 
animals are summarised in Table 1.1, which highlights those subunits present in the (frontal) 
cortex.
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Table 1.1: Distribution of nAChR subunit proteins within the mammalian brain.
Distribution data taken from: Picciotto et al., (2000); Gotti and Clementi, (2004); Jensen et al., (2005);
cortical expression highlighted in bold print.
nAChR subunit Distribution
a2 Primarily in the interpeduncular nucleus; lower levels in some cortical areas.
a3
PNS, high expression in the: medial habenula, dorsal habenula, interpeduncular 
nucleus, locus coeruleus, pineal gland, anteroventral nucleus of thalamus, 
subiculum of the hippocampus, some thalamic nuclei, striatum, ventral tegmental 
area. Absent horn midbrain. Significantly lower expression in the cortex and 
hippocampus.
a4
Throughout the brain. Always expressed with P2 subunit. Highest expression in 
the cortex, hippocampus and thalamus.
a5
Relatively few areas, highest in the substantia nigra, ventral tegmental area, 
medial habenula, striatum and some cortical regions.
a6
Highly colocalised with P3, high levels in catecholaminergic regions- substantia 
nigra, locus coemleus, interpeduncular nucleus, medial habenula, ventral 
tegmental area combines with p2 to represent 20 % of nAChRs in striatum.
a7
Throughout the brain. Highest expression in the cortex, hippocampus, amygdala 
and hypothalamus. Subunit is absent from thalamic regions and basal ganglia.
p2
Expressed in almost all regions. Expression overlaps with at least one a2, a4 or a6 
subunit. Highest expression in the cortex, hippocampus, thalamus and striatum.
P3
Highly colocalised with a6; high levels in catecholaminergic regions- substantia 
nigra, locus coeruleus, interpeduncular nucleus, medial habenula. Not present in 
the cortex.
P4
PNS, medial habenula, dorsal habenula, interpeduncular nucleus, locus coeruleus, 
pineal gland, anteroventral nucleus of thalamus. Significantly lower expression 
in cortex and hippocampus. Absent from midbrain. Expressed with a3. Not 
expressed in thalamic nuclei.
1.3.3 nJLChtRf, the G*FC ant£cognition
The ability of acute and chronic nicotine to enhance working memory and attention 
(for review see Levin et al., 2006) and of mecamylamine to decrease attentional efficacy (Mirza 
and Ian, 1998; Grottick and Higgins, 2000) is consistent with a role for nAChRs in cognition. 
This work has been complemented by investigations revealing that nicotine can reverse 
cognitive deficits induced following lesions of the cholinergic projections to the PFC (Decker et 
al., 1992).
The use of subtype-selective nAChR agonists and antagonists, in addition to the 
generation of nAChR subunit knockout mice, has confirmed a role for both a7 and a4p2* 
nAChRs in attention and working memory (Levin et al., 2006), both of which are present in the 
PFC (Alkondon and Albuquerque, 2004); these data are summarised below. It has yet to be
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determined what role the other nAChR subunits, such as a3* and a 6*, play in cognitive 
processes. However, at present there is no evidence for their presence in PFC (Table 1.1) and 
the relatively sparse distribution o f these nAChR subunits in the hippocampus suggests that they 
are unlikely to play a predominant role in mediating the beneficial effects o f nicotine on 
cognition.
cc7 nJICfi
Initial investigations into the distribution o f a7 nAChRs in the brain were carried out 
using [125I]aBgt or [3H]Methyl!ycaconitine (MLA) autoradiography. Both aBgt, an 8 KDa 
protein isolated from the venom o f the Taiwanese banded krait, Bungarus Multicinctus, and 
MLA, a norditerpenoid alkaloid produced by Delphinium Sp. are competitive antagonists at 
nAChRs. The former interacts with all aBgt-sensitive nAChRs (see above), o f which only a7 is 
present in mammalian brain. MLA is well documented as a competitive antagonist at a7 
nAChRs, although there is evidence that this compound becomes less selective at higher 
concentrations (Mogg et al., 2002).
These experiments have revealed relatively high levels o f a7 nAChRs in the cortex 
(Clarke et al., 1985; Mugnaini et al., 2002; Rasmussen and Perry, 2006). However, these studies 
highlight that frequently the most anterior tip of the frontal cortex, the PFC, is overlooked. 
Whilst Clarke and colleagues (1985) show clear labelling in this region by means of saggital 
sections (Fig 1.13) the majority o f coronal sections do not go beyond an area better defined as 
the frontal cortex (Mugnaini et al., 2002). Work within this lab has recently extended such 
studies, confirming that coronal PFC sections (corresponding to the region used for experiments 
detailed herein) to show a similar distribution o f [125I]aBgt binding sites as seen more 
posteriorly (Fig 1.13; Willcox et al., in preparation).
A B
Fig 1.13: [125I)aBgt autoradiography in the rodent brain
A: saggital section showing high levels of: [125I]aBgt binding in the PFC, shown by arrow; 
figure taken from Clarke et al., (1985), with permission B: Coronal taken at 4.2 mm anterior 
to Bregma showing [l25I]aBgt binding in the PFC, taken from Willcox et al., (in 
preparation), with permission.
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Using guinea pig PFC Lubin et al., (1999) identified a l  nAChR-immunoreactivity in 
layers II -  VI. This group then used dual immunoelectron microscopy to identify a l  nAChR- 
immunoreactivity on GABA-ergic dendritic shafts and soma as well as pre- and post- 
synaptically at (presumed glutamatergic) axospinous synapses. It should however, be noted that 
this investigation was carried out using the a l  nAChR antibody mAb 306 and the specificity of 
antibodies raised against nAChRs for immunocytochemistry experiments has been questioned 
(Jones and Wonnacott, 2005).
The lack of selective a l  nAChRs agonists and antagonists has hampered the 
pharmacological investigation into the involvement of this receptor in cognition. However, there 
is clear evidence for the involvement of this nAChR subtype in PFC-mediated cognition. The 
use of anabasine-related compounds by Meyer and colleagues first suggested a role for a l 
nAChR in working memory (see Levin et al., 2006). The synthesis of a l  nAChR agonist AR- 
R17779 enabled additional investigation into the role of the a l  nAChR. AR-R17779 has been 
shown to enhance working memory in both control and septo-hippocampal lesioned rats (8 -arm 
radial maze; Levin et al., 1999) as well as improve social recognition (Van Kampen et al., 2004) 
and long term win-shift acquisition in the eight-arm radial maze (Levin et al., 1999). However, 
AR-R17779 has been reported not to alter attention using the 5-CSRTT (Grottick and Higgins, 
2000; Hahn et al., 2003). GTS-21, a partial agonist of a l  nAChRs and antagonist of a4|32 
nAChRs and 5-HT3 receptors (Briggs and McKenna, 1998; Kem et al., 2004) improved 
performance in long-delay trials of a delayed-matching-to-sample test in monkeys (Briggs et al.,
1997). GTS-21 also improved performance in the Lashley III maze and one-way active 
avoidance, as well as increasing general learning and reference memory in the 17-arm radial 
maze in rats (Arendash et al., 1995). Interestingly this drug also improved cognition in aged rats 
(Bjugstad et al., 1996) and clinical trials with healthy volunteers has shown GTS-21 to improve 
attention, working and episodic memory (Kitagawa et al., 2003).
Recent studies have used four novel a l  nAChR ligands: (R)-N-(l-azabicyclo[2.2.2]oct- 
3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) (compound A, Cilia et al., 2005; Visanji et al., 
2006); N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-l-benzofuran-2-
carboxamide (ABBF; Boess et al., 2007); 4-bromophenyl-l,4-diazabicyclo[3.2.2]nonane-4- 
carboxylate (SSR 180711; Pichat et al., 2006; Hansen et al., 2007; Kristensen et al., 2007) and 
Ar-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride (PNU 282987; Hajos et 
al., 2005; Chan et al., 2007) to investigate attention, working memory and sensory-gating. 
Compound A reversed isolation-induced deficits in paired-pulse inhibition (Cilia et al., 2005), 
whilst ABBF improved working memory as determined by water maze analysis in aged rats as 
well as novel object recognition in mice (Boess et al., 2007). Administration of SSR 180711 has 
been shown to activate of both arc (Kristensen et al., 2007) and c-fos (Hansen et al., 2007)
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expression in the (pre)frontal cortex. This latter compound has also been shown to enhance 
episodic memory and reverse drug induced deficits in object recognition whilst increasing levels 
o f dopamine in the PFC via a7 nAChRs (Hansen et al., 2007). PNU 282987, which restores 
amphetamine-induced sensory gating (Hajos et al., 2005), has recently been shown to enhance 
both working and reference memory by activation o f a7 nAChRs in the PFC (Chan et al., 2007). 
However, it should be noted that these four a l  nAChR ligands are not yet commercially 
available; hence these studies are limited and not yet reproduced.
Positive allosteric modulators also serve as useful tools for investigating (a7) nAChR- 
mediated responses. The cholinesterase inhibitor physostigmine was the classical nAChR 
positive allosteric modulator, since its discovery 
other cholinesterase inhibitors, including tacrine and 
galantamine have been reported (Maelicke and 
Albuquerque, 1996). The best documented o f this 
group o f nAChR positive allosteric modulators is 
galantamine, a plant (snowdrop) derived alkaloid, 
which is an FDA approved treatment for 
Alzheimer’s disease (Pereira et al., 2002a). These 
compounds do not significantly increase the 
probability o f nAChR channel opening alone, but 
when added in conjunction with nAChR agonist 
they increase the nAChR-mediated response. The 
actions o f these compounds is selectively blocked 
by the the nAChR a  subunit antibody FK1, which 
binds to a region close to, but distinct, from the 
agonist binding site (Fig 1.14; Pereira et al., 2002a). Whilst these compounds all potentiate a l  
nAChR-mediated responses they all display low potency combined with cross-reactivity (see 
Broad et al; 2007). However, this compound class has recently been expanded with the addition 
o f PNU 120596 (Hurst et al., 2005). Although there are currently no reports o f this compound’s 
effect on PFC-mediated cognition Hurst et al., (2005) reported its ability to reverse 
amphetamine-induced auditory gating in rats (Fig 1.15).
Functional ablation o f the a l  nAChR by either genetic knock out in mice, or 
introduction o f anti-sense oligonucleotides has led to a clearer interpretation o f the involvement 
o f the a l  nAChR in attention and working memory. Using the 5-CSRTT Young et al., (2004) 
and Hoyle et al., (2006) have revealed the a l  nAChR knock out mouse to be impaired in all 
measurements o f attention. Curzon et al., (2006) furthered this work in the rat model using anti­
sense a l  oligonucleotide to decrease a l  nAChRs by 42% and 25% in the rat hippocampus and
rCOOH
Fig 1.14: Binding site of nAChR 
positive allosteric modulators
Schematic of an nAChR a subunit 
showing the region that contains the 
residue Lys-125, a major component of 
the galantamine binding site. Adapted 
from Pereira et al., (2002a).
- 2 2 -
________________________________________________________________________________________________________________________________________________________________________________________Introduction
cortex, respectively. This decrease in a l  nAChRs had a profound effect on spatial memory 
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Fig 1.15: PNU 120596 enhances nAChR-mediated currents and reverses amphetamine-
induced auditory gating deficit.
PNU 120596 enhances nAChR function A: Typical currents recorded in response to a 3 s 
pulse of either choline (1 mM) or ACh (100 pM), in the presence or absence of PNU 120596 
(1 pM; 1 min preincubation) in oocyte expressing the human a l  nAChR. B: Typical 
hippocampal auditory evoked potentials, in response to conditioning (black trace) and test 
(gray trace) auditory tones in control conditions after administration of D-amphetamine 
(Amph; 1.0 mg/kg, i.v.) and after a subsequent administration of PNU-120596 (1 mg/kg, 
i.v.). Figure taken from Hurst et al., (2005), with permission.
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As seen [l25I]aBgt autoradiography, most [3H]nicotine and [3H]ACh autoradiography 
investigations, carried out to label high-affinity (aBgt-insensitive) nAChRs, have failed to 
examine the anterior PFC, although using saggital sections (Clarke et al., 1985) it is clear that 
there is a high level o f [3H]nicotine and [3H]ACh binding sites throughout the cortex, including 
the PFC (Fig 1.16). Thalamic lesions have revealed that projections from this region in the PFC 
contain [3H]nicotine binding 
sites, consistent with the 
presence o f a4(32* (Sahin et al.,
1992; Lavine et al., 1997).
Although a parallel study has 
not been carried out with 
[l25I]aBgt most thalamic 
neurones express little, if any 
a l  nAChR mRNA (Seguela et 
al., 1993). Use o f the 02 
nAChR subunit knock out mouse (Zoli et al., 1998) identified four distinct nAChR subtypes, 1)
Fig 1.16: (3Hlnicotine autoradiography in the rodent brain
Saggital section showing high levels of: [3H]nicotine binding in 
the PFC, shown by arrow; figure taken from Clarke et al., 
(1985), with permission.
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the a7 as detected with aBgt; 2) the p2* that are responsible for >90 % of nicotine binding sites 
3) the a3p4* nAChR that are identified by their high affinity for epibatidine binding and 4) non- 
p2* that bind [3H]epibatidine and [3H]cytisine with high affinity in equilibrium binding 
experiments. This group concluded that only type 1, the a7 and p2* nAChRs, were present in 
the frontal cortex. Using immuoprecipation experiments on [3H]epibatidine affinity purified 
nAChRs, this group has also shown the presence of both a4|32 and a4a5p2 in cortex (Zoli et al.,
1998).
Multiple pharmacological tools have been used to dissect the involvement of a4p2* 
nAChRs in attention and working memory. Blondel et al., (2000) demonstrated that nicotine- 
induced enhancement of attention, measured using 5-CSRTT was attenuated in the presence of 
DHpE (a (32* nAChR antagonist) suggesting the involvement of a4|32* nAChRs in attention. 
Further studies using a variety P2* nAChR preferring agonists ABT-418, RJR 2403, SIB 1765F, 
TC-1734 and epibatidine have all demonstrated enhancement of working memory (Levin et al., 
2006). Of particular interest is the recent study of Chan et al., (2007) who, using 5-I-A-85380, 
reported that p2* nAChR activation in the PFC enhances working memory, but (unlike a7 
nAChR activation in this region) is without effect on reference memory.
The generation of a P2 nAChR knock out mouse showed that this subunit is important 
for attention and memory, with the knock out displaying a similar phenotype to animals 
following PFC lesions (Granon et al., 2003). Using lenti-viral techniques this group have 
elegantly shown that re-expression of the p2 subunit in the VTA restores the cognitive deficits 
seen in the p2 knock out (Maskos et al., 2005). Although the effect of nicotine on cognition has 
not been investigated in these knock out animals these data show the clear involvement of the 
P2 nAChR subunit and highlights the importance of the VTA -  PFC connections (Section 1.2.2; 
Fig 1 .2 ).
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1.4 Calcium, a n d  Signalling
Upon agonist binding the nAChR undergoes a conformational change that facilitates 
the entry of cations into the neurone (Section 1.3.1). Whilst Na+ and K+ ions comprise the 
majority of the flux there is also a significant influx of Ca2+. This influx is particularly 
interesting as, unlike VOCC and NMD A receptors (two of the main providers of extracellular 
Ca2+ influx); nAChRs do not require depolarisation to gate Ca2+. The ability of nAChRs to alter 
intracellular Ca2+ concentration facilitates the nAChR modulation of kinases and transcription 
factors as well as neurotransmitter release and subsequent possible formation of LTP (Dajas- 
Bailador and Wonnacott, 2004). Here we discuss:
• 1.4.1 Ca2+ homeostasis
• 1.4.2 Ca2+permeability of nAChRs by Ca2+
• 1.4.3 VOCCs and nAChRs
• 1.4.4 Intracellular Ca2+ stores and nAChRs
o 1.4.4.1 Presynaptic Ca2+ induced Ca2+ release and nAChRs
1.4.1 Ca2+ Homeostasis
Ca2+ is a universal, highly versatile signalling molecule (Smallridge, 2005). To achieve 
such a high level of versatility Ca2+ homeostasis must be tightly temporally and spatially 
regulated by cellular mechanisms that serve to increase (Ca2+ ‘on’) or decrease (Ca2+ ‘o ff)  
cytosolic Ca2+ levels (Fig 1.17; Bootman et al., 2001). For Ca2+ to act as a signalling molecule 
its concentration in the cytosol must be raised above the resting level (~ 100 nM) by Ca2+ flux 
from the extracellular medium or intracellular stores (Berridge et al., 2000).
Ca2+ ‘on’
Extracellular Ca2+ is the principle source of increases in intracellular Ca2+ (Berridge et 
al., 2003). Extracellular Ca2+ can enter the cell via multiple channels, including: ligand-gated 
cation channels, such as the nAChR, as discussed in Section 1.4.2, voltage-operated Ca2+ 
channels (VOCCs; Section 1.4.3) and store-operated Ca2+ channels (SOCCs; Fig 1.18). The 
release of Ca2+ from internal stores (Section 1.4.4) is controlled primarily by intracellular Ca2+ 
level; however, there is a clear role for other intracellular messengers, including inositol-1,4,5- 
triphosphate (IP3), cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate 
(Bootman et al., 2001; Section 1.4.4). Ca2+ entry through all of these routes is driven by the 
presence of a electrochemical gradient (micromolar -> nanomolar).
CHA‘PTtE (R^l: Introduction
The ability o f Ca2+ to amplify its own release from intracellular stores is known as 
Ca2+-induced Ca2+ release (CICR). As diffusion o f Ca2+ through the cytoplasm is greatly 
retarded by Ca2+ ‘o f f  mechanisms (see below) CICR serves as a mechanism to greatly enhance 
local Ca2+ concentrations and form Ca2+ microdomains, thereby propagating Ca2+ signals. Two 
intracellular Ca2+ store channels, IP3 and ryanodine receptors facilitate CICR (Roderick et al.,
2003).
Stimulu&
Fig 1.17: C a2+ homeostasis
Schematic showing Ca2+ ‘on’ (left) and Ca2+ ‘o ff (right) mechanisms. During ‘on’ reactions 
stimulation induces extracellular Ca2+ entry and the formation of second messengers, both of 
which release internal Ca2+ that is stored within the endoplasmic reticulum. This Ca2+ is 
subsequently bound by buffers or effector proteins (shown as blue crosses). During the 'off 
reactions, Ca2+ leaves the effectors and buffers and is removed from the cell by various 
exchangers and pumps. The Na+/Ca2+ exchanger (shown in pink) and the plasma-membrane 
Ca2+-ATPase remove Ca2+ to the outside, whereas the ER Ca2+-ATPase pumps Ca2+ back 
into the ER. Mitochondria also have an active function during the recovery process in that 
they sequester Ca2+ rapidly through a uniporter, and this is then released more slowly back 
into the cytosol to be dealt with by the ER. Adapted from Berridge et al., (2003).
- 2 6 -
C 7 0 ? ( P 2 7 : > ^  !'• Introduction
Ca2+ 'o f f
To maintain temporal and spatial Ca2+ microdomains the Ca ‘on’ reactions must be 
balanced by the presence of Ca2+ ‘o ff mechanisms. These Ca2+ removing pumps consist of the 
plasma-membrane Ca2+ ATPase (PMCA), the Na+/Ca2+ exchanger (NCX), the mitochondrial 
uniporter, and the endoplasmic reticulum Ca2+ ATPase (ERCA; Fig 1.17; Bootman et al., 2002). 
These Ca2+ ‘o ff proteins all have different affinities for Ca2+ and threshold levels. The PMCA 
and ERCA both have high Ca2+ affinity, enabling them to react to nanomolar increases in Ca2+ 
and reset the basal Ca2+ level (~ 100 nM; Berridge et al., 2003). In contrast the NCX and 
mitochondrial uniporter have greater transport rates than either of the Ca2+ ATPases, but their 
rate of Ca2+ removal is only optimal in the micromolar range (Berridge et al., 2003).
In addition to the Ca2+ ‘o ff pumps the human genome encodes over 200 Ca2+ binding 
proteins (Berridge et al., 2003). These proteins, which include parvalbumin, calretinin and 
calbindin in neurones (Bumashev and Rozov, 2005) serve as effectors of the Ca2+ signal, or as 
Ca2+ signal buffers. Similar to the Ca2+ off pumps these Ca2+ buffers display a range of affinities 
for Ca2+ and act to fine-tune the Ca2+ signal by sequestering Ca2+ at high concentrations and 
releasing it at low concentrations.
1.4.2 Ca2+ permea6iCity ofnj^Cfi^
Although the Ca2+ permeability of nAChRs has been the focus of many investigations, 
the use of different experimental approaches with native or heterologous systems has made it 
hard to compare data from different groups. These data have shown the Ca2+ permeability of 
nAChRs to exhibit a wide range of variations, perhaps suggesting discrete physiological roles 
(Fucile, 2004). Using the permeability ratio of PqJP^  the embryonic neuromuscular junction 
nAChR displays the lowest Ca2+ permeability (0.2; Fucile, 2004). However, the Ca2+ 
permeability of the adult neuromuscular junction nAChR is double that of its embryonic 
counter-part and comparable to some measurement of non-aBgt sensitive neuronal nAChRs; 
PqJPNa = 0.45 (Fucile, 2004).
Although the non-aBgt sensitive heteromeric nAChRs are abundantly expressed 
through out the CNS (Section 1.3.2; Table 1.1), measurements of their Ca2+ flux have been 
carried out in either peripheral neurones or heterologous systems. The PqJPNa values in the 
systems range from 0.78 -  1.65, with the a4* nAChR having a higher Ca2+ permeability than 
the a3* nAChRs (Fucile, 2004). This relative Ca2+ permeability is further altered by the addition 
of the a5 nAChR subunit, measuring currents in Xenopus oocytes Gerzanich et al., (1998)
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showed that addition o f the a5 nAChR subunit, with either a3p2 or a3p4 nAChR subunits, 
increased the Ca2+ permeability o f the resulting nAChR.
Ca2+ influx through the a7 nAChR has been extensively studied, with investigations o f 
rat a7 nAChR expressed in Xenopus oocytes showing this receptor to have a high Ca2+ 
permeability PcJPw* ratio o f ~  20 (Seguela et al., 1993). However, a7 nAChR responses in 
hippocampal neurones display a lower PcJP k* ratio o f 6.1 (Castro and Albuquerque, 1995); 
highlighting the variation between recombinant and native measurements. Whilst the Ca2+ flux 
o f the homomeric a9 nAChR. is too low to be measured (Fucile et al., 2006), when combined 
with the alO  nAChR subunit the resultant a 9 a l0  heteromeric nAChR has a Ca2+ permeability 
higher than any other ligand-gated ion channel (22 %; Bumashev and Rozov, 1998; Fucile et al., 
2006).
Apart from providing a direct route for extracellular Ca2+ flux into the cell through its 
intrinsic ion channel (Fig 1.18) the nAChR can also cause increases in intracellular Ca2+ via 
activation o f VOCCs, this Ca2+ can be augmented by Ca2+ release from intracellular Ca2+ stores, 
via CICR which can be further magnified by subsequent activation o f store-operated Ca2+ 
channels (Parekh and Putney, 2005).
Fig 1.18: Multiple routes of C a2+ flux following nAChR stimulation
Following application of agonist Ca2+ can enter via the intrinsic ion channel. Cation influx 
through the nAChR can subsequently cause depolarisation and open VOCCs. The Ca2+ 
may then be amplified by Ca2+ release from internal stores and SOCCs. Adapted from 
Dajas-Bailador and Wonnacott, (2004).
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1.4.3 VOCCs andnJLChQs
VOCCs are widely expressed, providing a predominant route for Ca2+ influx into 
excitable cells. Six functionally distinct VOCCs have been identified thus far: L-, N-, P-, Q-, R- 
and T-types. At the presynaptic terminal the prevalent VOCCs are the N-, and P-/Q-type (Reid 
et al., 2003). These channels, and the R-type to a lesser extent, are well characterised as having 
a role in neurotransmitter release (for review see Evans and Zamponi, 2006).
VOCCs are made up o f an a l ,  p, a28 (two subunits from the same gene) and y subunit 
(Fig 1.19). The a l  subunit is the largest subunit (190 kDa) and confers the VOCCs identity. 
This large subunit allows the VOCC to 
interact with multiple proteins (see 
below) and also contains multiple 
phosphorylation sites within its large 
cytoplasmic domains. Each a l  subunit 
comprises four transmembrane 
domains, each with six membrane 
spanning helices; plus a re-entrant loop 
that forms the Ca2+ selective pore. The 
L- (Cavl), R- (Cav2.3), N- (Cav2.2) and 
P-/Q- (Cav2 .1), and T- (Cav3) a l  
subunits all associate with the p 
(ancillary) subunit (Catterall, 1995).
Four p subunit isoforms have been identified to date. It is thought that the p subunit serves to 
stabilise the final a l  subunit conformation and deliver it to the cell membrane by masking an 
endoplasmic reticulum retention signal in the a l  subunit; as such the p subunit can regulate the 
density o f  the VOCC in the membrane. Electrophysiological experiments have shown the p 
subunit can also modulate the kinetics o f VOCCs, highlighting the importance o f their presence. 
The a28 gene forms a single protein that is subsequently cleaved to produce a2 and 8 
(auxiliary) subunits. These two subunits are covalently linked by a disulphide bond. The 8 
subunit has a single transmembrane region with a short intracellular portion which serves to 
anchor the protein in the plasma membrane. The y l (auxiliary) subunit is commonly found in 
skeletal muscle, although y l  and y3 may be associated with the P/Q and N-type channels in 
neurones. However, y2, y3, y4 and y8 are also associated with AMPA glutamate receptors, for 
review o f the VOCC auxiliary subunits (for review see Tseng et al., 2006).
At the presynaptic bouton there is strong pharmacological data for the co-existence o f 
N- and P-/Q-type VOCCs at a single release site, which all contribute to increases in









Fig 1.19: VOCC composition
Subunit composition of the VOCC, adapted from
Evans and Zamponi, (2006).
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intracellular Ca2+ following depolarisation (Wu and Saggau, 1994; Mintz et al., 1995). Whilst 
these studies showed that there are N- and P-/Q-type VOCCs at presynaptic terminals they did 
not demonstrate that these VOCCs are uniformly distributed. There is now robust evidence, 
stemming from data produced using FM1-43 (a fluorescent dye that can be incorporated into 
vesicles) in hippocampal cultures (Reuter, 1995), for the non-uniform distribution of VOCCs at 
the presynaptic terminal, even those terminals arising from the same afferent (Reid et al., 1997; 
Millan et al., 2002; 2003) These studies have been furthered using cortical synaptosomes, where 
immunocytochemistry and Ca2+ imaging have shown the N- and P-/Q-type VOCCs to be 
heterogeneously expressed. Pharmacology using co-conotoxin-GVIA or agatoxin-IVA revealed 
~47 % of terminals to contain the N-type VOCC, ~4 % the P-/Q-type VOCC with ~43 
containing all three VOCCs. Interestingly this left a proportion of synaptosomes (~ 6  %) 
insensitive to both inhibitors, suggesting the absence of N-, P-/Q-type VOCCs on a small 
proportion of nerve terminals. The N- and P-/Q-type VOCCs can all be purified in a complex 
with SNARE proteins syntaxin, SNAP-25, and synaptotagmin (Catterall, 1999; fig 1.27). This 
association would enable fast neurotransmitter release (~200 ps after an action potential Smith 
and Augustine, 1988). Exocytosis is discussed Section 1.6.3 below.
Three main methodologies have been employed to investigate a link between nAChR 
stimulation and VOCC activation. Using Ca2+ sensitive dyes and pharmacological tools 
application of nicotine has been shown to produce increases in intracellular Ca2+ via VOCCs in 
multiple tissue preparations including SHSY-5Y cells (Dajas-Bailador et al., 2002a), PC 12 cells 
(Gueorguiev et al., 1999), hippocampal cultures (Barrantes et al., 1995) and chick ciliary 
ganglia (Rathouz and Berg, 1994; Shoop et al., 2001). Presynaptic nAChR can also mediate 
neurotransmitter release by Ca2+-dependent exocytosis (Wonnacott, 1997). Experiments 
measuring [3H] dopamine release from striatal synaptosomes or [3H]noradrenaline from 
hippocampal slices have also shown that nAChRs are functionally linked to VOCCs (Soliakov 
and Wonnacott, 1996; Sershen et al., 1997; Kulak et al., 2001; Turner, 2004). These studies 
have been complemented by electrophysiological investigations (Harkins and Fox, 1998; 
Tredway et al., 1999). Of particular note is the electrophysiological study of Rathouz and Berg, 
(1994) who used electrophysiological recordings combined with Ca2+ imaging to investigate the 
coupling of nAChRs to different routes of Ca2+ flux in chick ciliary ganglia. Under 
physiological conditions where the cell was free to undergo membrane depolarisation 
application of nicotine increased intracellular Ca2+ predominantly via VOCC activation. 
However, when the membrane was clamped at resting potential increases in Ca2+ were 
comparable to those measured before, but independent of VOCC activation, indicating that 
whilst nAChRs are capable of initiating depolarisation they can also regulate Ca2+ dependent 
events in the neurone without the need for depolarisation (Rathouz and Berg, 1994).
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Whilst these studies have shown a link between nAChR stimulation and subsequent 
VOCC activation, many of these investigations have also revealed a VOCC-independent 
component of nAChR-mediated responses (Harkins and Fox, 1998; Tsuneki et al., 2000; Dajas- 
Bailador et al., 2002a), suggesting that not all of the measured response is a direct results of 
VOCC activation. These studies have all used the pan-acting nAChR agonists nicotine or 
acetylcholine. The use of nAChR antagonists has led to the speculation that the a7 nAChR may 
not be coupled to VOCCs as activation of this receptor in the presence of VOCC inhibitors still 
produces a detectable response (Rathouz and Berg, 1994; Gray et al., 1996; Radcliffe and Dani, 
1998; Tsuneki et al., 2000; Dajas-Bailador et al., 2002a).
1.4.4 IntraceCCuCar stores: C lC ^and nJLCh^J
The presence of Ca2+ microdomains, with strictly controlled temporal and spatial 
organisation, is fundamental for regulated exocytosis and cell signalling. These microdomains 
are formed by multiple factors including the presence of cytosolic proteins that serve to buffer 
increases in intracellular Ca2+ and prevent its propagation as well as organelles, which can either 
dampen (Ca2+ ‘o ff) or enhance the Ca2+ (Ca2+ ‘on’) signal.
Mitochondria versus endoplasmic reticuCum
In the 1960-70s mitochondria were considered the major Ca2+ storing organelle; the 
focus has now shifted to the endoplasmic reticulum (ER); although it is clear that these two 
organelles share a very dynamic relationship (for review see Meldolesi, 2001). The Ca2+ sensing 
ability of mitochondria is important both in cell death and respiration (Alonso et al., 2006); at 
the synapse the mitochondria can help to shape the Ca2+ signal produced by the ER. Although at 
resting [Ca2+] mitochondria have a low affinity for Ca2+, at higher Ca2+ concentrations they 
provide a rapid buffering system (Fig 1.17). As such the mitochondria have a pivitol role in 
sequestering the Ca2+ signal before later returning it to the ER (Landolfi et al., 1998; Meldolesi, 
2001). However, it has recently been suggested that mitochondria only buffer Ca2+ derived from 
VOCC, not intracellular stores (Nunez et al., 2007). ATP is essential to maintain Ca2+ 
homeostasis (Fig 1.17) therefore a close coupling between mitochondria and the ER is essential 
(Jackson and Thayer, 2006). Here we focus on the ER as the primary Ca2+ store in neurones.
The endoplasmic reticulum (ER) is one of the largest intracellular organelles, 
responsible for multiple cellular processes including synthesising/packaging proteins, signalling 
and the entry and release of Ca2+. Historically the majority of ER studies have been carried out 
in muscle where this structure was first identified (sarcoplasmic reticulum; for review see
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Berridge, 2002), however, here we will focus on the structure and function o f the ER in 
neurones, in particular its presynaptic location.
Consistent with its involvement in different functions the ER has a varied structure 
throughout the neurone. The ER wraps around the nucleus before extending through the soma 
out into the dendritic arborisation and, through the axon to presynaptic terminals (Fig 1.20). 
Within the soma it consists o f rough ER, 
participating in protein synthesis, as the 
ER extends into the projections it 
becomes the smooth ER responsible for 
both the pre- and post-synaptic Ca2+ 
signalling events including those that are 
involved in synaptic plasticity.
There are two well characterised 
types o f Ca2+ releasing channels on the 
ER, the inositol 1,4,5-triphosphate 
receptor (IP3R) and ryanodine receptor 
(RyR), both o f which are large tetrameric 
channel proteins that have a four-leaf 
clover-like structure when viewed using 
electron microscopy (Verkhratsky, 2005); 
these two Ca2+ channels are discussed in 
depth below. A third type o f intracellular 
Ca2+ channel has recently been identified, 
where NAADP serves as the agonist. These NAADP stores, which were first identified in the 
sea urchin egg (Lee and Aarhus, 1995), are insensitive to IP3 and ryanodine (Galione and Ruas,
2005). [3H]NAADP binding studies and autoradiography have identified NAADP binding sites 
to be heterogeneously distributed throughout the brain, with the highest levels o f expression in 
the midbrain and thalamus (Patel et al., 2000). However, the role o f NAADP receptors in 
mammalian neurones remains largely undefined (Bezin et al., 2006) due to a lack o f ligands, 
and therefore will not be discussed here in detail.
Fig 1.20: ER distribution throughout neurones
A: continuity of ER in rat Purkinje neurons from 
acutely isolated cerebellar slices, viewed with the 
lipophilic dye DiIC16. B: electron microscopy of 
synaptosomes prepared from whole rat brain, arrow 
heads indicate smooth ER. Taken from Terasaki et al., 
(1994) and McGraw et al., (1980), with permission.
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The IP3R family consists of three isoforms: IP3RI, IP3R2  and IP3R3, with the type 1 
adding extra diversity by giving rise to at least three alternatively sliced variants (Nucifora et al., 
1995). The IP3R most commonly exists as a homotetramer, but immunoprecipitation 
experiments carried out in Chinese hamster ovary cells suggest that these receptors can also 
exist as heterotetramers (Monkawa et al., 1995). The IP3R consist of three domains: an IP3 
binding domain, a coupling domain, and a transmembrane spanning domain (Meldolesi, 2001). 
IP3RS were originally identified in the cerebellum; all three isoforms have subsequently been 
identified throughout the brain (Verkhratsky, 2005). Using a variety of techniques from western 
blotting to electron microscopy of rat brain, Sharp et al., (1999) reported the IP3R1 to be 
enriched in Purkinje neurones in the cerebellum and neurones in the basal ganglia; the IP3R3  to 
be ubiquitously expressed throughout the brain (predominantly neuronal); by contrast IP3R2  
was only detected in glia. BP3RS are found in dendrites, dendritic spines, soma and axons (Sharp 
et al., 1993; Verkhratsky, 2005 and references therein).
There is complex regulation of the IP3RS, which are not classically associated with 
CICR (Bardo et al., 2006). Each receptor contains multiple serine-threonine- and tyrosine- 
kinase phosphorylation sites, in addition calcineurin can dephosphorylate the IP3R. This 
phosphatase forms a complex with the IP3R and the immunophilin binding protein, FKBP12, to 
regulate the phosphorylation state of the receptor and is, therefore, of fundamental importance 
for the dynamic control of Ca2+ fluxes (Cameron et al., 1995; Meldolesi, 2001). In the absence 
of IP3 the receptor displays a classical bell shape curve of activation, with increased open 
probability between resting (-100 nM) and -400 nM intracellular Ca2+. However, in the absence 
of IP3 higher levels of Ca2+ are inhibitory at the IP3R (Bezprozvanny et al., 1991). In contrast in 
the presence of IP3 reverses this mechanism to switch the effect of high (pM) Ca2+ from 
inhibitory to stimulatory (Adkins and Taylor, 1999).
(Ryanodine receptors
The ryanodine receptor (RyR), so named after the plant alkaloid ryanodine, is closely 
associated with the phenomenon of Ca2+-induced Ca2+ release (CICR). Ryanodine can have 
multiple actions at the RyR: At nanomolar concentrations, ryanodine increases the frequency of 
RyR channel opening, without affecting its conductance. At low micromolar concentrations, 
ryanodine promotes RyR channel opening, which is also characterised by an increase in the 
channel opening time. At higher micromolar concentrations ryanodine completely blocks the 
channel (Verkhratsky, 2005). These multiple actions most likely reflect the existence of high- 
and low-affinity binding sites for ryanodine within the RyR (Zucchi and Ronca-Testoni, 1997).
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Similar to the EP3R, the RyR is a large homotetrameric protein, with each subunit 
having a mass of ~ 560 kDa. Four RyR isoforms have been identified to date, RyRl, RyR2, 
RyR3 and RyR4, with the later being found solely in fish (Zucchi and Ronca-Testoni, 1997). 
RyRl-3 were originally described as ‘skeletal’, ‘heart’ and ‘brain’ isoforms respectively, 
however, a detailed study of RyR mRNAs and protein distribution in murine brain (and 
peripheral tissue), revealed all three isoforms to be widely present throughout the brain 
(Giannini et al., 1995). This, and other studies, revealed that the RyR3 (‘brain’) isoform has the 
lowest expression in the brain (~ 2 % total RyRs), however, it is the predominant isoform in the 
striatum (Giannini et al., 1995; Murayama and Ogawa, 1996). In cortical areas both RyRl and 2 
are present, with the latter dominating; the distribution of the RyR isoforms throughout the brain 
is discussed in Bouchard et al., (2003). At the cellular level a combination of light, fluorescence 
and electron microscopy has identified RyRs in hippocampal cortical axons, dendritic spines and 
dendritic shafts (Sharp et al., 1993; Ouyang et al., 1997). The RyR are also found in presynaptic 
locations (Fig 1.20; Bouchard et al., 2003). The function of these presynaptic Ca2+ stores is 
discussed below.
Studies utilising caged Ca2+ (Lamb and Stephenson, 1995), have identified Ca2+ to be 
the most critical modulator of RyR function; however, this receptor is also regulated by kinases, 
phosphatases and redox state (Butanda-Ochoa et al., 2006). Two mechanisms of activation have 
been proposed, one where there is a physical coupling between the VOCC and RyR, this is the 
case in the sarcoplasmic reticulum of muscle. In this scenario the VOCC would serve to sense a 
change in membrane potential, the subsequent conformational change would be the primary 
cause of RyR opening (see Zucchi and Ronca-Testoni, 1997 and references therein), although 
there may still be a role for Ca2+. The alternative hypothesis of activation is CICR (Fabiato, 
1983), where the RyR is activated by an increase in cytosolic Ca2+. The RyR, like the IP3R 
contains Ca2+ binding sites and as such can mediate CICR upon Ca2+ binding. In addition to 
direct binding of Ca2+ to the channel this cation also exerts effects on the channels through 
accessory proteins such as kinases and phosphatases that can regulate the channels sensitivity to 
Ca2+ (Roderick et al., 2003).
Although there is evidence for the existence of RyRs (predominantly type 3) on 
mitochondria in spleen (Uehara et al., 2004), liver (Feng et al., 1992) and heart (Beutner et al.,
2001) mitochondria are not classically thought of as an organelle directly involved with CICR. 
However there have also been reports of a Ca2+-induced Ca2+ release mechanism that directly 
involves mitochondria in bovine aortic endothelial cells (BAE), termed mCICR (Wood and 
Gillespie, 1998), RyRs have not yet been identified on mitochondria in neurones and there is no 
evidence for mitochondria having a direct role in CICR at the presynaptic terminal as such the 
ER is regarded as the primary Ca2+ store involved in CICR in the neurone, for a detailed review
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on mitochondria and nuclei as Ca2+ stores see Alonso et al., (2006).
It has yet to be established whether the RyR and IP3RS facilitate Ca2+ release from the 
same or distinct Ca2+ stores. Investigations to resolve this quandary have been hindered by the 
lack of highly selective pharmacological tools.
7lAChtRf ancC C l
nAChRs have been linked to CICR in a diverse range of neuronal preparations. Using 
hippocampal astrocytes that predominantly express the a l  nAChR Sharma and Vijayaraghavan, 
(2001) revealed that the Ca2+ entering via the a l  nAChR initiates CICR. This work has been 
extended to investigate the role of presynaptic CICR in nAChR-mediated neurotransmitter 
release, see section 1.4.4. A similar response was previously reported in mid-brain neurones. 
Although the authors attributed the CICR-mediated increases in intracellular Ca2+ to both p2* 
and a l  nAChRs, they suggested the initial route of extracellular Ca2+ entry is different, with the 
former eliciting VOCC activation and the latter predominantly allowing Ca2+ influx by the 
intrinsic channel (Tsuneki et al., 2000). The association between nAChRs and CICR has also 
been documented for somatic spines emanating from chick ciliary ganglion neurones (Shoop et 
al., 2001); and in PC12 (Gueorguiev et al., 2004; Dickinson et al., 2007; see Section 5.1.5) and 
SH-SY5Y cell lines (Dajas-Bailador et al., 2002a).
Gueorguiev and colleagues have shown that nicotine- and epibatidine-mediated 
increases in intracellular Ca2+, in PC 12 cells, are a direct result of CICR (Gueorguiev et al., 
1999, 2000, 2004). There is also evidence for the involvement of a l  nAChRs in this response. 
Data produced in a later study using nicotine in the presence of the a l  nAChR antagonist aBgt 
suggested that a l  nAChRs mediate CICR in SHSY-5Y cells (Dajas-Bailador et al., 2002a). This 
was further substantiated in the report of (Ren et al., 2005) who showed MLA-sensitive GTS- 
21-mediated neuroprotection in PC 12 cells to be reliant upon CICR.
Interestingly two recent studies in Drosophila have shown a component of nAChR- 
responses to be mediated via CICR. In a recent novel study Martin et al., (2007) performed Ca2+ 
imaging on transgenic flies expressing a bioluminescent Ca2+ reporter (GFP-aequorin), this 
group elegantly showed an initial rise in Ca2+ following nicotine application, followed by a 
second Ca2+ wave that was blocked by modulators of intracellular Ca2+ stores. This second Ca2+ 
wave to be decreased in the Drosophila mutant dunce (Martin et al., 2007), which is known to 
be impaired in learning and memory (Dudai et al., 1976), consistent with a role for CICR in 
memory, Section 1.4.4.1. Campusano et al., (2007) have supplemented these findings, reporting
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both a VOCC-sensitive and insensitive component to aBgt-sensitive nicotine-evoked increases 
in intracellular Ca2+ in Drosophila Kenyon cells, with the latter component being mediated via 
CICR.
1.4.4.1 (Presynaptic ClCP^cincCnfiChPy
Presynaptic CICR can only occur if there is ER present at the presynaptic bouton. 
Morphological analysis using high resolution electron microscopy (McGraw et al., 1980; Fig 
1.20) and immunocytochemical procedures (Hartter et al., 1987; Benedeczky et al., 1994) has 
revealed the presence of presynaptic ER. The ability of these organelles to sequester 
physiological levels of Ca2+ supports the suggestion that presynaptic ER functions in a similar 
manner to sarcoplasmic reticulum to buffer and release Ca2+ (Bouchard et al., 2003). Using 
[3H]ryanodine binding to subcellular fractions and autoradiography Padua and colleagues 
(Padua et al., 1991, 1992, 1996) have confirmed the presence of RyR in the presynaptic zone, 
with hippocampal Percoll™-purified synaptosomes containing nearly four times more 
ryanodine-binding sites than the mitochondrial control (Padua et al., 1996).
Although these data illustrate the presence of ER and RyRs at the presynaptic terminal 
they do not reveal their physiological purpose. In the hippocampus, miniature GABAA-mediated 
synaptic currents can be recorded in the presence of tetrodotoxin and calcium channel 
antagonists (Collingridge et al., 1984; Otis et al., 1991). Savic and Sciancalepore, (1998) went 
on to demonstrate that these tetrodotoxin-sensitive-GABA receptor mediated currents still 
occurred in the absence of extracellular Ca2+ and were altered in the presence of thapsigargin or 
caffeine. The link between presynaptic CICR and neurotransmitter release gained momentum 
following the seminal paper from Llano et al., (2000). In this study the authors used multiple 
lines of investigation to demonstrate that large-amplitude miniature inhibitory postsynaptic 
currents (mIPSCs) are mediated from CICR; having confirmed the presence of presynaptic 
RyRs using western blotting and immunocytochemical techniques this group then showed that 
prolonged absence of external Ca2+ or 100 jiM ryanodine can prevent large-amplitude mIPSCs. 
This work was furthered in 2001 by Emptage et al., who showed, using Ca2+ imaging, that 20 
pM ryanodine can decrease action-potential evoked increases in intracellular Ca2+ at the 
presynaptic terminal (Fig 1.21).
Emptage and colleagues went on to ask whether this CICR was physiologically 
relevant to nicotine-mediated neurotransmitter release using the phenomenon of paired-pulse 
facilitation (PPF), a widely used model of short-term plasticity. Ryanodine was without effect 
on the amplitude of the first evoked response, however, the relative facilitation of the second
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response (75 ms later) was greatly reduced when this modulator was present (Fig 1.21). The 
block o f mEPSCs, pharmacologically augmented by the application o f nicotine, in the presence 
o f ryanodine also suggests a role for CICR in nicotine-enhanced spontaneous firing (Emptage et 
al., 2001). Subsequent investigations have reported that nicotine-triggered small random 
presynaptic calcium spikes at the nerve terminals innervating the mouse vas deferens or 
hippocampal slices are dependent upon CICR (Brain et al., 2001; Sharma and Vijayaraghavan, 




100 m s 50 m s
Fig 1.21: CICR contributes to action potential-evoked C a2+ currents in presynaptic
boutons and presynaptic PPF
A: Ca2+ fluorescence measured with Oregon green-488 BAPTA-1 in hippocampal 
neurones. Data shows action-potential mediated increases in presynaptic Ca + in the 
absence (ACSF) or presence (Ryan) of 20 |iM ryanodine. Data are presented as percentage 
change in fluorescence. B: Example trace of PPF in hippocampal neurones; ryanodine was 
without effect on the first response, but greatly reduced the enhancement of the second 
response. Taken from Emptage et al., (2001); with permission.
The propensity o f nicotine, acting at presynaptic nAChRs, to enhance synaptic 
plasticity events such as long term potentiation (LTP); a putative cellular correlate of memory 
formation, was first documented in 1994 (Sawada et al., 1994). This ability o f nAChRs to alter 
LTP is in accordance with its capacity to enhance cognitive functions. As well as studies 
showing that nicotine can modulate synaptic efficacy in an extracellular Ca2+-dependent manner 
(Radcliffe and Dani, 1998; Ge and Dani, 2005), there are also data showing that stimulation 
with GTS-21, an a l  nAChR agonist could also cause LTP (Hunter et al., 1994). The ability o f 
GTS-21 and 5-iodo-A-85380 (p2* nAChR agonist) to enhance LTP suggests a role for multiple 
nAChRs in this phenomenon (Hunter et al., 1994; Fujii et al., 2000). Indeed the ability o f 
nicotine to cause modulation o f synaptic plasticity events in the meso-limbic system is thought 
to underlie the addictive properties o f this compound (Wonnacott et al., 2005).
At bullfrog cholinergic synapses LTP requires CICR (Cong et al., 2004). Welsby et al., 
(2006) later showed that nicotine, acting at hippocampal a l  nAChRs, could enhance LTP (Fig
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1.22) and this enhancement was attenuated in the presence o f ryanodine (Fig 1.22). Furthering 
the hypothesis that intracellular Ca2+ stores are essential for synaptic plasiticity.
A O DHpE
•  DHPE + nicotine
O MLA
•  M_A +nicotine
C  ^  O Ryanodine
•  Ryanodine + nicotine
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Fig 1.22: Nicotine-mediated enhancement of hippocampal LTP is via a7 nAChR and
CICR
Nicotine (5 pM) enhances high frequency stimulation (HFS)-induced LTP. This 
enhancement was A: insensitive to DHpE ' '  “ , ' B: blocked by 100 nM MLA and C: 20 
pM ryanodine. Figure taken from Welsby et al., (2006), with permission.
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1.5 (Ex}racetInCar SignaC-^guCated %jnase
In the presynaptic terminal increases in Ca2+ can initiate multiple signalling cascades. 
O f particular interest to this thesis is the link between nAChR-mediated increases in 
intracellular Ca2+ and extracellular-signal regulated kinase activation (ERK). nAChRs can 
increase phosphor-ERKl/2 levels in multiple tissue preparation, in addition in its presynaptic 
location ERK 1/2 has been associated with synaptic plasticity. Here we discuss:
• 1.5.1: ERK1/2: activation and synaptic plasticity
• 1.5.2: nAChRs, ERK1/2 and synaptic plasticity
1.5.1 (E(RJQ/2: activation and synaptic plasticity
ERK 1/2, along with JNK, p38MAPK, and ERK5 make up the mitogen activated 
protein kinase (MAPK) family. All o f the MAPKs 
are activated by a sequential phosphorylation 
cascade o f kinases (MAPKKK MAPKK->
MAPK), which serve to internalise an extracellular 
signal (Fig 1.23). ERK 1/2 are activated by 
multiple different extracellular stimuli: growth 
factors, hormones and neurotransmitters, which 
can act at G-protein coupled receptors, tyrosine 
kinase receptors or ion channels; thereby initiating 
a wide variety o f  intracellular signalling that all 
converge on the ERK cascade (Rubinfeld and 
Seger, 2005). As such it is perhaps not surprising 
that ERK 1/2 have been associated with a diverse 
array o f cellular processes (Yoon and Seger,
2006), including regulation o f cell survival and 
apoptosis (Lu and Xu, 2006), development (Krens 
et al., 2006), addiction (Lu et al., 2006) and 
learning and memory (Giovannini, 2006), here we 
will focus on the latter.
Using hippocampal synaptosomes (Pereira et al., 2002b) demonstrated that MEK 
inhibitors block KCl-evoked [3H]glutamate release, consistent with the involvement o f 
presynaptic ERK 1/2 in glutamate release. Multiple studies investigating LTP have suggested a 
strong role for ERK 1/2 in this phenomenon. Infusion o f MEK inhibitors abolishes hippocampal
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Fig 1.23: The ERK1/2 Pathway
Schematic showing the cascade of kinase 
activation leading to ERK 1/2 




and amygdaloid brain derived neurotrophic factor (BDNF)-induced LTP (Davis et al., 2000; 
Pandey et al., 2006) and electrically-evoked hippocampal (English and Sweatt, 1996, 1997), 
cortical (Cristo et al., 2001) and amygdaloid LTP (Schafe et al., 2000).
Consistent with LTP being the cellular correlate for memory, in vivo studies have 
suggested that ERK1/2 plays a role in learning and memory. Atkins et al., (1998) revealed a 
substantial increase in hippocampal phosphorylated ERK2 following cue and contextual fear 
learning; ERK1 was only increased following cue fear conditioning. An infusion of MEK 
inhibitors into the hippocampus impairs inhibitory avoidance memory in behavioural tests 
(Izquierdo et al., 1998; Walz et al., 1999; Quevedo et al., 2004; Igaz et al., 2006). These studies 
were recently furthered by Chai et al., (2006) who initiated short- (10 min) and long- (24 hr) 
term retention tests after inhibitory avoidance training and subsequently measure ERK 1/2 
activation in multiple brain regions. This group showed a marked increase in ERK 1/2 
phosphorylation in the medial amydala and the anterior cingulate, motor and lateral orbital 
cortex following the short-term test. In comparison the phophorylated levels of ERK 1/2 were 
increased in the prelimbic cortex and central amygdala following the long-term retention test. 
These data show the involvement of ERK 1/2 in multiple regions, with different involvement in 
different test of memory. The infusion of MEK inhibitors into the entorhinal cortex also impairs 
long-term spatial memory (Walz et al., 1999; Hebert and Dash, 2002).
In conjunction with the growing interest in the PFC as the executive centre of the brain 
(Section 1.2.3) there have recently been several reports documenting changes in PFC ERK1/2 
phosphorylation levels in behavioural tests. The foremost of these investigations was carried out 
by Runyan et al., (2004); this group showed that inhibition of ERK1/2 in the rat medial PFC 
impaired memory retention. Subsequent work has shown that ERK 1/2 inhibition in the medial 
PFC attenuates retention of extinction memory tested on the following day; ensuing experiments 
identified a significant decrease in ERK2 phosphorylation levels in this region (Hugues et al.,
2006). PFC levels of phosphorylated ERK1/2 have also been shown to alter in the reactivation 
of memory that is dissociated from context (Botreau and Gisquet-Verrier, 2006); stress tests 
(Gerrits et al., 2006).
Whilst the majority of investigations into the mechanisms of LTP and memory 
formation have focused on post-synaptic proteins, in an elegant study Kushner et al., (2005) 
demonstrated that there is a presynaptic function for ERK 1/2 in these processes. This group 
observed that hippocampus-dependent learning stimulated the ERKl/2-dependent 
phosphorylation of synapsin-1 (Section 1.6.3). Having established that H-ras isoform p21ras is 
abundantly expressed in axon terminals this group went on to manipulate the H- 
ras/ERKl/2/synapsin-l presynaptic pathway by transgenic activation of p21ras in glutamatergic
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neurones in the frontal cortex. These mice showed increases in mEPSCs and subsequent LTP as 
well as enhanced spatial learning and contextual fear conditioning (Kushner et al., 2005).
1.5.2 nflChtRj, (E(Rld ancCsynaptic pfasticity
The ability o f ERK to modulate synaptic plasticity events makes it a possible route by 
which nicotine can mediate its behavioral effects. The propensity o f nAChR to phosphorylate 
ERK 1/2 is well documented (Dajas-Bailador and Wonnacott, 2004). In vitro experiments 
carried out using hippocampal slices (Dineley et al., 2001), cultured spinal cord neurones 
(Toborek et a!., 2007), PC 12 cells (Nakayama et al., 2001, 2006), SHSY-5Y cells (Dajas- 
Bailador et al., 2002b), NE1-115 cells (Tomizawa and Casida, 2002), and bronchial epithelial 
cells (Tsai et al., 2006) have all shown nAChR activation to result in increases in ERK1/2 
phosphorylation levels. These studies have primarily used nicotine, however, due to the diverse 
preparations used different nAChRs have been activated, whilst Dineley et al., (2001) 
demonstrated that both nicotine and p-amyloid (42 residue peptide) increase ERK2, but not 
ERK1 phosphorylation via a7 nAChRs, Nakayama et al., 2001, (2006) revealed that nicotine, 
acting at non-a7, presumed a3p4 nAChRs, increased both ERK1 and 2 phosphorylation in 
PC 12s cells via a Ca2+ influx through L-type VOCCs.
As discussed in Section 1.4.4.1 nicotine can modulate LTP. Western blot analysis 
subsequently showed an increase in 
ERK 1/2 phosphorylation following 
nicotine-induced LTP formation. In vivo 
studies investigating the effect o f nicotine 
on ERK 1/2 phophorylation levels have 
tended to focus on nicotine as an addictive 
substance, rather than studying its 
cognitive enhancing properties. These 
studies have however, shown that chronic 
nicotine increased ERK2, and to a lesser 
extent ERK1 phosphorylation levels in 
both the PFC and amygdala (Brunzell et 
al., 2003); with no significant change in 
either protein in the VTA or nucleus accumbens. This work was furthered in a substantial study 
by Valjent et al., (2004) who demonstrated that 0.2 and 0.4 mg/kg nicotine (20 min prior to 
perfusion), as well as cocaine, morphine, THC (cannabinoid receptor agonist) and but not 
raclopride, increased ERK1/2 phosphorylation in the PFC (Fig 1.24). Indeed the infusion of
Sal Nic
Fig 1.24: Nicotine increases 
ERK1/2 phophorylation.
Labelling of phospho-ERKl/2 
using DAB, following saline (sal) 
or nicotine (nic, 0.4 mg/kg; s.c.); 
20 min prior to perfusion. Top 
panel: PFC; bottom panel: CA1 
area of the hippocampus. Scale 
bar = 30 gm. Taken from Valjent 
et al., (2004), with permission.
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MEK inhibitors directly into the medial PFC disrupts fear extinction-induced LTP and increases 
the return of the fear response (Hugues et al.2006), consistent with this kinase having an 




One documented route by which ERK 1/2 can mediate neurotransmitter release and 
synaptic plasticity is via glutamate release (Pereira et al., 2002b; Kushner et al., 2005). 
Glutamate (Fig 1.25), as a neurotransmitter, is responsible for the majority of excitatory 
signalling in the brain and is thought to be the 
neurotransmitter present at greater than 50 % of synapses 
(Snyder and Ferris, 2000). It was also the first 
neurotransmitter to be implicated with LTP formation and 
has been shown to mediate this phenomenon in both the 
PFC and hippocampus. In this project we have used the 
technique of superfusion to examine the ability of specific nAChR subtypes to modulate 
glutamate release, using [3H]D-aspartate as a surrogate for glutamate and subsequently 
investigated the cellular mechanisms involved in nAChR-mediated release. Here we discuss:
• 1.6.1 Glutamate as a neurotransmitter
• 1.6.2 Nicotine, glutamate and the PFC
• 1.6.3 Glutamate release
• 1.6.4 Synaptosomes: D-aspartate as a surrogate for L-glutamate
1.6.1 CjCutamate as a neurotransmitter
The precise control of neurotransmitter release is fundamental for concerted organised 
signalling within the brain. Following its release from the presynaptic terminal the spatial and 
temporal signalling initiated by glutamate is tightly regulated (Fig 1.26).
Glutamate receptors can be both ionotropic: NMDA, AMPA and kainate receptors; or 
metabotropic (mGlu) receptors: (for review see Kew and Kemp, 2005). These receptors have 
differing affinities for glutamate, spatial and temporal profiles as well as co-factor requirements, 
thereby allowing them to couple to different intracellular signals. In addition to glutamate 
receptors there are also multiple excitatory amino acid transporters at the synapse, illustrating 
the complex regulation of glutamatergic signalling (Marcaggi and Attwell, 2004).
To date five excitatory amino acid transporters (EAATs) have been identified with 
different locations and abundances throughout the CNS. GLAST (EAAT1) and GLT-1 
(EAAT2) are both located predominantly on glia cells, with EAAT3-5 residing primarily on 
neurones (Danbolt, 2001). Whilst EAAT3 is widely expressed throughout the brain in contrast 
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(Dunlop, 2006). Uptake o f released glutamate is greatest into glial cells, where it is converted to 
glutamine by glutamine synthetase (Fig 1.26) before being exported back to neurones via 
glutamine transporters, where it is converted back to glutamate by the neurone-specific enzyme 
glutaminase (for review see Marcaggi and Attwell, 2004).
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Fig 1.26: A glutamatergic synapse
Schematic showing the fate of glutamate (Glu) following its release from the presynaptic 
terminal. The majority of the glutamate is taken up my transporters on glia, which surround 
the synapse. Once in the glia the glutamate is converted to glutamine that is returned to the 
neurone to replace the transmitter pool, Gln-T: glutamine transporter. Adapted from Conti 
and Weinberg, (1999).
1.6.2 Nicotine, gCutamate and the (PTC
In conjunction with the mesolimbic dopamine inputs from the VTA, glutamatergic 
afferents from the thalamus, hippocampus and amygdala are implicated in the executive 
functions o f the PFC (section 1.2). Consistent with a central role for the PFC in executive 
functions multiple studies have suggested that glutamatergic dysfunction in this region may be 
the underlying cause o f multiple cognitive diseases, including schizophrenia 
(hypoglutamatergic; Tamminga, 2006), obsessive compulsive disorder (hyperglutamatergic; 
Carlsson, 2001), attention deficit hyperactivity disorder (hypoglutamatergic; Carlsson, 2001).
As described in Section 1.3.4 nicotine has been shown to enhance measures o f
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cognitive function attributed to the PFC. There is evidence, generated using electrophysiology, 
demonstrating the ability of both a l  and non-a7 nAChRs to modulate glutamate release in 
hippocampal and VTA neurones (Gray et al., 1996; Radcliffe and Dani, 1998; Fujii et al., 2000; 
Ge and Dani, 2005). In the PFC the data are scarcer; however, there is direct evidence for the 
modulation of glutamatergic transmission by nAChRs.
Electrophysiological recordings from the medial PFC have demonstrated that 
activation of presynaptic (32* nAChRs can increase the frequency of mEPSCs (Vidal and 
Changeux, 1989; 1993). Gil et al., (1997) showed that electrical stimulation of the thalamus, the 
predominant source of PFC glutamatergic innervation (Section 1.2.2), generated mEPSCs in the 
PFC. This group showed these responses to be enhanced following bath application of nicotine, 
which was sensitive to MLA, suggesting the involvement of a l  nAChRs. Interestingly inter- 
cortical synapses that were sensitive to GABA-inhibition were unaltered in the presence of 
nicotine (Gil et al., 1997). Nicotine-enhanced mEPSCs were abolished following thalamic 
lesions, which also decreased [3H]nicotine binding by 40 % in the prelimbic PFC (Gioanni et 
al., 1999; Lambe et al., 2003). Considering the sensitivity of thalamocortical evoked mEPSCs to 
MLA (Gil et al., 1997), it is interesting to note that 02 nAChR knock out mice do not show this 
phenomenon (Lambe et al., 2003), although it should be noted that this latter study was carried 
out looking specifically at layer V of the medial PFC. Gil et al., (1997) also reported a 
difference in nAChR pharmacology mediating this response in mice and rats, with the latter 
being insensitive to MLA, consistent with the data generated using the 02 nAChR knock out 
mouse. Gioanni et al., (1999) elegantly combined in vivo electrophysiology and microdialysis of 
unilateral thalamic leisoned rats to further this work. From these investigations they reported the 
nicotine-mediated responses to be sensitive to DH0E, mecamylamine and MLA, consistent with 
the involvement of multiple nAChR subtypes, for review see (Clarke, 2004).
Direct evidence for the presence of release-mediating presynaptic nAChRs on 
excitatory amino acid terminals in human cortex was provided by Marchi et al., (2002). Using 
[3H]D-aspartate as a surrogate for glutamate (Section 1.6.4) this group reported that nicotine can 
mediate release from cortical synaptosomes, but only if the synaptosomes were depolarised in 
the presence of KC1. Pharmacological analysis showed this response to be evoked by non-a7 
nAChRs (Marchi et al., 2002). This group has gone on to show that a l  nAChRs can elicit 
[3H]D-aspartate release from mouse cortical synaptosomes (Grilli et al., 2005), but only in the 
presence of nAChR positive modulator 5-hydroxyindole. Similarly this group could not detect 
nicotine-evoked release from mouse cortical synaptosomes, unless in the presence of ATP (Patti 
et al., 2006). The enhancement of ATP-evoked release in the presence of nicotine was abolished 
following preincubation with aBgt, leading the authors to conclude that P2X7 receptors exert a 
permissive role on a7 nAChRs. Whilst these studies (Marchi et al., 2002; Grilli et al., 2005;
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Patti et al., 2006) used whole cortical preparations data recently published form this laboratory 
shows presynaptic a7 and 02* nAChRs mediating [3H]D-aspartate release in the rat frontal 
cortex (Rousseau et al., 2005). This work showed that the a l  nAChR can enhance electrical- 
mediated [3H]D-aspartate release from rat frontal cortex minces. Nicotine elicited [3H]D- 
aspartate release from this preparation without the need for depolarisation and this release was 
mediated by both a l  and 02* nAChRs. Although this could be due to a difference in the tissue 
preparation it is perhaps more feasible that this discrepancy is due to a difference in 
methodology, namely the superfusion technique.
1.6.3 gCutamate retease
Glutamate can be released from excitatory amino acid terminals via two routes, EAAT 
reversal or Ca2+-dependent exocytosis as discussed below.
(EAAcT reversaC
Glutamate can be released from excitatory amino acid terminals via the reversal of 
EAATs. This is a Ca2+-independent process that is known to occur under high extracellular 
concentrations of KC1, which occur in the pathological conditions of ischemia (following 
stroke) or epileptic seizure. Whilst potassium can cause glutamate release via vesicular release 
(Section 1.6.2) its primary method of action is to cause the EAAT to reverse (Nicholls and 
Attwell, 1990). This release, which is blocked by EAAT inhibitor TBOA (Phillis et al., 2000), 
gives rise to a rapid increase in extracellular glutamate which causes a further membrane 
depolarisation, releasing further glutamate. Excess of extracellular potassium disrupts the 
potassium concentration-gradient that is essential for the correct functioning of the EAAT (Fig 
1.26). As such the EAAT can no longer remove the glutamate from the extracellular cleft. The 
net effect of this release is usually neurotoxic insult to the cells. Experiments using VOCC and 
EAAT inhibitors have shown that high concentrations of KC1 cause both L-glutamate and 
[3H]D-aspartate release from cortical cultures and hippocampal slices by EAAT reversal 
(Roettger and Lipton, 1996; Jensen et al., 2000).
Ca2+-dependent exocytosis
Synchronous exocytosis is controlled by tight spacial and temporal regulation, 
governed by intracellular Ca2+ concentration. To enable rapid release of neurotransmitters 
vesicular exocytosis is restricted to the presynaptic active zone, defined as the site where 
vesicles cluster, dock and fuse, which can be clearly identified on electron micrographs by a 
highly organised electron-dense web (Schoch and Gundelfinger, 2006).
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A relatively high (10 -  100 jiM) local concentration o f Ca2+ is required to stimulate 
rapid exocytosis. These high levels o f cytosolic Ca2+ can arise from extracellular routes 
(VOCCs; Section 1.4.2) and/or CICR from intracellular stores (Section 1.4.3). However, the 
importance o f the 
VOCCs as the primary 
route o f Ca2+ entry 
during action potential- 
mediated exocytosis has 
been the focus o f 
multiple studies. These 
investigations have 
concluded that VOCCs 
are tethered to the 
active zone, where they 
can facilitate rapid 
delivery o f Ca2+ to 
target proteins; indeed immunoprecipication experiments have shown the VOCCs can be linked 
to multiple exocytotic proteins (Spafford and Zamponi, 2003; Fig 1.27).
VesicCe targeting and docking
A breakthrough in the identification o f proteins involved in exocytosis was achieved by 
Rothman and colleagues who, investigating organelle fusion in yeast (Clary et al., 1990), 
identified a soluble ATP hydrolysing enzyme: N-ethylmaleimide-sensitive protein (NSF) and its 
interacting proteins, termed soluble NSF-attachment proteins (SNAPs). This group went on to 
determine these SNAPs in the mammalian brain together their binding partners, SNARESs 
(SNAP receptors). This work was furthered to reveal the three fundamental SNAREs, which are 
the basis o f and essential for exocytosis: synaptobrevin/VAMP, SNAP-25 and syntaxin 
(Montecucco, 1998). This work has lead to the body o f thought that v- (vesicular) and t- (target 
membrane localisation) SNAREsf couple to bring the vesicle in contact with the presynaptic 
membrane which attracts SNAPs and NSF to catalyse membrane fusion.
Structural studies o f the SNARE core complex shows four helical bundles, with 
syntaxin and synaptobrevin each contributing one helix and SNAP-25 providing two helixes 
(Fasshauer et al., 1998; Sutton et al., 1998). The formation o f this core exocytotic machinery has 
been shown to induce the mixing o f the phosolipid bilayer thereby creating fusion, with the
f SNAREs are also commonly referred to as R- or Q-SNAREs, with the former providing an arginine and 
the latter a glutamine to the core SNARE complex Fasshauer et al., (1998).
[Ca2+] < 10 pM [Ca2*] < 1 0 - 2 0  pM [Ca2*] > 10 pM
ii V esicle I
SNAP-25
C a2* C a2+
Fig 1.27: SNARE attachm ents to VOCCs 
Model of the sequential Ca2+-dependent interactions of multiple 
SNARE proteins VOCCs/vesicles from resting to VOCC opening and 
subsequent vesicle fusion. Stg: synaptotagmin, Stx: syntaxin; adapted 
from Catterall, (1999).
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SNARE complex forming the minimal machinery required for fusion (Tucker et al., 2004). At 
present the formation of the SNARE complex prior to binding is still poorly understood. It is 
known that syntaxin can exist in both open and closed conformation in the absence or presence 
of syntaphilin or Munc-18 and that snapin competitively binds to the syntaxin binding site on 
SNAP-25 indicated that there is a complex mechanism involved to produce the SNARE 
complex (Jahn et al., 2003). Although the precise formation of the SNARE complex prior to 
fusion is still unknown it is widely accepted that synaptotagmin is the Ca2+ sensor that is 
essential for Ca2+-dependent vesicle fusion. The current hypothesis is that increases in Ca2+ 
cause synaptotagmin to bind to both the vesicular and presynaptic membrane thereby helping 
the formation of the SNARE core complex and facilitating neurotransmitter release (for review 
see Rizo et al., 2006).
VesicCe pooCs, the cytoskeleton andsynapsins
Vesicles at the presynaptic terminal can be separated into two ‘pools’: the ready 
releasable pool, which is thought to be primed and the reserve pool. Although the classical 
theory defined the ready releasable pool as being located at the plasma membrane and the 
reserve pool as a more ‘distal’ pool the view on this is now rapidly changing, with the current 
mode of thought that reserve vesicles can be located near the presynaptic membrane, but require 
an extra step, such as protein phosphorylation prior to fusion (Kavalali, 2006).
Protein phosphorylation plays a significant role in neurotransmitter exocytosis, indeed 
it has been suggested the protein phosphorylation is sufficient to induce exocytosis in the 
absence of Ca2+ (Hille et al., 1999) and it is generally thought to serve to enhance transmission, 
playing an important role in synaptic plasticity. Many presynaptic proteins are substrates for 
protein kinases, these include: SNAP-25, synaptobrevin, syntaxin and synapsin (Klenchin and 
Martin, 2000). The majority of studies into protein kinase involvement in exocytosis have 
centred on the ability of phorbol activators* of PKC to initiate exocytosis in a PKC inhibitor- 
sensitive fashion (for review see Morgan et al., 2005), however, other protein kinases have also 
been implicated in exocytosis, including PKA (for review see Seino and Shibasaki, 2005), 
CaMKI and ERK1/2 (for review see Turner et al., 1999).
The stringent maintenance of vesicle location at the presynaptic bouton is provided by 
the cytoskeleton: spectrin, actin and associated proteins. Although these cytoskeleton proteins 
do not have a direct role in exocytosis they are Ca2+-sensing. Therefore, following Ca2+ entry 
they can undergo conformational changes to markedly alter the vesicular distribution in the
* These data must be treated with a certain level of caution as phobol esters have direct, PKC-independent 
actions on synaptic proteins, including Munc-13 (Rhee et al., 2002).
- 1 8  -
CJ('Mx1KcK I: Introduction
presynaptic terminal (see protein phosphorylation and exocytosis, below). Synapsins, which 
make up approximately 1 0  % of vesicular proteins, provide the link between the cytoskeleton 
and the reserve vesicular pool.
As described in section 1.5 nAChRs can promote ERK1/2 phosphorylation that is 
subsequently involved in LTP and memory. One of the primary targets for ERK 1/2 at the 
presynaptic terminal is synapsin. The seminal work on this protein has stemmed from 
Greengard and colleagues (Greengard et al., 1993). There are five synapsin isoforms: la, lb, Ha, 
lib and HI all of which contain multiple phosphorylation sites for CAMKI, IV and PKA (site 1); 
CAMKH (sites 2 and 3) and ERK1/2 (sites 4, 5 and 6 ; Leenders and Sheng, 2005). 
Phosphorylation of synapsins results in a decreased affinity for actin, thereby providing a 
mechanism by which vesicles can translocate to the presynaptic membrane. Indeed 
phosphorylation of this protein via ERK 1/2 is essential for BDNF-mediated glutamate release 
from cortical synaptosomes (Jovanovic et al., 2000) and is postulated to have a role in LTP via 
the ERK1/2 pathway (Kushner et al., 2005; see Section 1.5.1).
1.6.4 Synaptosomes: (D-aspartate as a surrogate fo r  L-gCutamate
For this project we have used a P2 synaptosome preparation (see Section 2.4.2) to 
investigate presynaptic nAChR-mediated excitatory amino acid release. The synaptosomal 
preparation is formed by homogenising tissue which causes terminals to shear off from their 
axonal attachments thereby forming synaptosomes (Nicholls, 2003). The synaptosomes are then 
separated from the homogenate via differential centrifugation. Synaptosomes maintain all the 
features of the intact nerve terminal, yet prevent cross talk between nerve terminals to be 
avoided, making them a suitable preparation for the study of neurotransmitter release from 
presynaptic nerve terminals in isolation. A purer synaptosome-rich preparation can be produced 
by separating the homogenate on the Percoll™ gradient (Dunkley et al., 1986).
The measurement of nAChR-mediated glutamate release from PFC synaptosomes is 
pivotal to this project; as such the accurate measurement of this neurotransmitter is fundamental. 
Three methods of measuring glutamate release from tissue preparations (given either electrical 
or chemical stimulation within a superfusion system) have been described: [3H]L-glutamate 
release has been measured (Rodriguez et al., 1997), L-glutamate release has been detected and 
quantified both by HPLC (Kamisaki et al., 1995; Halmos et al., 2002; Patti et al., 2006) and via 
the use of a fluorometric on-line continuous monitoring system (via NAD NADH) as first 
described in Nicholls and Sihra (1986).
Our laboratory has previously shown enzymatic detection to be very variable when
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measuring L-glutamate release (Rousseau and Wonnacott, unpublished observation) and have 
subsequently investigated L-glutamate release using [3H]D-aspartate as a surrogate (Rousseau et 
al., 2005). D-Aspartate and L-glutamate are thought to be taken up into neuronal tissue 
preparation via the same EAAT mechanism (Danbolt, 2001), although the affinity of the 
transporter for the former is two-fold lower for than L-glutamate (Danbolt, 2001). Although D- 
aspartate can be metabolically degraded by D-aspartate oxidase (Hashimoto and Oka, 1997) the 
rate of degradation is not comparable to degradation of L-glutamate (or L-aspartate). This 
relatively slow rate of metabolism implies that the radioactivity released from the brain 
preparation is more likely to still be attached to the D-aspartate. D-Aspartate has been utilised 
for the majority of the studies characterising EAATs (Danbolt, 2001); of more relevance to this 
project it, has frequently been used as a surrogate for glutamate release (Marchi et al., 2002; 
Grilli et al., 2005; Rousseau et al., 2005; Patti et al., 2006).
Although the use of D-aspartate as an analogue for L-glutamate has previously received 
criticism (Nicholls, 1989; Nicholls and Attwell, 1990), it is important to realise that this arose 
from the lack of evidence for vesicular packaging of D-aspartate and its subsequent Ca2+- 
dependent release. Investigations carried out over the last decade have confirmed the 
requirement of Ca2+ in D-aspartate release (Simonato et al., 1993, Palmer and Reiter, 1994; 
Muzzolini et al., 1997; Savage et al., 2001; Rousseau et al., 2005) as well as a Ca2+-independent 
release, due to EAAT reversal following depolarisation, as seen with L-glutamate (Nicholls and 
Attwell, 1990; Szatkowski et al., 1990; Phillis et al., 2000; Rousseau et al., 2005). The question 
of vesicular incorporation was addressed by Fleck et al., (2001). In this study the group used 
immunoprecipation to isolate rat synaptic vesicles, confirming the presence of both D-aspartate 
and L-glutamate within the same vesicular pool. [3H]D-aspartate release is analogous to 
endogenous glutamate release measured in parallel from potassium and electrically stimulated 
hippocampal slices (Muzzolini et al., 1997); and nicotine-stimulated cortical synaptosomes 
(Patti et al., 2006), showing its validity as a surrogate marker in release assays.
Although the presence of D-amino acids within bacteria is well documented, where 
they form the basis of cell walls, until relatively recently it was assumed that amino acids were 
only present in their L-form within mammals. However, in 1986 Lajtha and colleagues 
identified the D-isoform of aspartate within the mammalian brain and peripheral tissues. 
Hashimoto and colleagues went on to further these findings and identify the presence of D- 
serine (Hashimoto et al., 1992; Hashimoto and Oka, 1997; Snyder and Kim, 2000). They 
showed D-serine to have a similar distribution to that of the NMDA receptor, suggesting a 
regulatory role. Later work revealed D-serine to have a similar potency to glycine at the NMDA 
co-agonist ‘glycine’ binding-site (for review see Snyder and Kim, 2000). It is interesting to note 
that the levels of D-aspartate within the human frontal cortex have been reported as 0.36 jimol/g
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(L-aspartate 0.21 pmol/g) at gestational week 14; by week 41 it has diminished to trace levels 
(Hashimoto and Oka, 1997), suggesting that D-aspartate may play a (neurotransmitter) role 
within this region during development.
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1.7 Aims
As discussed above the PFC is thought to be the locus for many cognitive processes, 
including attention and working memory, which are enhanced by nicotine. Nicotine, acting at 
presynaptic nAChRs is known to modulate glutamate release in other brain regions and it has 
been postulated that this is one way in which it could exert beneficial effects on cognition. Here 
we characterised the cellular mechanisms of nAChR-mediated excitatory amino acid release 
from PFC synaptosomes. The aims of this thesis are outlined below
Characterisation o f  nAChd&mediatedexcitatory amino acidreteasefrom (PTC
As discussed in Section 1.3.4, due to the anterior position of the PFC it is often ignored 
in protein distribution studies, as such here we have investigated the levels of a7 nAChRs in this 
region compared to other brain regions (Section 3.2.1). We have previously reported that 
nicotine can mediate [3H]D-aspartate release from a more posterior region, the frontal cortex. 
Due to the previous controversy surrounding the use of [3H] D-aspartate as a marker for 
excitatory amino acids we have characterised the uptake properties of both [3H] D-aspartate and 
[3H]L-glutamate into both PFC synaptosomes and vesicles (Section 3.2.3). We went on to 
optimise the excitatory amino acid release system, comparing KC1- and nicotine-evoked [3H]D- 
aspartate and [3H]L-glutamate release from PFC synaptosomes (Section 3.2.4), to validate the 
use of [3H]D-aspartate as a surrogate for [3H]L-glutamate in release studies The majority of 
investigations into nAChR-mediated neurotransmitter release have used the non-selective 
nicotinic agonist nicotine. We have characterised the ability of nAChR selective agonists to 
mediate [3H] D-aspartate release from P2 synaptosome prepared from the PFC
nACh^mediatedpHfo-aspartate retease from PTC: cettuCar mechanisms
Following nAChR stimulation Ca2+ can enter the nerve terminal via the nAChR’s 
intrinsic ion channel or VOCC activation (Section 1.4.2), where either route can subsequently 
be augmented by CICR (Section 1.4.3). In the past there have been questions raised as to 
whether D-aspartate release occurs via Ca2+ dependent exocytosis or EAAT reversal (Section
1.6.1). Therefore, we asked the question of whether nAChR subtype-mediated [3H]D-aspartate 
release is Ca2+-dependent and what is the route of this influx (Section 4.2.1). As nAChRs have 
previously been linked with CICR (Section 1.4.3) we set out to establish the presence of RyRs 
in our synaptosomal preparation (Section 4.2.4) and investigate the involvement of CICR in our 
nAChR subtype-mediated [3H]D-aspartate release (Section 4.2.3). ERK1/2 has strong links with 
both synaptic plasticity and memory (Section 1.5.1). nAChR can mediate the activation of 
ERK 1/2 in diverse preparations (Section 1.5.2), here we have investigated the role of this kinase 
in specific nAChR subtype-mediated [3H]D-aspartate release (Section 4.2.5). Subsequently we 
have directly looked at the ability of a7 and |32* nAChRs to phosphorylate ERK1/2 (Section
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4.2.5).
njiCh^niecfiatecf increases in intraceHufar Cn2+ in (PCI2 ceCCs
Thus far we have investigated the cellular mechanisms of a7- and (32* nAChR-mediated 
[3H]D-aspartate release using synaptosomes (Section 1.6.2). Using the PC 12 cell line (Section
5.1.2), which endogenously expresses multiple nAChR subunits (Section 5.1.3) as well as 
VOCCs and intracellular Ca2+ stores (Section 5.1.4-5) we have been able to investigate whether 
the coupling of specific nAChR subunits to different types of Ca2+ channels is spatially 
restricted to the presynaptic terminal. Using nAChR subtype-selective ligands in the presence of 
selective VOCC inhibitors and modulators of intracellular Ca2+ stores we addressed whether a7- 
and p2* nAChR-mediated increases in intracellular Ca2+ in PC 12 cells were coupled to discrete 
Ca2+ pathways.
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2.1 Materials
• [3H] D-aspartate (specific activity 10-30 Ci/mmol) and [3H] L-glutamate (specific 
activity 10-30 Ci/mmol) were purchased from PerkinElmer (Zaventem, Belgium).
• [3H]Epibatidine (54 Ci/mmol), [125I]a-bungarotoxin ([125I]aBgt 249 Ci/mmol), the 
enhanced chemiluminescence (ECL) plus detection kit, horseradish peroxidase- 
conjugated anti-rabbit IgG secondary antibody, nitrocellulose membrane and Percoll™ 
were purchased from Amersham Biosciences (Buckinghamshire, UK).
• (R.)-N-(l-Azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide 
(compound A) and PNU 120596 were gifts from Dr James Kew, GlaxoSmithKline 
(Psychiatry CEDD, Harlow, UK).
• Rat adrenal pheochromocytoma cell line (PC 12 cells) was a gift from Dr Darwin Berg 
(University of California, USA).
• Anti-ryanodine antibodies: 2049 and 1093 (rabbit), were gifts from Prof Tony Lai 
(Cardiff University, Cardiff, UK).
• (-)-Nicotine, choline, dihydro-P-erythroidine (DHpE), cadmium chloride, verapamil, 
caffeine, ryanodine, mecamylamine, RPMI 1640 medium, horse serum, fetal bovine 
serum, 1-glutamine, penicillin and streptomycin were purchased from Sigma-Aldrich 
Co. (Poole, Dorset, UK).
• Xestospongin-C, dantrolene and thapsigargin were purchased from Calbiochem 
(Beeston, Nottingham, UK)
• 5-Iodo-A-85380 dihydrochloride (5-I-A-85380), DL-f/ireo-p-benzoyloxyaspartic acid 
(TBOA), L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC), co-conotoxin GVIA, co- 
conotoxin MVIIC and methyllycaconitine (MLA) were purchased from Tocris 
Cookson (Bristol, UK).
• a-Bungarotoxin (aBgt), fluo-3 AM, pluronic FI27, a-bungarotoxin Alexa Fluor® 488 
(aBgt-488) and all fluorescent secondary antibodies were purchased from Molecular 
Probes (PoortGebaow, The Netherlands).
• Anti-synaptophysin (mouse, monoclonal), VGlutl (guinea pig and rabbit polyclonal) 
and VGlut2 (guinea pig and rabbit polyclonal) antibodies were purchased from 
Synaptic Systems (Gottingen, Germany)
• GFAP (rabbit, polyclonal) was purchased from BioGenex (San Ramon, CA, USA)
• Vectorsheild® mountant was purchased from Vector Laboratories Inc., Burlingame, 
Canada
• Coomassie Plus™ and BCA™ protein assay kit were purchased from Pierce 
(Rockford, IL, USA).
• Optiphase ‘Safe’ was purchased from Wallac Scintilation Products, Fisher Chemicals 
(Loughborough, UK).
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• All other chemicals were of analytical grade and obtained from Sigma-Aldrich Co. 
(Poole, Dorset, UK).
• Male Sprague-Dawley rats (250 -  350 g) were obtained from the University of Bath 
animal house breeding colony.
Table 2.1: nAChR agonists/modulators used
Compound Structure Action
Compound A
c & ^ Q
g7 nAChR agonist 
(De Filippi et al., 2002; 
O'Neill et al., 2002; Cilia 
et al., 2005; Visanji et al., 






1  /N H  nh
h c  i f j  Y  Y Y cH3
\  / Y Y  o  N—0  
0
Cl
a7 nAChR positive 
allosteric modulator
(Hurst et al., 2005; 
Dickinson et al., 2007).
5-I-A-85380
$2* nAChR agonist 
(Mukhin et al., 2000; 
Kulak et al., 2002; Mogg 
et al., 2004; Dickinson et 
al., 2007).
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2.2 Equipment
• Homogeniser: Cilenco® rotor with attached Teflon™ homogenisor.
• Centrifuge/rotor: Beckman Coulter Avanti™ J-25 centrifuge with JA25.15 rotor.
• Superfusion system: 12 parallel open chamber modified Brandel® superfusion 
apparatus (Model SF-12; Brandel, Gaithersburg, MD), containing Whatman GF/B 
filter discs.
• Millipore® Manifold filtration system with Whatman GF/C filter discs.
• Scintillation Counter: Packard Tri Carb 1600® TR Liquid scintillation analyser.
• 96 well plate reader: Anthos 2020 microplate reader; Anthos Labtec Instruments, 
Austria.
• Confocal imaging system: Zeiss LSM 510 confocal microscope.
• Fluorimeter: Fluoroskan Ascent fluorescent plate reader: Labsystems, Helsinki, 
Finland
• Western blotting: mini vertical electrophoresis apparatus: Bio-rad Laboratories, 
Hertfordshire, UK; semi-dry blotter: Sigma-Aldrich Co., Poole, Dorset, UK; Epi Chem 
Darkroom: UVP Lab Products, Cambridge, UK.
2.3 (Buffers
• Krebs-Bicarbonate (KB): in mM; NaCl 118, KC1 2.4, CaCl2 .H20  2.4, MgS04 1.2, 
KH2P0 4 1.2, Na2HC03 25, glucose 10; oxygenated with 95% 0 2/5% C 02 for 1 hour 
and adjusted to pH 7.4.
• Sucrose-Hepes: 0.32 M sucrose, 5 mM Hepes (pH 7.4).
• 0.32 M sucrose (binding assays): 0.32 M sucrose, 1 mM EDTA, 0.1 mM PMSF, 0.01 
% sodium azide (pH 7.4).
• 50 mM phosphate buffer (binding assays): 50 mM phosphate buffer (pH 7.4), 
containing 1 mM EDTA, 0.1 mM PMSF, 0.01 % sodium azide
• [125I]aBgt binding assay buffer: 40 mM K2HP04, 10 mM KH2P04, 1 mM EDTA,
0.1 mM PMSF, 0.01 % NaN3, 0.1 % (w/v) BSA (pH 7.4).
• Phosphate Buffered Saline (PBS): 10 mM phosphate buffer containing NaCl 150 
mM and KC1 2 mM, (pH 7.4).
• Tyrode's salt solution (TSS): in mM 137 NaCl, 2.7 KC1, 1.0MgCl2, 2.5 CaCl2, 
0.2 NaH2P04, 12 NaHC03, 5.5 glucose; (pH 7.4).
• Synaptosome lysis buffer (for vesicle uptake): 10 mM Tris-Maleate containing 0.1 
mMEGTA
• Synaptosome lysis buffer (for western blotting): 50 mM Tris, 50 mM glycine, 2 %
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sodium dodecyl sulphate (SDS) 4 % p-mercaptoethanol , 4 M urea, 1.5 mM sodium 
orthovanadate.
• Western sample buffer (4x): 125 mM Tris-HCl pH 6 .8 ; 4% SDS; 50 % Glycerol; 
0.02 % bromophenol blue, 20 % P-mercaptoethanol.
• Tris-buffered saline (TBS): 137 mM Sodium chloride; 20 mM Tris-HCl ,pH 7.6.
• TBS-Tween (TBS-T): TBS containing 0.1 % Tween.
• Ponceau-S stain: 0.1 w/v ponceau-s in 5 % acetic acid.
• Coomassie stain: 5 % coomassie blue in 40 % methanol, 10 % acetic acid.
• Coomassie de-stain: 40% methanol, 10 % acetic acid.
• Stripping buffer: 100 mM 2-mercaptoethanol, 2 % SDS, 62.5 mM Tris-HCl pH 6.7.
2.4 Met Hods
2.4.1 PrefrontaC cortex dissection
Male Sprague-Dawley rats of approximate weight (250-350 g) were killed by cervical 
dislocation and the brains rapidly removed. Prefrontal cortex tissue (approximately 80 mg per 
brain) was dissected by cutting approximately 3 mm posterior to the most anterior tip of the 
brain, after removing the olfactory lobes. This region corresponds to approximately 1 mm 
anterior to the corpus collosum and 4 mm anterior from Bregma. Tissue was placed 
immediately in ice-cold sucrose buffer.
2.4.2 Synaptosome preparation
2.4.2.1 <P2 synaptosome preparation
Synaptosomes were isolated by differential centrifugation (Soliakov et al., 1995). For 
each superfusion or western blot experiment PFC from two male Sprague-Dawley rats were 
homogenised 10% (w/v) in ice-cold sucrose buffer at pH 7.4 by 12 strokes of the glass/Teflon 
homegenisor attached to the Cilenco® rotor, set at a rotation speed of 2000 rpm.
This homogenate was transferred to a polycarbonate centrifuge tube (16 ml) and 
centrifuged for 10 min at 1000 g (Sorvall® SM-24 rotor and Beckman Coulter Avanti™ J-25 
centrifuge). The resulting supernatant (SO was centrifuged using the same rotor for 20 min at 
20000 g. The supernatant (S2) was discarded and the resulting pellet (P2) was resuspended in 4 
ml of ice-cold KB buffer and triturated gently using a 1 ml pipette for 20 s and then centrifuged 
for 10 min at 1000 g. The supernatant from this final spin was removed and the pellet was re- 
suspended in 2 ml of KB buffer (giving a final concentration of 2 - 3 mg/ml), triturated for 30 s
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and left on ice to await further experimentation.
2.4.2.2 (PercoCP^  purified synaptosomes
Percoll™ was filtered through 45 pm Millipore SM filters to remove coagulates. Four 
solutions o f SH buffer, containing 1 mM EDTA, were made up consisting o f 23, 15, 10 and 3% 
(v/v) Percoll™ respectively, pH 7.4. Starting with the highest percentage Percoll™/sucrose 
solution, 2 ml o f  each o f the solutions were layered 
sequentially using a peristaltic pump (via tubing fitted with a 
12 g needle) set at a rate o f 0.5 ml per min in polycarbonate 
centrifuge tubes. Four centrifuge tubes were prepared in this 
manner and then left in the fridge at < 4 °C overnight 
(Thome et al., 1991).
PFC supernatant (2 ml; Si fraction; described in 
2.4.2.1 above) was layered onto the gradients (using a 20 g 
needle attached to the tubing). The gradients were then 
centrifuged for 5 min (not including 
acceleration/deceleration times) at 32,500 g, with slow 
acceleration and no brake (Sorvall SM-24 rotor and 
Beckman Coulter Avanti™ J-25 centrifuge).
This produced five visible fractions, numbered sequentially from the top with fraction 
1 (Fig 2.1). Fraction 4 (F4) was carefully removed using a Pasteur pipette and put into two 
centrifuge tubes. These fractions were made up to 10 ml o f cold sucrose buffer and centrifuged 
at 20,000 g for 15 min. The resulting pellet was re-suspending with cold KB buffer 
centrifugation at 20,000 g was repeated leaving a small pellet o f synaptosomes.
2 .4.3 pJ{]J4mino acid uptake into G*FC synaptosomes
All uptake experiments were carried out on PFC P2 synaptosomes in KB (prepared as 
described in Section 2.4.2.1). [3H]L-glutamate and [3H]D-aspartate uptake into PFC 
synaptosomes uptake was determined at 4 °C and 37 °C. PFC synaptosomes (80 pi) were added 
to LP4 tubes and equilibrated at 4 °C or 37 °C for 15 min. [3H]L-glutamate or [3H]D-aspartate 
(20 pi o f  0.8 pM) was then added to the LP4 tube to give a final concentration o f 0.2 pM 






Fig 2.1: Protein bands produced 
during synaptosome preparation 
using a discontinuous Percoll™ 
gradient.
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To investigate the concentration dependence of [3H]L-glutamate and [3H]D-aspartate 
uptake into PFC synaptosomes, [3H]amino acids concentration was varied over the range of 
0.01 - 1 pM. To confirm [3H]L-glutamate and [3H]D-aspartate uptake was occurring via a 
transporter-mediated process, the effect of the transporter blockers TBOA and PDC was 
determined. These EAAT inhibitors were added to the synaptosomes 15 min before the addition 
of [3H]L-glutamate and [3H]D-aspartate (final concentration 0.2 pM).
At the end of the 15 min incubations with [3H] amino acid the samples were filtered 
through GF/C filters using a Millipore® Manifold filtration system. Each filter was washed three 
times with 5 ml cold KB and the filters were removed and placed into scintillation vials. 
Optisafe liquid scintillant (4 ml) was added to each of the vials that were then counted for 
radioactivity using a Packard Scintillation counter (Packard Tri Carb 1600 TR Liquid 
scintillation analyser). All of the experiments were carried out in triplicate and filtered in a 
random order. Two aliquots (20 pi) of [3H] amino acid was added directly to the scintillation 
vials containing 4 ml of Optisafe liquid scintillant and also counted for radioactivity (counting 
efficiency = 46 %) to determine total [3H]amino acid present during the incubation.
2.4.4 [3J{]jAmino acid uptake into a presynaptic vesicCefraction
PFC P2 synaptosomes were incubated with [3H] L-glutamate and [3H] D-aspartate, as 
described in 2.4.3 for 15 min at 4 °C or 37 °C. Following this incubation period P2 
synaptosomes were osmotically shocked using 10 mM Tris-Maleate containing 0.1 mM EGTA 
(~ 0.8 ml/g original tissue; Christensen et al., 1990) this preparation was then centrifuged at 
17000 g for 20 min. The supernatant (containing the synaptic vesicles) was filtered through 
GF/C Millipore filter and counted for radioactivity, see 2.4.3.
To confirm that the synaptosomes had been lysed lactate dehydrogenase (LDH) 
release was measured using the CytoTox-ONE™ Homogeneous Membrane Integrity assay 
(Promega). Control synaptosomes and synaptosomes that had been subjected to osmotic shock 
were equilibrated to 22 °C and an equal volume of Cyto-Tox-ONE™ reagent added for 10 min. 
Fluorescence (excitation: 560 nm; emission: 590 nm) was measured using a fluorescent plate 
reader. Background fluorescence was determined by measuring fluorescence from buffer plus 
CytoTox-ONE™ and was subtracted from values for synaptosomes.
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2.4.5 [35f]j4mino acid release from (PTC synaptosomes -  superfusion
PFC P2 synaptosomes, prepared as described in 2.4.2.1, were preloaded with [3H]L- 
glutamate or [3H]D-aspartate (final concentration 0.2 pM) for 15 min at 37 °C. Aliquots (120 pi; 
approximately 0.2 mg o f protein) were added to each o f  the 12 parallel open chambers o f a 
modified Brandel® superfusion apparatus (Fig 2.2; Model SF-12; Brandel, Gaithersburg, MD; 
Soliakov et al., 1995) containing Whatman GF/B filter discs.
F
Fig 2.2: Diagram of the 12 open-chamber Brandel® superfusion system 
Synaptosomes, pre-loaded with [JH]amino acid are loaded directly onto the A: GFB 
Whatman filters. B: collecting probes are placed in test tubes containing the superfusate 
(KB ± antagonist and/or agonist) which are kept at 37°C in a water bath C. A peristaltic 
pump D pumps the buffer onto the synaptosomes, buffer containing radioactivity is then 
collected via tubing E attached to peristaltic pump F which pumps the superfusate into G an 
automated collection tray.
Synaptosomes were superfused at a rate o f ~  0.8 ml/min with KB. After a 24 min 
wash period, two-min fractions o f perfusate were collected. After a further 4 min, nAChR 
agonist and/or depolarising agent in KB or KB alone as a control, were delivered to the 
chambers as a 90 s pulse, separated from the bulk buffer flow by 2 s air gaps. Synaptosomes 
were superfused for a further 16 min with KB. The radioactivity in each fraction was measured 
in a Packard Tri Carb 1600 TR Liquid scintillation analyser. When present, inhibitors or 
modulators were included in the perfusing buffer for 10 min prior to agonist stimulation (except 
for PNU 120596 which was applied for 2 min prior to stimulation and aBgt, PDC or TBOA 
which were applied throughout). Antagonists/modulators were present during the stimulation
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and remained throughout the rest of the experiment (with the exception of PNU 120596, which 
was removed in parallel with the agonist). To determine the Ca2+-dependency of KC1- and 
nAChR-evoked release, synaptosomes were perfused with Ca2+-ffee KB, replacing CaCl2 with 
2.4 mM MgCl2 containing 2 mM EGTA throughout the experiment. Each condition was carried 
out in triplicate within each experiment.
Radioactivity remaining in the synaptosomes at the end of the experiment was 
determined by counting the filters from the superfusion chambers. Total radioactivity present in 
synaptosomes at the time of agonist stimulation was calculated as the sum of subsequently 
released [3H]D-aspartate plus radioactivity remaining on the filters (Rousseau et al., 2005; Fig 
2.3).
For release experiments, superfusion data were analysed by fitting a double exponential decay 
equation to the baseline data (Soliakov et al; 1995) using the Sigma plot (v.2.0) programme for 
Windows 3.1 (Jandel Scientific):
y =  a e bx + ce *
where a and c are initial release (at x=0 ) in each phase, b and d are the decay constants in each 
phase, and x is the fraction number. Evoked [3H]D-aspartate release was calculated as the area 
under the peak, defined as points two points, fractions 5 and 6  (Fig 2.3), and expressed as a 
percentage of the total radioactivity present in the synaptosomes at the point of stimulation 
(fractional release, Fig 2.3). This was taken to be the sum of subsequently released [3H]D- 
aspartate plus that on the filters (synaptosomes).
Data are presented as fractional release, which has been adjusted for buffer-evoked 
[3H]D-aspartate response (Fig 2.3C). Values in histograms and concentration response curves 
represent the mean ± S.E.M of the number of independent experiments carried out, with each 
experiment consisting of 2 or 3 replicate chambers for each condition. Statistical analysis of 
data was carried out using Student’s unpaired t-test or one-way ANOVA with post hoc Tukey’s 
or Dunnett’s analysis, as stated in the figure legends. Values of/? < 0.01 or p  < 0.05 were taken 
to be statistically significant.
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1 2212 2246 -34.9
2 2259 2223 35.3
3 2140 2198 -58.3
4 2153 2170 -17.5
5 2959 2140 818.9
6 2285 2107 177.8
7 2113 2071 41.6
8 2052 2032 19.3












1 2119 2167 -48.6
2 2197 2213 -16.5
3 2271 2251 19.7
4 2265 2279 -14.4
5 2382 2295 86.3
6 2264 2297 -33.6
7 2269 2282 -134
8 2278 2246 31.2
9 2167 2187 -20.3
Total CPM present 
at stimulation
Released CPM Fractional Release Adjusted for Buffer
Nicotine 10 pM
254838.0843 996.6744 0.3911 0.3712
Buffer
270970.5507 53.8158 0.0199 0.0000
Fig 2.3: Analysis of superfusion data
Data collected from two superfusion chambers following stimulation with A: nicotine (10 pM), B: 
KB alone. Graphs show temporal profiles of release with and computer-generated baseline. Tables 
show raw data and derived baseline (CPM). C: Calculation of fractional release from two plots 
shown above, fractional release is determined as released CPM (peak) as a percentage of radioactivity 
present at the point of stimulation.
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2.4.6 (Preparation of<P2 mem6ranesfor [125I]a<Bgt 6indmg
P2 membranes were prepared from the brain regions of interests as described by 
Davies et al., (1999). PFC (dissected as described in 2.4.1), hippocampus, cortex minus PFC or 
whole brain (minus cerebellum) were frozen in liquid nitrogen and stored at -  20 °C until 
required. Tissue samples were homogenised (10 % w/v) in 0.32 M sucrose containing 1 mM 
EDTA, 0.1 mM PMSF and 0.01 % sodium azide. The homogenate was centrifuged at 1000 g 
for 10 min. The supernatant was removed and kept on ice, the pellet was resuspended in 0.32 M 
sucrose and re-centrifuged at 1000 g for 10 min. The two supernatants fractions were combined 
and centrifuged at 12000 g for 30 min. The resultant pellet was re-suspended in 50 mM 
phosphate buffer (pH 7.4), containing 1 mM EDTA, 0.1 mM PMSF and 0.01 % sodium azide, 
membranes were stored (250 pi aliquots) at -  20 °C and thawed on the day of use.
2.4.6.1 [12SI]cd3gt saturation and competition 6inding
All assay conditions were carried out in triplicate. For inhibition of [125I]aBgt binding 
to brain membranes 25 pi of drug was added to 20 -  26 pi P2 membranes (-100 pg). [,25I]aBgt 
(25 pi, final concentration 1 nM) was added and the total volume was made up to 100 pi with 
PBS. For total binding the drug was replaced with assay buffer, for non specific binding drug 
was replaced with nicotine (final concentration 1 mM). For saturation binding 100 pg protein 
was incubated in various concentrations of [125I]aBgt (0.2 -  5 nM) in the presence and absence 
of nicotine (final concentration 1 mM). Samples were vortexed and incubated for 4 hours at 37 
°C, before addition of 1 ml assay buffer and further incubation at 37 °C for 1 hour; samples 
were then chilled at 4 °C for 30 min. Samples were filtered using a Brandel cell harvester 
through a double thickness of Gelman GFA/E filter paper, bottom filter soaked in 0.3 % PEI in 
water, top filter in 4 % milk powder in PBS overnight (Whiteaker et al., 2000). Filters were 
counted for 125I in 4 ml Optiphase ‘Safe’, using a Packard Scintillation counter (counting 
efficiency = 65 %)
For [,25I]aBgt competition binding, non-specific binding was subtracted and IC50 
values determined by non-linear regression analysis, by fitting data to the Hill equation using 
SigmaPlot V2.0 for Windows (Jandel Corp., San Rafael, USA). K[ values were calculated from 
the IC5o values using the Cheng and Prusoff relationship (Cheng and Prusoff, 1973) assuming a 
Kd value of 0.55 nM for [125I]aBgt binding to rat brain membranes (Section 3.2.1, Table 3.1).
For [125I]aBgt saturation binding experiments specific binding was calculated 
following subtraction of non-specific binding from total binding. B^x and Kd were calculated 
using the non-linear regression equation:
CJ0i<FT}ElM^ 2: Material' <&'. Methods
Y _  B max .X  
Kd + X
Where Y = [[125I]aBgt] (nM) and X = total binding (fmol/mg) using Graphpad Prism V3.0 for 
Windows (Graphpad Software; San Diego, USA).
2.4.7 CeCC Culture
PC 12 cells (Fig 2.4) were cultured as described by Blumenthal et al., (1997; PC12-C). 
Cells were grown at 37 °C in a humidified incubator under 7% C 0 2 in RPMI 1640 medium with 
5% heat-inactivated fetal bovine serum, 10% heat-inactivated donor horse serum with 2 mM 
glutamine and 50 U/ml penicillin/streptomycin. Cells were plated at a density o f 5.5 xlO4 
cells/cm2 into poly-D-lysine (5 pg/ml) coated 96 well plates for calcium fluorimetry, or 24 well 
plates for ligand binding assays, 24 h later.
Fig 2.4: Light microscope image of the 
PC12 cells used in this project
2.4.8 In situ radioligand 6inding to nACh^ in <PC12 cell Cine
Total [3H]epibatidine or [l25I]aBgt binding to PC 12 cells grown in 24 well plates for 
24 h was carried out as described by Ridley et al., (2001). Culture medium was removed from 
the wells and replaced with medium containing 0.1% BSA and 2 nM [3H]epibatidine or 10 nM 
[125I]a-Bgt. Cultures were then incubated at 37 °C for 2 h or 4 h, respectively. Non-specific 
binding was determined in the presence o f 1 mM nicotine. Cultures were washed 3 times in 
warm PBS and solubilised in 0.5 ml 0.1 M NaOH. Optiphase ‘Safe’ (2 ml) was added and the 
samples were counted for radioactivity in a Packard 1600 Tricarb counter. Protein analysis was 
carried out using Coomassie Plus™ Protein Assay Kit (Pierce Biotechnology, Rockford, IL, 
USA).
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2.4.9 Calcium TCuorimetry
Increases in intracellular Ca2+ in confluent cultures of PC 12 cells grown in 96-well 
plates were monitored as described by Dajas-Bailador et al. (2002a). PC 12 cells were washed 
twice with TSS and incubated with the membrane-permeable Ca2+-sensitive dye fluo-3-AM (10 
|iM) and 0.02% pluronic F127 for 1 h at room temperature in the dark. Cells were then washed 
twice with TSS, before adding 80 pi buffer with or without inhibitors per well. After 10 min (20 
min for aBgt) fluorescence (excitation 485 nm, emission 538 nm) was recorded for 5 s using a 
Fluoroskan Ascent fluorescent plate reader. KC1 or agonist (20 pi) was added and changes in 
fluorescence were monitored for a further 20 s. At the end of each experiment maximum and 
minimum fluorescence were determined by addition of 0.2 % Triton (Fmax) followed by 
40 mM MnCl2 (Fmin). Data were calculated as a percentage of Fmax -  Fmin. Values in the 
presence of inhibitors were expressed as a percentage of the control responses carried out in 
parallel in the absence of blockers. Ca2+ dependence was determined in Ca2+-ffee TSS 
containing 2 mM EGTA.
2.4.10 Microscopy
2.4.10.1 Transmission electron microscopy o f  synaptosomes
PFC P2 and Percoll™ synaptosomes (Section 2.4.2) were fixed in PBS containing 4 % 
PFA and 1 % gluteraldehyde for 30 min at room temperature. Synaptosomes were washed 
thoroughly and post-fixed in 0.5 % osmium for 15 min. Samples were washed before being 
dehydrated through an ethanol serious 50, 70, 90, 100, 100 % ethanol for 10 min. Synaptosomes 
were cleared in propylene oxide, two washes of 10 min and layered in Durocopan resin 
overnight. Cured resin blocks were cut to give 65 nm sections using an Reichert Jung Ultra E 
microtome. Sections were mounted onto pioloform coated grids and viewed using the JEOL 
1200 transmission electron microscope.
2.4.10.2 ImmunoCa6eCing o f  synaptosomes
Percoll purified or P2 synaptosomes were layered onto poly-D-lysine coated slides (1 
ml of synaptosome suspension per slide) in a humidified chamber, and incubated for 45 min at 
room temperature to allow the synaptosomes to adhere. Slides were rinsed in KB to remove 
non-adherent synaptosomes. Slides were rinsed in KB and fixed in PBS; containing 4% 
paraformaldehyde (PFA) for 10 min. Slides were washed in PBS to remove fixative and 
incubated in PBS containing 10 % normal goat serum, 0.5 % BSA and 0.05 % Triton-XlOO for 
30 min at room temperature. Primary antibodies (see Table 2.2 for dilutions) were added in PBS 
containing 1 % normal goat serum, 0.5 % BSA and 0.05 % Triton-XlOO. Slides were incubated
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overnight at 4 °C in a humidified chamber. After three 5 min washes with PBS, slides were 
incubated with secondary antibody solution in 1% normal goat serum, 0.5% BSA and 0.1% 
Triton-XlOO in PBS (see table 2.2 for dilutions) for 1 h at room temperature in the dark. Slides 
were washed three times in PBS for 5 min, to remove excess secondary antibodies before 
mounting with Vectorshield™ and viewing under the Zeiss LSM 510 confocal microscope.
2.4.10.3 Immunofa6eCCing o f  (PC 12 ceCCs
PC 12 cells were grown on poly-D-lysine coated coverslips. Cells were rinsed in PBS 
before fixing in 4 % formaldehyde for 20 min. Cells were washed thoroughly and incubated 
with 10 % NGS, 0.5 % BSA and 0.05 % Triton-XlOO in PBS for 30 min before addition of the 
appropriate primary antibodies diluted in 1 % NGS, 0.5 % BSA and 0.05 % Triton-XlOO in PBS 
overnight at 4 °C in a humidified chamber. Coverslips were washed thoroughly before addition 
of appropriate secondary antibody in 1 % NGS, 0.5 % BSA and 0.05 % Triton-XlOO for 1 hour 
at room temperature in the dark. Coverslips were washed and mounted using Vectorshield™ and 
viewing under the Zeiss Axiovert 100 M microscope combined with an LSM 510 confocal 
system.
2.4.10.4 cCBgt-488 Ca6effing o f  (PC 12 ceffs
PC 12 cells grown on poly-D-lysine coated coverslips. Cells were rinsed in PBS before 
incubation for 10 min in the presence of absence of 1 mM nicotine at room temperature. 
Coverslips were inverted onto aBgt-488 (200 nM; 1:500 dilution) in PBS containing 0.1 % BSA 
in the presence of absence of 1 mM nicotine for 1 hour at room temperature. Coverslips were 
washed before fixing in 4 % formaldehyde for 20 min. Coverslips were washed thoroughly and 
mounted using Vectorshield™ and viewing under the Zeiss Axiovert 100 M microscope 
combined with an LSM 510 confocal system
2.4.10.5 Confocaf microscopy
Immunolabelled synaptosomes and PC 12 cells were analysed using the Zeiss multi­
tracking protocol, which eliminates the possibility of fluorochrome ‘cross-talk’ through the use 
of sequential fluorochrome excitation. Fluorochromes were excited using an argon laser at 
488nm (505-530nm emission filter), a helium-neon laser at 543nm (560-615nm filter) and a 
helium-neon laser at 633nm (650nm emission filter). To ensure that the respective fluorescence 
emissions were recorded at the same level, the emission pinhole for each track was set at 1 airy
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Table 2.2: Antibody concentrations and sources
Antibody/label Species Source Dilution
aBgt-488 — Molecular Probes 1:500
GFAP Rabbit Chemicon 1:1000
Synaptophysin Mouse & Rabbit Chemicon 1:1000
VGluTl Rabbit Synaptic Systems 1:1000
VGluTl Guinea Pig Synaptic Systems 1:5000
VGluT2 Rabbit Synaptic Systems 1:500
VGluT2 Guinea Pig Synaptic Systems 1:2500
|3-Tubulin Mouse Sigma-Aldrich 1:300
Topro3 ... Molecular Probes 1:1000
Alexa-488/596/644 Mouse/Rabbit/Guinea Pig Molecular Probes 1:750
Ryanodine 2149 Rabbit Tony Lai 1:200
Ryanodine 1083 Rabbit Tony Lai 1:200
pERKl/2 Rabbit Santa Cruz 1:2000






PFC cortex synaptosomes were prepared as described in 2.4.2.1. Synaptosomes (80 
pi) were added to ependorf tubes and equilibrated at 37 °C for 30 min. Agonist (20 pi) was 
added to the tube and triturated for 10 s before incubating at 37 °C for the stated stimulation 
period. Where present inhibitors, or modulators, were added 10 min before stimulation (except 
aBgt, which was present for 30 min). The reaction was stopped by the addition of 2 x lysis 
buffer (Section 2.3; Pereira et al., 2002b) and subsequent boiling at 95 °C for 5 min. Protein 
concentration was determined using the Pearce BCA™ protein assay. Samples were diluted 
with running buffer (Section 2.3) and run immediately.
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2.4.11.2‘Western 6Cotting
Equal amounts o f boiled samples (10 pg) were resolved using 10 % SDS-PAGE run at 
100 V for 1.5 h before semi-dry blotting onto nitrocellulose membrane; ponceau-s staining was 
carried out to confirm total transfer. Blots were rinsed and left in block (TBS-T containing 5 % 
full fat milk powder) for at least 1 h. Western blotting was performed using phospho-specific or 
total, anti-ERK diluted in TBS-T containing 1 % milk powder, left overnight at 4 °C (Table 2.2 
for dilutions). Following extensive washing in TBS-T, blots were incubated with HRP- 
conjugated anti-rabbit IgG (Table 2.2 for dilutions).
Electro Chemi-
Luminesence (ECL-PLUS) western 
blotting reagents were used for 
detection o f bands. Blots were 
visualised using an Epi Chem 
Darkroom (UVP Lab Products; 
Cambridge, UK). Band intensity 
was calculated using Scion Image 
software for Windows (Scion 
Corporation, Maryland, USA). Data are expressed as a percentage o f the respective control as 
stated in the figure legends. Statistical analysis o f data was carried out using a one-way 
ANOVA with post hoc Tukeys or Dunnett’s analysis, as stated in the figure legends. Values of 
p  <0.01 or p  <0.05 were taken to be statistically significant.
Fig 2.5: Representative picture of SDS-PAGE 
gel with coomasie stain
-  Chapter Three -
Characterisation ofnA.Ch^medaatetC e%citatoiy 
amino acid release from (ETC synaptosomes






(y{yt'FI'l:/}{ 3: Characterisation o f njlCh[K: mediated eye. it alory amino acid ref ease jrom (PFC synaptosomes
3.1 Introduction
3.1.1 Jlims o f  this chapter
The work described in this chapter was performed on the ‘anterior PFC’, dissected as 
described in Section 2.4.1, with the aim of:
Confirming the presence ofoc7 nUCh^y within the rat <5*FC
As discussed in Section 1.3.4 a7 nAChR protein and subunit mRNA distribution in the 
rodent brain has previously been investigated, however, these studies have overlooked the 
anterior PFC. In order to study the cellular mechanisms underlying a7 nAChR-evoked 
excitatory amino acid release it was first necessary to characterise the levels of this nAChR in 
the anterior PFC. Here we have used [125I]aBgt saturation binding assays to determine a7 
nAChR protein levels in the PFC for comparison with that in other regions.
Substantiating the validity of<D-aspartate as a surrogate for L-gCutamate
Although [3H]D-aspartate has been widely used as a surrogate for L-glutamate, its use 
has previously been criticised (Section 1.6.3). To confirm that [3H]D-aspartate behaves in a 
comparable manner to [3H] L-glutamate with respect to uptake and release the [3H] amino acids 
into synaptosomes and subsequently vesicles was measured. Experiments were also carried out 
to compare KCl-evoked [3H]D-aspartate and [3H]L-glutamate release from PFC synaptosomes.
Characterising the specific nJLCh  ^ subtypes that mediate pjflo-aspartate release from (PTC 
synaptosomes
Evidence for nAChR modulation of glutamatergic release has previously been 
discussed (Section 1.6.1.1). This lab has previously shown nicotine to evoke [3H]D-aspartate 
release from frontal cortex synaptosomes. The use of nAChR subtype selective antagonists 
revealed this release to be mediated by both a7 and 02* nAChRs (Rousseau et al., 2005). Here 
we have taken advantage of selective pharmacological tools to further investigate the role of 
these nAChR subunits in [3H]D-aspartate release from PFC synaptosomes.
To stimulate a7 nAChRs we have used a novel a7 nAChR selective agonist, (R)-N-(l- 
azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) (Compound A; De Filippi et 
al.„ 2002; O'Neill et al., 2002; Cilia et al., 2005; Table 2.1). De Filippi et al., (2002) have 
previously reported this compound to be a potent agonist of human a l  receptors expressed in 
GH4 cells (EC50 14 ± 2 nM by FLIPR). Responses to non-a7 nAChRs were investigated using 
the 02* nAChR agonist 5-iodo-A-85380 (Mukhin et al., 2000; Mogg et al., 2004; Table 2.1).
-  69 -
C K A (PTtEP^3: Characterisation o f  njQChOCmediated excitatory amino ac id  release from  (PTC synaptosomes
3.2 (RpsuCts
3.2.1 oc7 nACh^CeveCs in the rat PTC
Saturation binding o f [125I]aBgt to P2 membranes was used to investigate the density 
o f a7 nAChRs in the PFC in comparison to other brain areas. P2 membranes were prepared 
ffom hippocampus, PFC, cortex minus PFC and whole brain as described in Section 2.4.6. 
Membranes were incubated with [125I]aBgt (0.2 -  5 nM) in the absence or presence o f 1 mM 
nicotine, to distinguish specific from non-specific binding (Fig 3.1). Bmax and Kd values were 
calculated using non-linear regression as described in the Methods. [125I]aBgt saturation binding 
to P2 membranes revealed a significantly greater Bmax for PFC than whole brain (Table 3.1). 
However, the Bmax for PFC was not statistically significantly different ffom the rest o f the 
cortex (Table 3.1). The Bmax for [125I]aBgt binding in the hippocampus was the highest o f the 
regions investigated (Fig 3.1; Table 3.1), consistent with previous reports (Davies et al., 1999). 
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Figure 3.1: | l25I|aB gt saturation binding to P2 membranes
Specific binding of [l25I]aBgt to P2 membranes ffom hippocampus (green), PFC (red), 
cortex minus PFC (blue) and whole brain (pink). Specific binding was calculated by 
subtraction of non-specific binding (in the presence of 1 mM nicotine) from total binding 
(in the absence of 1 mM nicotine). Data points were fitted to a binding isotherm using 
GraphPad Prism as described in the methods and show mean ± SEM (n = 3).
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Table 3.1: Saturation binding of [12SI]aBgt to rat brain P2 membranes.
Significantly different to whole brain *p < 0.05, **p < 0.01; significantly different to PFC < 0.01 
(one-way ANOVA with post-hoc Tukey’s test, n = 3).
Whole Brain PFC Cortex minus 
PFC
Hippocampus
Bmax (fmol/mg) 37.2 ± 1.8 55.0 ±2.7* 43.41 ±2.2 96.9 ± 4.2 **n
Kd (nM) 0.56 ±0.09 0.54 ± 0.09 0.74 ±0.11 0.51 ±0.07
3.2.2 Characterisation o f  <P2 versus PercoCP^-purified(PFC synaptosomes
P2 synaptosomes (Section 2.4.2) are widely used to study neurotransmitter release 
(Raiteri and Raiteri, 2000; Salminen et al., 2004; Azam and McIntosh, 2005; Rousseau et al., 
2005) Although preparation of P2 synaptosomes is a relatively quick process this sample 
contains other constituents, including free mitochondria, membrane fragments and a large 
proportion of myelin. P2 synaptosomes can be further purified to enrich the synaptosome 
preparation using a Percoll™ gradient (Section 2.4.2.2; Dunkley et al., 1988). This procedure 
produces five fractions, of which F4 is considered to be pure synaptosomes. Here we have 
compared P2 and Percoll™ (F4)-purified PFC synaptosomes using electron and confocal 
microscopy as well as KCl-evoked [3H]D-aspartate release assays.
3.2.2.1 <P2 versus (PercoUP^-purfiedPFC synaptosomes: morphology
Preliminary experiments were carried out using transmission electron microscopy 
(TEM) for high magnification analysis of P2 versus Percoll™-purified PFC synaptosomes. 
Synaptosomes were prepared as described in section 2.4.2, with fixation in 4 % PFA with 1 % 
gluteraldehyde. Synaptosomes were post-fixed in 0.5 % osmium, embedded in Durcupan resin, 
counter stained with 4 % uranyl acetate and lead nitrate and viewed using the JEOL JEM 1200 
TEM.
Synaptosomes, identified by their high density of vesicles, were abundant in both 
preparations. Both P2 and Percoll™ PFC synaptosomes contained multiple mitochondria (Fig
3.2) as well as organelles resembling ER (Fig 1.17 for comparison). Although the P2 
preparation contained more ‘ghost’ synaptosomes that had lysed and therefore lost their 
vesicle/mitochondria as well as more unidentified membrane fragments than the Percoll 
preparation overall the morphology of the P2 and Percoll™ synaptosomes were surprisingly
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similar (Fig 3.2).
A B
Figure 3.2: Electron m icrographs of P2 and Percoll™ PFC synaptosomes
PFC A: P2; B: Percoll™, PFC synaptosomes were embedded in Durcupan resin and 
counter stained with 4 % uranyl acetate and lead nitrate and viewed using the JEOL 
JEM 1200 TEM. Arrow head: mitochondria; double arrow: vesicles; arrow: ER. 
Representative pictures shown, n = 2. Scale bar = 200 nm.
Although the two preparations appeared very similar using TEM this may be due to the 
methodology employed. To ensure thorough distribution of the Durcupan resin the 
synaptosomes were added to this embedding medium and allowed to move to the bottom by 
diffusion overnight. Although this method of embedding is the most suitable for synaptosomes 
it is unlikely the samples distributed themselves homogenously through the resin. As sections 
were cut solely from the bottom of the hardened resin we may have failed to see differences in 
the samples, apparent further through the resin block.
3 2 2 2  22 versus TercofP^-purified T fC  synaptosomes: neurocfiemicaC mariners
W e further characterised the PFC P2 and Percoll™ synaptosomes at the level of 
confocal microscopy. Synaptosomes were prepared as described in Section 2.4.2 and layered on 
to poly-D-lysine slides before incubation with antibodies as described in Section 2.4.10.2. PFC 
P2 and Percoll™ synaptosomes were labelled with anti-synaptophysin and anti-GFAP to 
determine the relative abundance of synaptosomes and glial inclusion bodies, respectively (Fig 
3.3A). Although purely qualitative, these experiments showed a slightly higher level of GFAP- 
positive structures to synaptophysin-positive structures in the P2 synaptosomes than their 
Percoll™-purified counterparts (Fig 3.3A).
As the focus of this thesis is excitatory amino acid release we next characterised the
- 7 2 -
Cy/yi-F]r£ ’lf{ 3: Characterisation o j njlCh'i{: medialed excitatory amino acidrefeasefrom  <H:C synaptosomes
relative abundances of glutamatergic markers, vesicular glutamate transporters (VGluTs) in P2 
and Percoll™ synaptosomes double labelled with synaptophysin. Although three VGluT 
isoforms have been identified only VGluTl and 2 localise specifically to glutamatergic synaptic 
terminals (Herzog et al., 2006). VGlutl-positive structures were profuse in both P2 and 
Percoll™ PFC synaptosomes, consistent with this isoform being the most abundant in the cortex 
(Nakamura et al., 2005). Indeed the majority of synaptosphysin-positive structures were also 
labelled with VGluTl (Fig 3.3B). The proportion of VGluTl- to synaptophysin-positive 
structures did not appear different in the P2 and Percoll™ PFC synaptosomes. In comparison to 
VGluTl, but consistent with previous literature (Nakamura et al., 2005; Herzog et al., 2006) 
VGluT2-positive labelling was less abundant than that seen for VGluTl (Fig 3.3B, C). 
However, as with VGluT 1, the proportion of VGluT2- to synaptophysin-positive structures was 
comparable in the P2 and Percoll™ PFC synaptosomes.
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Figure 3.3: GFAP and VGluT labelling of P2 and Percoll™  PFC synaptosomes 
Left panel: P2; Right panel: Percoll™, PFC synaptosomes were layered onto poly-D- 
lysine coated slides and labelled with A: Synaptophysin and GFAP; B: Synaptophysin and 
VGluTl; C: Synaptophysin and VGluT2. Scale bar = 20 pm
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3.2.2.3 (P2 versus (PercoCP^-purifiecf G*FC synaptosomes: TffC-evo^ef [3fC]<D-aspartate 
reCease
Having confirmed that both P2 and Percoll™ PFC synaptosomes contain a similar 
proportion of glutamatergic terminals, we next ascertained whether KC1 could evoke [3H]D- 
aspartate, a surrogate for L-glutamate (Section 1.6.3; 3.2.3), release using superfusion (Section 
1.6.3).
Synaptosomes were prepared as described in Section 2.4.2. Homogenate ffom two 
PFCs was divided equally to prepare P2 and Percoll™ synaptosomes. and re-suspended in 1 ml 
of KB. Synaptosomes (120 pi), loaded with 200 nM [3H]D-aspartate were added to each 
superfusion chamber and release experiments were carried out with P2 and Percoll™ PFC 
synaptosomes in parallel.
Synaptosomes were superfused for 24 min prior to basal fraction collection (Section
2.4.5). Two minute fractions were then collected as ‘basal release’. As described in Section
2.4.5.1 a double exponential decay was fitted to this release to determine ‘basal’ (Fig 2.3). This 
basal release was lower for Percoll™ than P2 PFC synaptosomes (Fig 3.4; 992 ± 85 CPM and 
1240 ±152 CPM, respectively; n = 2).
Following 4 min of basal collection a 90 sec pulse of 12 mM KC1 (Rousseau et al., 
2005) or buffer was added. To prevent diffusion of the applied stimulus this pulse was separated 
ffom the bulk buffer flow by an air gap (2 sec). The [3H]D-aspartate released by KC1 or buffer 
was determined as described in Section 2.4.5.1. Although the ‘peak’ (Fig 3.4) produced 
following application of buffer was smaller for Percoll™ than P2 synaptosomes when this 
release was calculated as percentage of radioactivity present (ffactional release) there was no 
difference (0.13 ± 0.01 and 0.12 ± 0.02 for Percoll™ and P2 synaptosomes, respectively; n = 2).
KC1 (12 mM) evoked significantly more [3H]D-aspartate release than buffer alone ffom 
both P2 and Percoll™ synaptosomes (Fig 3.4). The fractional [3H]D-aspartate release evoked by 
12 mM KC1 was comparable from Percoll™ and P2 PFC synaptosomes (1.4 ± 0.1 versus 1.2 ± 
0.1 fractional release, corrected for buffer-evoked release as described in Section 2.4.5.1, Fig 
2.3, n = 2).
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Figure 3.4 [3H]D-aspartate release from ra t P2 and Percoll™ PFC synaptosomes
PFC synaptosomes were loaded with 200 nM [3H]D-aspartate, superfused with KB and 
stimulated with a 90 s pulse of KCI. A: P2; B: Percoll™; PFC syanaptosomes 
representative profiles of [JH]D-aspartate following stimulation with 12 mM KCI (blue) or 
buffer alone (grey).
These release data reaffirm that P2 synaptosomes are suitable for studying the release 
o f excitatory amino acids. Indeed it is interesting to note that fraction 5 o f the Percoll™ gradient 
is devoid o f synapsin-1, but contains synaptosomes, suggesting that this gradient separates 
synaptosomes into distinct sub-categories (Dunkley et al., 1988). As this protein is o f  particular 
interest to this project (Section 1.6.2.2) it adds credence to using the P2 synaptosomes. We have 
used P2 PFC synaptosomes throughout the rest o f  this project.
3.2.3 (Dzftspartate versus L-C}Cutamate: Vpta^e into Q*FC @2 synaptosomes and 
vesicles
The use o f [3H]D-aspartate as a surrogate for [3H]L-glutamate has previously received 
criticism (Section 1.6.4), here we have compared [3H]D-aspartate and [3H]L-glutamate uptake 
into PFC P2 synaptosomes. The concentration-dependence o f [3H]D-aspartate and [3H]L- 
glutamate uptake into PFC P2 synaptosomes was investigated by incubating the synaptosomes 
with increasing concentrations o f either [3H]D-aspartate or [3H]L-glutamate for 15 min (Fig 
3.5A). Uptake o f both amino acids was investigated at low concentrations, similar to those used 
for release experiments, and as such saturation was not reached for either amino acid. Uptake o f 
both [3H]D-aspartate or [3H]L-glutamate was concentration-dependent, with no significant 
difference in the amount o f [3H]D-aspartate or [3H]L-glutamate incorporated into the PFC P2 
synaptosomes at any o f the concentrations used (Fig 3.5 A).
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Figure 3.5: |3H]L-Glutamate and |3H|D-aspartate uptake into PFC synaptosomes
A: PFC P2 synaptosomes were incubated with various concentrations of [JH] L-glutamate 
(red) or [3H]D-aspartate (green) for 15 min at 37 °C before filtration. Radioactivity 
remaining on the filters was converted to pmoles of [3H]amino acid, points represent the 
mean ± SEM from 3 separate experiments. B: PFC synaptosomes were incubated with 0.2 
pM [JH]L-glutamate (red) or [3H]D-aspartate (green) for 15 min at 37 °C or 4 °C. Bars 
represent the mean ± SEM from 3 separate experiments; significantly different to 37 °C 
control **p < 0.01 (Student’s t-test).
Control experiments were carried out where the filters were washed with 10 nM HC1 in 
place o f KB. The radioactivity measured on these filters (121.0 ± 24.7 cpm) was not 
significantly different to background (78.1 ± 23.6 cpm). Uptake o f 200 nM [3H]D-aspartate and 
[3H]L-glutamate were not statistically different (115.2 ± 20.6 and 78.5 ± 14.7 pmol/mg protein, 
respectively; Fig 3.5) and were significantly greater than control filters washed in 10 nM HC1. 
This lab has previously used a loading concentration o f 200 nM when investigating [3H]D- 
aspartate from frontal cortex synaptosomes/minces (Rousseau et al., 2005). Therefore, we 
further investigated [3H]D-aspartate and [3H]L-glutamate uptake at this concentration.
Initial experiments revealed that [3H]D-aspartate and [3H]L-glutamate uptake was an 
active process with experiments carried out at 4 °C showing significantly less uptake (74.3 ± 9.1 
and 68.8 ± 4 . 1  % decrease, respectively; Fig 3.5B). Two structurally distinct inhibitors o f 
EAATs, DL-threo-beta-benzyloxyaspartate (TBOA) and L-trans-pyrrolidine-2,4-dicarboxylate 
(PDC; Waagepetersen et al., 2001) were used to investigate the role o f EAATs in [3H]d- 
aspartate and [3H]L-glutamate uptake. In the presence o f 100 pM TBOA or PDC (15 min pre­
incubation) uptake o f [3H]D-aspartate into PFC P2 synaptosomes was reduced by 74.3 ± 9.1 and 
51.1 ± 4.3 %, respectively. [3H]L-Glutamate uptake into PFC P2 synaptosomes was reduced to a 
comparable extent to that o f  [3H]D-aspartate, 68.7 ± 4.1 and 52.4 ± 5 . 1  % decrease in the 
presence o f TBOA or PDC, respectively (Fig 3.6).
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Figure 3.6: Sensitivity of |3H|L-glutamate and |3H]D-aspartate uptake into PFC 
synaptosomes to EAAT inhibitors
PFC P2 synaptosomes were incubated with 100 pM TBOA or PDC for 15 min before 
addition of 0.2 pM [3H]L-glutamate (red) or [3H]D-aspartate (green) for 15 min at 37 °C. 
Points represent the mean ± SEM from 3 separate experiments. Significantly different from 
control *p < 0.05, **p< 0.01 (one-way ANOVA, with post-hoc Dunnett’s test).
Figures 3.5 and 3.6 show the similarities o f  [3H]D-aspartate and [3H]L-glutamate 
uptake into rat PFC synaptosomes; however, they do not address whether the [3H]D-aspartate is 
being taken up into vesicles. Using the vesicle separation paradigm o f Christensen et al., (1990) 
synaptosomes were loaded with either [3H]D-aspartate or [3H]L-glutamate (200 nM) for 15 min 
at 37 °C, lysed in 0.1 mM EGTA, 10 mM Tris-maleate and centrifuged (17,000g; 10 min) to 
isolate the crude vesicle fraction as supernatant (Section 2.4.4). To confirm that this method was 
lysing the synaptosomes the ‘CytoTox-ONE™ Homogeneous Membrane Integrity Assay’ 
(lactate dehyrodgenase, LDH) was used. This assay confirmed the synaptosomes were lysed by 
0.1 mM EGTA, 10 mM Tris-maleate, as this sample contained 308.0 ± 19.5 % the LDH of 
control synaptosomes, which corresponded to 89.2 ± 7.3 % o f the Triton-X control (n = 3; data 
not shown).
Using these conditions significantly more [3H]D-aspartate than [3H]L-glutamate was 
incorporated into the vesicular fraction; 31.1 ± 1.6 and 24.1 ± 0.8 pmol/mg synaptosomal 
protein, respectively (p < 0.05, student’s t-test, n =3; Fig 3.7). These uptake values 
corresponded to 26.9 ± 5.1 % and 30.7 ± 0.3 % o f [3H]D-aspartate or [3H]L-glutamate uptake 
into synaptosomes, respectively. To control for [3H]amino acid attaching to membrane 
fragments the addition o f [3H]amino acid post-lysis was also examined (Section 2.4.4). Under 
these conditions[3H]D-aspartate and [3H]L-glutamate remaining on the filters was 10.6 ± 1.4 %
- 78-
CKj^(PTtE(R^3: Characterisation o f  nJ^Ch^mediated excitatory amino ac id  release from  <FFC synaptosomes
and 12.9 ± 3.0 % vesicle control, respectively (n = 4).
Uptake o f both [3H]D-aspartate and [3H]L-glutamate into the crude vesicular fraction 
were significantly reduced when the experiment was carried out at 4 °C, or in the presence o f 
TBOA. [3H]D-aspartate uptake into this fraction was decreased by 64.2 ±2.1 % at 4 °C and 55.6 
± 1.3 % in the presence o f TBOA (100 pM, 15 min preincubation; Fig 3.4). Similarly [3H]L- 
glutamate uptake into this fraction was decreased by 58.5 ± 2.3 % at 4 °C and 41.9 ± 1.3 % in 
the presence o f TBOA (Fig 3.7)
4 ’C TBOA 4 ’C TBOA
fH jL-G lutam ate fH jD -A spartate
Figure 3.7: [3H|L-glutamate and |3H |D-aspartate uptake into PFC vesicular fraction
PFC synaptosomes were incubated with 200 nM [3H]L-glutamate (red) or [’H]D-aspartate 
(green) at 37 °C in the absence or presence of 100 pM TBOA or at 4 °C. Synaptosomes 
were lysed, centrifuged and filtered; radioactivity remaining on the filters was converted to 
pmoles [3H]amino acid, points represent the mean ± SEM ffom 4 separate experiments 
carried out in duplicate. Significantly different to control *p < 0.05, **p < 0.01 (one-way 
ANOVA, with post-hoc Dunnett’s test).
These data show that [3FI]L-glutamate and [3H]D-aspartate are taken up into PFC 
synaptosomes/vesicles in a similar manner and reaffirm that [3H]D-aspartate is a suitable 
surrogate for [3H]L-glutamate for release experiments.
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3.2.4 (D-JLspartate versus L-QCutamate: % £t- and nicotine-evokedreCease from (PTC 
<P2 synaptosomes
The data thus far indicate that [3H]D-aspartate and [3H] L-glutamate behave in an 
analogous way when investigating uptake properties. However, these data do not confirm 
whether they are similar in terms of release. Using a KCI stimulus we measured [3H]D-aspartate 
and [3H]L-glutamate release ffom rat PFC P2 synaptosomes using superfusion (Section 1.6.3;
2.4.5).
As previously described in Section 3.2.2.3, synaptosomes were loaded with 200 nM 
[3H]D-aspartate or [3H] L-glutamate and superfused for 24 min prior to basal fraction collection 
(Section 2.4.5). Basal release was similar for both [3H]D-aspartate and [3H]L-glutamate, with the 
CPM values consistently in the range of 1800 -  2200 CPM, consistent with a similar level of 
basal release for both [3H]amino acids as the specific signal was similar for both.
Following 4 min of basal collection a 90 sec pulse of 12 mM KCI (Rousseau et al., 
2005) or buffer was added, separated ffom the bulk buffer flow by an air gap (2 sec). The [3H]d- 
aspartate or [3H] L-glutamate released by KCI or buffer was determined as described in Section 
2.4.5.1. Buffer-evoked release of [3H]D-aspartate or [3H]L-glutamate was not significantly 
different; 0.09 ± 0.01 and 0.10 ± 0.02 fractional release, respectively (n = 10). KCI (12 mM) 
consistently evoked both [3H]D-aspartate and [3H]L-glutamate release (Fig 3.8). However, the 
release of [3H]L-glutamate was significantly greater than that of [3H]D-aspartate (2.1 ± 0.2 
versus 1.4 ± 0.1 fractional release, corrected for buffer-evoked release, Fig 2.3; p  < 0.05, 
Student’s t-test, n = 4; Fig 3.8).
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Figure 3.8: KCl-evoked (3H]I.-glutamate and [3H]D-aspartate release from rat PFC
synaptosomes
PFC synaptosomes were loaded with 0.2 pM [’H] L-glutamate or [3H]D-aspartate, 
superfused with KB and stimulated with a 90 s pulse of 12 mM KCI. A: Representative 
profiles of [3H]L-glutamate or [3H]D-aspartate (green) release in response to stimulation by 
a 90 s pulse of 12 mM KCI. B: 12 mM KCl-evoked [3H]L-glutamate or [3H]D-aspartate 
(green) release (red); data are shown as fractional release, adjusted for buffer-evoked 
release, bars represent the mean ± SEM from 4 separate experiments. Significantly different 
to evoked [3H]L-glutamate release, *p < 0.05, Student’s t-test.
As the focus o f this thesis is nAChR-mediated EAA release we next looked at the 
ability o f nicotine to induce [3H]L-glutamate and [3H]D-aspartate release. As previously reported 
for frontal cortex synaptosomes (Rousseau et al., 2005) nicotine (10 -  300 pM) consistently 
evoked [3H]D-aspartate release from PFC synaptosomes (Fig 3.9). Nicotine-evoked [3H]D- 
aspartate release from PFC synaptosomes was concentration-dependent, with [3H]D-aspartate 
release evoked by 300 pM nicotine being over double that measured following stimulation with 
10 pM nicotine stimulation (0.67 ± 0.1 versus 0.30 ± 0.09 fractional release; Fig 3.9). 
Interesting the shape o f the release profile also altered with increasing nicotine concentration. 
Whilst the majority o f [3H]D-aspartate release evoked by 10 pM nicotine-evoked was located in 
one fraction, the 300 pM nicotine-evoked release was equally distributed across two fractions 
(Fig 3.9). Nicotine (< 300 pM)-evoked [3H]D-aspartate release was significantly lower than 12 
mM KCl-evoked release. Concentrations o f nicotine higher than 300 pM were not investigated 
due to the possible non-selective actions o f this compound at higher concentrations.
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Figure 3.9: Nicotine-evoked |3H|D-aspartate release from rat PFC synaptosomes
PFC synaptosomes were loaded with 0.2 pM [ H]D-aspartate, superfused with KB and 
stimulated with a 90 s pulse of varying concentrations of nicotine. A: Representative 
profiles of [’H]D-aspartate release following stimulation with buffer (grey) 10 pM nicotine 
(blue) or 300 pM nicotine (green). B Concentration-response curve for nicotine-evoked 
[JH]D-aspartate release, data are shown as fractional release, adjusted for buffer-evoked 
release; points represent the mean ± SEM from at least 4 separate experiments. 
Significantly different to buffer alone release, *p < 0.05, **p <0.01; Student’s t-test.
Although nicotine consistently evoked [3H]D-aspartate release, nicotine failed to elicit 
robust [3H]L-glutamate release. Nicotine evoked release from an individual experiment 
(triplicates) were consistent, however, on average 50 % o f the experiments using [3H]L- 
glutamate failed to give a measurable response (Fig 3.10). We tried to overcome this variability 
between individual experiments by altering variables;
• KCI content o f the KB was doubled (2.4 -  4.8 mM) as a higher concentration has been 
used in previous [3H]L-glutamate release experiments (Kamisaki et al., 1995; Nishihara 
et al., 1995; Bonanno et al., 1997).
•  Stimulation and fraction collection time were both decreased, in case we were unable to 
detect a smaller, consistent, response with the original timings (Westphalen and 
Hemmings Jr, 2003).
•  Previous studies have used different loading concentrations o f [3H]L-glutamate, so we 
investigated a range o f loading concentrations from 4 -  200 nM, the amount o f  protein 
loaded in to each o f the wells was also altered (Rodriguez et al., 1997; Raiteri et al., 
2001; Marchi et al., 2002)
•  To ensure [3H]L-glutamate was not taken up by the synaptosomes before being 
collected TBOA was added throughout the superfusion experiment.
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However, in all cases the data still remained inconsistent. Using data solely from those 
experiments that gave results, nicotine (300 pM)-evoked release o f [3H]L-glutamate or [3H]D- 
aspartate is not significantly different (0.50 ± 0.2 and 0.67 ± 0.1 fractional release, respectively). 
However, the large variation between individual experiments meant using [3H]L-glutamate was 
not viable. Therefore [3H]D-aspartate has been used as a surrogate for [3H]L-glutamate 
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Figure 3.10: Nicotine-evoked [3H|L-glutamate release from rat PFC synaptosomes
PFC synaptosomes were loaded with 0.2 pM [3H]L-glutamate, superfused with KB and 
stimulated with a 90 s pulse of 300 pM nicotine. A, B: Representative profiles, points 
represent the mean ± SEM of triplicate determinates from identical experiments carried out 
on two consecutive days.
3.2.5 (pfarmacotogicaCcharacterisation o f nftCh^evo^ecfpfffo-aspartate reCease
3.2.5.1 Nicotine
Having confirmed that nicotine evokes [3H]D-aspartate release from rat PFC 
synaptosomes (Fig 3.9) experiments with nAChR antagonists were carried out to determine the 
nAChR subtypes mediating this response. [3H]D-aspartate release evoked by either 10 or 300 
pM nicotine was markedly attenuated in the presence o f mecamylamine (20 pM; 98.6 ± 4.4 and
84.4 ± 11.9 % decrease, respectively), consistent with nicotine acting at nAChRs (Fig 3.11). 
However, as previously reported for frontal cortex synaptosomes (Rousseau et al., 2005) 10 and 
300 pM nicotine-evoked [3H]D-aspartate release ffom PFC synaptosomes were differentially 
sensitive to aBgt. Whilst 10 pM [3H]D-aspartate release was significantly inhibited by aB gt 
(79.6 ± 16.0 % decrease o f  control); 300 pM nicotine-evoked release was unaltered in the 
presence o f aBgt (13.6 ±  16.4 % decrease o f  control; Fig 3.11).
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Figure 3.11: nAChR pharmacology of nicotine-evoked [3H|D-aspartate release from
rat PFC synaptosomes
PFC synaptosomes were loaded with 0.2 pM [’H]D-aspartate, superfiised with KB and 
stimulated with 10 or 300 pM nicotine. A: Representative profiles 10 pM nicotine-evoked 
release in the absence (grey line) or presence (green line) of aBgt (40 nM). B: 10 or 300 
pM nicotine in the presence or absence of aBgt (40 nM, 40 min preincubation) or 
mecamylamine (mec, 20 pM, 10 min incubation); bars represent the mean ± SEM from 4 
independent experiments, significantly different to appropriate control **p <0.01, one-way 
ANOVA, with post-hoc Dunnett’s test.
To further explore a l  and non-a7 nAChR-mediated [3H]D-aspartate release we have 
utilised subtype-selective agonists.
3.2.5.2 C om pound
The sensitivity o f  10 pM nicotine-evoked [3H]D-aspartate release to aBgt suggests the 
presence o f a l  nAChR capable o f  mediating [3H]D-aspartate release in the PFC. Here we have 
used compound A to further characterise this response. Initial experiments were carried out to 
determine the IC5o o f compound A on [125I]aBgt binding. PFC membranes (75 pg) were 
incubated with 1 nM [125I]aBgt and serial dilutions o f compound A (1 fM -  100 pM; Fig 3.12). 
Compound A displaced [125I]aBgt binding to rat PFC membranes with a IC5o value o f 94.8 ± 2.8 
nM (Fig 3.12).
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Fig 3.12 Compound A inhibition of | ,25IlaBgt 
binding to rat PFC P2 membranes
P2 membranes were incubated with 1 nM 
[125I]aBgt and serial dilutions of compound A as 
described in the Methods. Data points were 
calculated as % of total specific binding in the 
absence of compound A and were fitted to the 
Hill equation. Each point represents the mean ± 
SEM of at least three experiments, each 
conducted in triplicate.
L o g 10 [C o m p o u n d  A] M
Compound A applied to PFC synaptosomes, preloaded with 0.2 pM  [3H]D-aspartate 
produced a very potent bell-shaped concentration-response (Fig 3.13); with concentrations <10' 
17 and >10'6 M not producing measurable [3H]D-aspartate release (Fig 3.13). The nAChR 
subtypes mediating [3H]D-aspartate release evoked by 10 nM and 1 pM compound A was 
investigated.
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Fig 3.13 Compound A-evoked [3H|D-aspartate 
release from PFC P2 synaptosomes
PFC synaptosomes were loaded with 0.2 pM 
[3H]D-aspartate, superfused with KB and 
stimulated with compound A. Points represent the 
mean ± SEM from at least 3 independent 
experiments.
The presence o f the a7 nAChR antagonist aBgt significantly reduced [3H]D-aspartate 
release evoked by both 10 nM and 1 pM  compound A (Fig 3.14). Both concentrations o f 
compound A were equally sensitive to aBgt; 75.1 ± 9.0 and 70.2 ± 14.5 % inhibition o f 10 nM 
and 1 pM compound A-evoked [3H]D-aspartate release, respectively (Fig 3.14). Mecamylamine 
(20 pM) decreased [3H]D-aspartate release evoked by 10 nM and 1 pM compound A; 75.1 ± 9.0 
and 70.2 ± 14.5 % inhibition, respectively (Fig 3.14). This decrease was not significantly 
different to that seen in the presence o f aBgt (Fig 3.14).
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Figure 3.14: Compound A mediated |3H]D-aspartate release from rat PFC
synaptosomes
P2 PFC synaptosomes were loaded with 0.2 pM [3H]D-aspartate, superfused with KB and 
stimulated with 10 nM or 1 pM compound in the presence or absence of nAChR 
antagonists. A, C: Profiles of [’H]D-aspartate release in response to stimulation with a 90 s 
pulse of 10 nM or 1 pM compound A in the absence (dark green) or presence (light green) 
of 40 nM aBgt. B, D: nAChR pharmacology of 10 nM and 1 pM compound A-evoked 
[3H]D-aspartate release from rat PFC synaptosomes. Synaptosomes were stimulated by a 90 
s application of compound A in the presence or absence of aBgt (40 nM), DHpE (1 pM) or 
mecamylamine (Mec, 20 pM). Where present antagonist was introduced into the perfusing 
buffer 10 min (Mec, DHpE ) or 30 min (aBgt) before agonist application and remained 
throughout the experiment. Responses were calculated as fractional release and expressed 
as a percentage of the respective agonist control; bars represent the mean ± SEM of at least 
four independent experiments. Significantly different from control **p < 0.01; one-way 
ANOVA, with post hoc Dunnetf s analysis.
Compound A-evoked [3H]D-aspartate release from PFC synaptosomes was insensitive 
to 1 pM DHpE (89.32 ± 2.2 and 102.9 ± 8.9 % o f 10 nM and 1 pM compound A controls, 
respectively, Fig 3.14), confirming that at both o f these agonist concentrations compound A was 
mediating [3H]D-aspartate release by activation o f a7 nAChRs.
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3.2.5.3 W V 120596
Section 5.2.3 reports the dramatic increase in a7 nAChR-mediated increases in 
intracellular Ca2+ following pre-incubation with the a7 nAChR positive modulator PNU 120596 
(Hurst et al., 2005). PNU 120596 (0.1 -  100 pM) did not inhibit [125I]aBgt binding to PFC P2 
membranes (data not shown). The addition o f a 90 s pulse o f 10 pM PNU 120596 to superfused 
P2 PFC synaptosomes did not alter [3H]D-aspartate release compared to buffer-evoked release 
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Figure 3.15: |3H|D-aspartate release evoked from P2 PFC synaptosomes by compound
A plus PNU 120596
P2 PFC synaptosomes were loaded with 0.2 pM [3H]D-aspartate and superfused with KB in 
the presence or absence of modulators. A Profiles of [3H]D-aspartate release in response to 
stimulation with a 90 s pulse of 10 nM compound A in the absence (dark green) or presence 
(dark blue) of 10 pM PNU 120596 (2 min preincubation), grey line shows response to 10 
pM PNU 120596 alone. Points represent the mean ± SEM of triplicate determinates from a 
single experiment. B nAChR pharmacology of 10 nM compound A plus 10 pM PNU 
120596-evoked [3H]D-aspartate release from rat PFC synaptosomes. Synaptosomes were 
incubated with PNU 120596 for 2 min before stimulation by a 90 s application of 10 nM 
compound A or in the presence or absence of aBgt (40 nM) or mecamylamine (Mec, 20 
pM). Where present antagonist was introduced into the perfusing buffer 10 min (Mec) or 30 
min (aBgt) before agonist application and remained throughout the experiment. Responses 
were calculated as fractional release and expressed as a percentage of the respective agonist 
control; bars represent the mean ± SEM of at least three independent experiments. 
Significantly different from control **p <0.01; one-way ANOVA, with post hoc Tukey’s 
analysis.
Pre-incubation with 10 pM PNU 120596 for 2 min significantly enhanced [3H]D- 
aspartate release evoked by 10 nM compound A (212.5 ± 12.5 % Fig 3.15). Interestingly the 
addition o f PNU 120596 altered the temporal profile o f [3H]D-aspartate release, broadening the 
peak o f release. [3H]D-aspartate evoked by 10 nM compound A is collected in one fraction (Fig
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3.14-15), however, in presence o f PNU 120596 this release is spread over two fractions (Fig 
3.15). This release was abolished in the presence o f mecamylamine or aBgt (93.8 ± 12.7 and
93.5 ± 9.6 % inhibition, respectively; Fig 3.15).
3.2.5A 5-Iodo-A-85380
Previous studies in this laboratory using nicotine and selective antagonists implicated 
the involvement o f (32* nAChRs in [3H]D-aspartate release from frontal cortex synaptosomes 
(Rousseau et al., 2005). Here we have furthered this work using PFC synaptosomes and the 02* 
nAChR selective agonist 5-iodo-A-85380 (5-I-A-85380; Mukhin et al., 2000). Initial 
experiments were carried out to determine the affinity o f 5-I-A-85380 at a7 nAChRs using 
[125I]aBgt competition binding to PFC P2 membranes. 5-I-A-85380 displaced [125I]aBgt binding 
to rat PFC membranes with a IC5o value o f 32.0 ±1.1 pM  (Fig 3.16). This IC5o value is over two 
magnitudes o f order greater than that seen for compound A (94.8 nM; Fig 3.12) and suggests 
that 5-I-A-85380 has a relatively low affinity for a l  nAChRs
120
o> 100 Fig 3.16: 5-I-A-85380 inhibition o f*—
r~ | ,25IJaBgt binding to rat PFC P2 membranes
m 80 P2 membranes were incubated with 1 nM
o>
rr»
[125I]aBgt and serial dilutions of 5-1-A-85380
CD 60 as described in the Methods. Data points were
40
calculated as % of total specific binding in the
2 absence o f compound A and were fitted to the
ov- 20
0
Hill equation. Each point represents the mean ±
3? SEM of at least three experiments, each 
conducted in triplicate.
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L o g io  [5-lodo-A -85380] M
As seen with frontal cortex synaptosomes (Rousseau et al., 2005) 5-I-A-85380 evoked 
[3H]D-aspartate release from PFC synaptosomes in a concentration-dependent manner (Fig 
3.17). As previously seen for [3H]D-aspartate release evoked by 300 pM  nicotine, but not 
compound A (10 nM or 1 pM), 5-I-A-85380-evoked release had a broad release profile, 
spanning two fraction collections (Fig 3.18A, C).




i s  ® 0)
i s






Fig 3.17: 5-I-A-85380-evoked (3H|D- 
aspartate release from PFC P2 synaptosomes
PFC synaptosomes were loaded with 0.2 pM 
[3H]D-aspartate, superfused with KB and 
stimulated with 5-I-A-85380. Points represent 
the mean ± SEM from at least 3 independent 
experiments.
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L o g 10 [5-I-A-85380] M
Using nAChR antagonists we characterised the [3H]D-aspartate release evoked by both 
10 nM and 10 pM 5-I-A-85380. [3H]D-aspartate release evoked by 10 nM 5-I-A-85380 was 
insensitive to aBgt (109.1 ± 15.9 % o f control; Fig 3.18A, B); but blocked to a similar extent by 
both mecamylamine and DHpE (80.0 ± 5.9 and 82.3 ± 10.2% decrease, respectively, Fig 3.18A, 
B). In contrast 10 pM  5-I-A-85380-evoked [JH]D-aspartate release was reduced in the presence 
o f aBgt (35.4 ± 13.9 % inhibition, Fig 3.18C, D), although this was not statistically significant 
(one-way ANOVA with post-hoc Dunnett’s test; n = 3). Both DHpE and mecamylamine 
significantly reduced 10 pM 5-I-A-85380-evoked [3H]D-aspartate release, however, the 
inhibition produced by mecamylamine was greater than that produced by DHpE (51.1 ±  3.9 and 
72.9 ± 4.7 % inhibition, respectively, Fig 3.18C, D).
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Figure 3.18: 5-I-A-85380 mediated (3H|D-aspartate release from rat PFC
synaptosomes
PFC synaptosomes were loaded with 0.2 pM [3H]D-aspartate and superfiised with KB in the 
presence or absence of nAChR antagonists. A, C: Profiles of [’H]D-aspartate release in 
response to stimulation with a 90 s pulse of 10 nM or 10 pM 5-I-A-85380 alone (dark red) 
or in the presence of 40 nM aBgt (light green) or 1 pM DHPE (light red), points represent 
the mean ± SEM of triplicate determinates from one experiment. B, D: nAChR 
pharmacology of 10 nM and 10 pM 5-I-A-85380-evoked [JH]D-aspartate release from rat 
PFC synaptosomes. Synaptosomes were stimulated by a 90 s application of A, B: 10 nM or 
C, D: 10 pM; 5-I-A-85380 in the presence or absence of aBgt (40 nM), DHPE (1 pM) or 
mecamylamine (Mec, 20 pM). Where present antagonist was introduced into the perfusing 
buffer 10 min (Mec, DHpE) or 30 min (aBgt) before agonist application and remained 
throughout the experiment. Responses were calculated as fractional release and expressed 
as a percentage of the respective agonist control; bars represent the mean ± SEM of at least 
four independent experiments. Significantly different from control *p < 0.05 **p < 0.01; 
one-way ANOVA, with post hoc Dunnett’s analysis.
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3.2.6 %\CC-evo^ed[3fC](D-aspartate reCease
KC1 is used as a comparative stimulus throughout this thesis. KC1, which causes 
depolarisation, is widely used to study neurotransmitter release with most studies measuring 
excitatory amino acid release from synaptosomes using 12 -  35 mM (Simonato et al., 1993; 
Muzzolini et al., 1997; Pereira et al., 2002b; Rousseau et al., 2005). A KC1 concentration- 
response curve for evoked [3H]D-aspartate release was generated to determine the KC1 
concentration that produces a similar level o f  [3H]D-aspartate release to a7 and |32* nAChR- 
mediated release (Fig 3.14). 8 mM KC1 produced a comparable level o f  [3H]D-aspartate to that 
seen following application o f 10 nM compound A or 5-I-A-85380 (0.37 ± 0.03 versus 0.38 ± 
0.01 and 0.31 ± 0.01 % fractional release, respectively, Fig 3.19); this response was also similar 
in magnitude to 10 pM  nicotine (Fig 3.19) Therefore, this concentration has been used 
throughout the rest o f  this thesis.
A B
Nic (nM) KCI (mM)
Figure 3.19: KCl-mediated |3H|D-aspartate release from PFC synaptosomes
P2 synaptosomes loaded with 0.2 pM [3H]D-aspartate were superfused with KB and 
stimulated with A: KB containing increasing concentrations of KCI; points represent the 
mean ± SEM of at least three experiments. B: Fractional release of [3H]D-aspartate from rat 
PFC synaptosomes, evoked by nicotine (10 and 300 pM), 10 nM compound A (CA), 10 nM 
5-I-A-85380 (5-I-A) and KCI (8 and 12 mM). Bars represent the mean ± SEM of at least 
three independent experiments.
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3.3 (Discussion
3.3.1 Summary
The results in this have chapter have:
• Shown the similarities between P2 and Percoll™ purified PFC synaptosomes using 
confocal/electron microscopy as well as the [3H]D-aspartate release (superfusion) assay, 
confirming the presence of glutamatergic terminals in both samples and concluding that 
P2 synaptosomes are a suitable preparation for studying the mechanisms of presynaptic 
nAChR-mediated neurotransmitter release.
• Substantiated that [3H]D-aspartate behaves in an analogous manner to [3H]L-glutamate 
in both uptake and release assays, thereby validating the use of [3H]D-aspartate as a 
surrogate for L-glutamate in release assays.
• Confirmed the presence of the a7 nAChR in PFC P2 membranes. The abundance of this 
receptor was shown to be significantly greater in this region than whole brain, 
consistent with nicotine eliciting some of its cognitive effects via the a7 nAChR in the 
PFC.
• Demonstrated that nicotine can evoke [3H]D-aspartate release from PFC P2 
synaptosomes by activating both a l and (32* nAChRs, thereby confirming the presence 
of multiple subtypes of functional presynaptic nAChRs on glutamatergic terminals in 
this region. These data also confirmed that selective a l and P2* nAChRs agonists can 
evoke [3H]D-aspartate release from PFC P2 synaptosomes.
3.3.2 nfLCfoRy in the (PTC
Nicotine has been shown to enhance cognitive processes associated with the PFC 
(Section 1.2.3); however, the presence and relative abundance of nAChR subtypes in this 
anterior region has been relatively overlooked (Section 1.3.3). Studies using mRNA probes and 
[3H]MLA/[125I]aBgt autoradiography/saturation binding (Clarke et al., 1985; Seguela et al., 
1993; Whiteaker et al., 1999; Terry Jr et al., 2000; Rasmussen and Perry, 2006) have shown a l 
nAChRs to be present throughout the mammalian brain, with the highest levels being located in 
the hippocampus, olfactory regions and cerebral cortex (layers I, IV, V and VI). Whilst some 
studies have revealed strong [,25I]aBgt binding in the PFC using autoradiography (Willcox et al, 
in preparation, Clarke et al 1985), [125I]aBgt saturation binding levels for the PFC have not 
previously been reported. The presence of a l nAChRs in the PFC was confirmed in this project
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using [125]aBgt saturation binding. The levels of [125I]aBgt binding and the predicted Kd values 
for Spague-Dawley hippocampus, whole brain and cortex are comparable to those reported by 
Davies et al., (1999). In accordance with previous reports these data show the hippocampus to 
contain the largest density of [125]aBgt binding sites out of the regions tested (Sargent, 2000), 
the PFC was also relatively enriched with [,25I]aBgt binding sites, containing significantly more 
[,25I]aBgt binding sites than whole brain and 25 % more than the rest of the cortex.
The abundance of non-a7 nAChR subunits in PFC P2 synaptosomes and tissue 
prepared in Bath was investigated in Dr Cecilia Gotti’s laboratory (Milan, Italy) using nAChR 
subtype immunoprecipitation experiments (Vailati et al., 1999). The results of these experiments 
are shown in Table 3.2, the presence of the a.7 nAChR subunit was not examined using this 
method due to antibody constraints (Jones and Wonnacott, 2005). As discussed in Section 1.3.2, 
the near total ablation of [3H]nicotine binding in the brains of a4 or p2 nAChR subunit knock 
out mice (Picciotto et al., 1995; Marubio et al., 1999) confirmed earlier postulations that the 
a4p2 nAChR is the predominant heteromeric subtype in the brain (Whiting and Lindstrom, 
1987; Whiting et al., 1991). Therefore it is perhaps not surprising that these two subunits are the 
most abundant within both PFC P2 synaptosomes and tissue. The amount of a4 and p2 nAChR 
subunit protein detected in these experiments were comparable, this, combined with the absence 
of P3 and p4 nAChR subunit protein is in accordance with these subunits forming an a4p2* 
nAChR. Whilst these data suggest the a4p2 nAChR is the predominant heteromeric nAChR 
subunit in the PFC the presence of small, but significant, levels of a3 and a5 nAChR subunit 
protein indicates that these nAChR subunits may also play an important role in nAChR- 
mediated responses in the PFC. As discussed in Section 1.3.2 the a5 nAChR subunit does not 
form a functional nAChR when expressed alone or with any p nAChR subunit. However, 
consistent with its role as a ‘scaffolding’ nAChR subunit, the a5 nAChR can form functional 
nAChR when expressed with a and p nAChR subunits (Ramirez-Latorre et al., 1996). Whilst 
the addition of this subunit does not alter epibatidine binding kinetics it does lower the 
activation and desensitisation threshold of the resulting nAChR (Ramirez-Latorre et al., 1996; 
Wang et al., 1996) In contrast the a3 nAChR subunit can form functional nAChRs when 
expressed with either the p2 or p4 nAChR subunit. The lack of p4 nAChR subunit protein in the 
PFC (Table 3.2) suggests that the a3 nAChR is likely to be associated with the P2 nAChR 
subunit, perhaps in association with other nAChR subunits. Although it is hard to conclude from 
these data in which neurones these nAChR subunits reside, the relatively low expression of both 
a3 and a5 in the brain in general (Table 1.1) is consistent with the hypothesis that the a3* 
nAChRs may be located on glutamatergic projections from thalamic nuclei and/or dopaminergic 
projections from the VTA whereas the a5* nAChRs are more likely to be preferentially located 
on dopaminergic neurones projecting from the VTA or substantia nigra (Table 1.1 and Fig 1.2). 
In conclusion it is possible to hypothesise from these data that the a4p2 nAChR is primary
- 93 -
Characterisation o f  nJft.Cf'R:. m ediated'excitatory amino acid'refeasejrom  (ixFC synaptosomes
heteromeric nAChR in the PFC, however, there may also be a302, a3a402, a4a5p2 and a3a5p2 
nAChRs present.
Table 3.2: nAChR subunit levels (fmol/mg protein) in PFC synaptosomes and tissue, this work was 
carried out in collaboration with C. Gotti (n = 4).
Tissue Synaptosomes
a l 0.0 2.4 ± 2
o3 10.4 ±1.96 9.6 ±2.3
a4 86.2 ± 6.7 101.0 ±6.3
a5 11.1 ±2.97 18.7 ± 1.4
a6 3.4 ±2.5 3.7 ±2.0
02 99.2 ± 5.9 106.3 ± 7.9
03 0.12 ±0.12 0
04 1.9 ± 1.2 3.4 ±2.3
Synaptosomes and tissue were also prepared in parallel from the striatum for 
immunoprecipitation experiments. Consistent with previous data from Dr Gotti’s laboratory, 
which reported that approximately 90 % of nAChRs in the rat striatum contained the p2 nAChR 
subunit (Zoli et al., 2002), the p2 subunit was the most abundant p nAChR subunit and was 
detected as a similar level to that seen in the PFC. The level of a4 nAChR protein in the 
striatum was also consistent with that seen in the PFC, however, in the striatum there was also a 
significant quantity of a6 , p3 and p4 nAChR subunit protein that was not identified in the PFC. 
The presence of these subunits was expected, as previous experiments have shown the nAChR 
population in the striatum is comprised of approximately 70 % a4p2* and 20 % a4a6p2*; with 
the latter being expressed solely on dopaminergic neurones (functional data Zoli et al., 2002). 
The lack of a 6  nAChR subunit protein in the PFC is in agreement with pharmacological data 
indicating a lack of involvement o f a6p2* nAChRs in dopamine release in this region 
(Livingstone et al., in preparation).
The PFC P2 synaptosomes sent to C. Gotti are analogous to those used to study 
presynaptic nAChR-mediated [3H]D-aspartate release in this Chapter and Chapter Four. As 
shown in Table 3.2, the levels of nAChR subunits in both P2 synaptosomes and tissue from the 
PFC are very similar, consistent with the majority of the nAChR subunits present in the PFC
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residing in the P2 fraction. Although it is important to remember that the P2 sample will contain 
membrane fragments and post-synaptic densities, these data are consistent with a current mode 
of thought that the majority of the nAChRs are presynaptic (Wonnacott, 1997; Sher et al., 2004) 
where they can function to modulate neurotransmitter release.
3.3 .3  <P2 versus (PercoCP™ ■purified<FFC synaptosomes
At the start of this project we set out to compare P2 versus Percoll™ purified PFC 
synaptosomes and verify the use of P2 synaptosomes. The process of tissue homogenisation, in 
an isotonic solution results in membrane disruption at points of low resistance or high stress. In 
the case of brain tissue homogenisation gives rise to synaptosomes, formed by the shearing off 
of nerve terminals, as well as membrane fragments and subcellular organelles (Nicholls, 2003). 
Synaptosomes can be separated out of the homogenate using differential centrifugation. A low 
( 1 0 0 0  g) speed centrifugation serves to pellet the majority of cell debris and nuclei, whilst 
synaptosomes, myelin and mitochondria remain in the Si fraction. Centrifugation of Sj at a 
higher (2 0 , 0 0 0  g) speed produces a pellet containing synaptosomes, myelin and mitochondria: 
the P2 synaptosome preparation. This P2 pellet can be further purified using a sucrose gradient.
Traditionally sucrose gradients formed with 0.8 M and 1.2 M sucrose are used to 
resolve the constituents of the resuspended P2 pellet (Gray and Whittaker, 1962). The relatively 
light myelin fraction remains at the top of the gradient, whilst the mitochondria and 
synaptosomes become separated due to their relative water content, whilst mitochondria 
sediment through the 1.2 M sucrose, following dehydration, the synaptosomes form a layer at 
the 0.8/1.2 M interface. However, this method is not ideal due to the hypertonicity of the 
sucrose that can cause alteration of the synaptosomes’ cytoskeleton, ultimately resulting in 
shrinkage (Day et al., 1971). This has been overcome using gradients composed of increasing 
densities of Percoll™. Percoll™ consists of 15 -  30 nM silica particles which are coated in 
polyvinylprrolidone (PVP), rendering them non-toxic. The Percoll™ separation method 
(Dunkley et al., 1986) produces five separate fractions. Biochemical and microscopy analysis 
has previously shown fraction 4 to be the most enriched in synaptosomes, whilst containing the 
lowest level of myelin, extrasynaptosomal mitochondria and plasma membranes (Dunkley et al., 
1988; Thome et al., 1991). As such we used this fraction, isolated from rat PFC and referred to 
as ‘Percoll™’ is our comparison experiments with P2 synaptosomes.
As previously reported by Dunkley et al., (1988) preliminary electron microscopy 
studies showed both the P2 and Percoll™ fractions to be remarkably similar, both being highly 
enriched with synaptosomes containing vesicles, as well as containing mitochondria. In both
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cases the synaptosomes were similar in size, shape and general morphology, however, the P2 
synaptosomes tended to have more membrane fragments in the fields of view examined than the 
Percoll™ synaptosomes, although this difference was not quantified. The similarity of the P2 
and Percoll™ fractions is surprising given the separation of an Sj fraction on a Percoll™ 
gradient produces multiple fractions with distinct morphology when examined using electron 
microscopy (Dunkley et al., 1988). However, the methodology used may explain these 
similarities. Both P2 and Percoll™ synaptosomes were embedded by layering the solutions onto 
Durocopan resin and subsequent sedimentation. Sections were then taken from the bottom of the 
resin block for analysis (Section 2.4.10.1). Due to the heterogeneity of the synaptosome 
preparations it is possible that this method of embedding will have resulted in a differential 
distribution of the synaptosomes. Therefore it is possible that the sections viewed are not 
representative; however, it is clear from these preliminary studies that both P2 and Percoll™ 
synaptosome preparations contain synaptosomes, identified by the inclusion of a large amount 
of vesicles, as well as the presence of mitochondria and ER-like organelles.
Although the PFC is a region widely regarded as having a relatively high glial cell -  
neurone ratio (Sherwood et al., 2006) the level of GFAP-positive structures in both PFC P2 and 
Percoll™ synaptosomes was minimal in relation to synaptophysin-positive structures (Fig 3.3). 
Of primary importance was the similarity seen in the ratio of GFAP- to synaptophysin-positive 
structures in both the P2 and Percoll™ synaptosomes. The majority of these synaptophysin- 
positive structures were glutamatergic terminals as determined by co-labelling with VGluT 
markers, consistent with the well established role of glutamate as a neurotransmitter in the 
cortex, as described in Section 1.6. In accordance with data from our laboratory (Willcox et al., 
in preparation) VGluT2-postive structures were less abundant than VGluT 1 in both the P2 and 
Percoll™ synaptophysin-labelled synaptosomes. These experiments show that the proportion of 
synaptophysin- to VGluT 1- and VGluT2-positive structures was comparable in both the P2 and 
Percoll™ synaptosomes.
The use of confocal and electron microscopy highlighted the similarities between P2 
and Percoll™ PFC synaptosomes. We have previously demonstrated that KCI can evoke [3H]D- 
aspartate release from P2 frontal cortex synaptosomes (Rousseau et al., 2005). 12 mM KCI 
evoked [3H]D-aspartate release from both P2 and Percoll™ synaptosomes. Although baseline 
release for Percoll™ PFC synaptosomes was slightly lower than that of P2 PFC synaptosomes, 
probably due to the presence of more ‘leaky’ synaptosomes in the less refined P2 preparation, 
fractional [3H]D-aspartate release evoked by KCI was not significantly different for either the P2 
or Percoll™ PFC synaptosomes.
The ease of preparation and the similarities of P2 and Percoll™ PFC synaptosomes in
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the preliminary experiments carried out, underlie the decision to use P2 PFC synaptosomes 
throughout the rest of this project.
3.3.4 (D-aspartate as a surrogate fo r  L-gCutamate
[3H]D-aspartate is widely used as a surrogate for [3H]L-glutamate in both release 
experiments and localisation experiments (Section 1.6.3.1), indeed we have previously used 
[3H]D-aspartate as a surrogate for [3H]L-glutamate (Rousseau et al., 2005). However, the 
suitability of this surrogate has previously been questioned due to a lack of evidence for 
vesicular packaging of D-aspartate and its subsequent Ca2+-dependent release (Nicholls, 1989; 
Zhou et al., 1995). In response to these concerns Fleck et al., (2001) demonstrated that D- 
aspartate and L-glutamate were both taken up into a vesicular pool, substantiating the use of D- 
aspartate as a surrogate for L-glutamate. We have confirmed these findings, using a crude 
vesicular fraction isolated from PFC synaptosomes. Uptake of both [3H]D-aspartate and [3H]L- 
glutamate into PFC synaptosomes and subsequently PFC vesicles was via the EAATs and 
temperature-dependent. Consistent with the findings of Fleck et al., (2001) approximately 30 % 
of either the [3H] D-aspartate or [3H] L-glutamate taken up into the PFC synaptosomes was 
located in the crude vesicle preparation. The similarities of both [3H]D-aspartate and [3H]L- 
glutamate uptake substantiates the use of [3H]D-aspartate as a surrogate for [3H]L-glutamate.
Further support for the use of [3H]D-aspartate as a marker for glutamate release is 
provided by the comparative superfusion experiments. [3H]D-aspartate and [3H]L-glutamate 
release elicited following application of KCI (12 mM) was comparable (2.1 ± 0.2 and 1.4 ± 0.1 
fractional release, respectively). The temporal KCl-evoked [3H]D-aspartate and [3H]L-glutamate 
release profiles were also similar, further validating the use of [3H]D-aspartate as a surrogate for 
[3H]L-glutamate in release studies.
Previous studies of nicotine-evoked [3H]D-aspartate or endogenous L-glutamate release 
have indicated the requirement for a concurrent stimulation, with application of 5- 
hydroxyindole (Grilli et al., 2006), ATP (Patti et al., 2006), KCI (Marchi et al., 2002), 4- 
aminopyridine (Wang et al., 2006) or electrical current (Beani et al., 2000; Rousseau et al., 
2005). However, Rousseau et al., (2005) previously reported that nicotine alone can elicit [3H]D- 
aspartate release from frontal cortex synaptosomes. In accordance with these previous findings 
for frontal cortex synaptosomes, nicotine evoked [3H]D-aspartate release in a concentration- 
dependent manner. [3H]D-aspartate release following nicotine application is relatively small; 
this is particularly apparent when comparing nicotine-evoked release to KCl-evoked release. 
Whilst most excitatory amino acid release studies use 12-35 mM KCI stimulation (Simonato et
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al., 1993; Muzzolini et al., 1997; Pereira et al., 2002b; Rousseau et al., 2005) here we have 
shown here that nicotine-evoked excitatory amino acid is more comparable to release evoked by 
8  mM KCI, the lowest concentration to significantly increase release above basal (Fig 3.19). 
Our ability to consistently measure such a low level of excitatory amino acid release following 
application of nicotine stimulation may explain the discrepancy between our results and those of 
other authors who report the need for a concurrent stimulation (Beani et al., 2000; Marchi et al., 
2002; Grilli et al., 2006; Patti et al., 2006). Indeed Patti et al (2007) recently stated that 
epibatidine did not evoke [3H]D-aspartate release from cortical synaptosomes, whilst showing in 
the text that it increased [3H]D-aspartate release by ~ 0.2 %. The responses to nicotine (10 pM) 
in this project are not substantially different to this value (0.3 %; Fig 3.9) and yet are 
statistically significant compared to buffer controls and consistently blocked by nAChR 
antagonists. Our capability of measuring these responses is probably explained by the increased 
sensitivity of the modified Brandel superfusion system used in these experiments (Soliakov et 
al., 1995).
Interestingly, although KCI (12mM)-evoked [3H]D-aspartate and [3H] L-glutamate 
release were comparable, there were substantial differences in nicotine-evoked release. Whilst 
nicotine consistently evoked [3H]D-aspartate release, results for [3H]L-glutamate were highly 
variable. As the initial [3H]D-aspartate versus [3H]L-glutamate experiments were carried out 
with 12 mM KCI it is possible that it is more difficult to reproducibly detect such small changes 
in [3H]L-glutamate. Of course there are also other factors and variables. [3H]L-glutamate release 
may be more sensitive than [3H] D-aspartate to small day-to-day variations in making drugs and 
buffers. The readiness of [3H]L-glutamate, but not [3H]D-aspartate, to undergo metabolic 
conversion may also cause this marker to be more affected by small changes in the rats’ 
environment prior to being culled due to subsequent alteration of the neuronal metabolic rate. It 
is, however, reassuring to note that when there was nicotine-evoked release of [3H] L-glutamate 
it was similar in magnitude to [3H]D-aspartate release. Indeed three recent investigations have 
confirmed that nAChR agonist-induced release of [3H]D-aspartate is comparable to release of 
endogenous L-glutamate (Grilli et al., 2006; Patti et al., 2006; Patti et al. 2007).
3.3.5 nj4.Cfi(^ su6type-mecCiatecC [3Jf](D-aspartate release from <FFC synaptosomes
As discussed in Section 1.3.3, nicotine has been shown to enhance cognitive processes 
by activation of both a7 and (32* nAChRs in the PFC (see Mansvelder et al., 2006). Although 
nAChRs have been shown to facilitate dopamine, serotonin and noradrenalin release from this 
region (Rao et al., 2003) and previous studies have suggested a putative role for presynaptic a7 
nAChR (located on glutamatergic afferents projecting from the prefrontal cortex) in
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glutamatergic transmission within the VTA (Nomikos et al., 2000), the role of functional 
presynaptic nAChRs in excitatory amino acid modulation in the PFC itself has not been 
investigated. Using a larger region of frontal cortex that includes the PFC it was previously 
shown in this laboratory that both presynaptic a l  and (32* nAChRs are able to mediate 
excitatory amino acid release. From this finding the authors speculate that the heterogeneity of 
nAChR subtypes mediating nicotine-evoked [3H] D-aspartate release from frontal cortex 
synaptosomes may serve distinct signalling functions. Using synaptosomes prepared from the 
more anterior region (PFC), we have undertaken a more detailed interpretation of nAChR 
heterogeneity, including analysis of the cellular pathways coupled to these nAChR subtypes.
Application of the general nAChR non-competitive antagonist mecamylamine, at a 
relatively high concentration (20 pM) that has been shown to inhibit a l  and non-a7 nAChRs 
(Chavez-Noriega et al., 1997), confirmed [3H]D-aspartate release evoked by both 10 and 300 
pM was mediated via nAChRs. Employment of the highly potent a l  nAChR selective 
competitive antagonist aBgt (Davies et al., 1999) confirmed that in the PFC, as seen in the 
frontal cortex (Rousseau et al., 2005), a l  nAChRs mediate low nicotine (10 pM) evoked [3H]D- 
aspartate whereas the effect of higher concentrations (300 pM) is mediated via non-a7 nAChRs 
(Fig 3.11). The a l  nAChR-component of [3H]D-aspartate release evoked by 10 pM is in 
accordance with previous reports of the concentration of nicotine required to activate rat or 
human a l  nAChRs (Alkondon and Albuquerque, 1995; Gerzanich et al., 1995; Gray et al., 
1996), the lack of a detectable a l  nAChR-mediated component in 300 pM nicotine-evoked 
[3H]D-aspartate release probably effects the propensity of this nAChR to rapidly desensitise. It 
was previously shown that the a l  nAChR agonist choline and (32* nAChR agonist 5-I-A-85380 
are capable of evoking [3H] D-aspartate release from frontal cortex synaptosomes (Rousseau et 
al., 2005). To enable further analysis of solely a l  or non-a7 nAChR mediated release in the 
PFC we characterised nAChR subtype selective tools compound A (a l nAChR agonist, Cilia et 
al., 2005; Visanji et al., 2006) and 5-I-A-85380 ((32* nAChR agonist, Mukhin et al., 2000; 
Mogg et al., 2004).
oc7 nflCd^mediated excitatory amino acid retease
Compound A (Table 2.1) was used to activate a l  nAChRs. Compound A has 
previously been reported as a highly selective agonist for the human a l  nAChR expressed in 
both GH4 cells and oocytes (EC50 = 14 ± 2 nM and 950 ± 850 nM; respectively) with no cross­
reactivity at other nAChR subtypes or 5HT3Rs (De Filippi et al., 2002). Although compound A 
is clearly a potent agonist in vitro, in vivo investigations have yielded mixed data: whilst Cilia et 
al., (2005) reported that isolation-induced pre-pulse inhibition was attenuated following
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administration of compound A (10 mg/kg, i.p.), preliminary studies carried out by O’Neill and 
colleagues have reported compound A (10 mg/kg, s.c.) to be without effect on a variety of 
behavioural tasks including pre-pulse inhibition, forced swim test and the 8 -arm radial maze 
(O'Neill et al., 2002) and to have no neuroprotective actions in the 6 -hydroxydopamine in vivo 
model of Parkinson’s disease (O'Neill et al., 2002; Visanji et al., 2006). However, as compound 
A is not commercially available, there have been few studies, and the route of administration 
and doses used may not have been optimum (Visanji et al., 2006).
We have shown compound A to displace [125I]aBgt binding to PFC membranes with an 
IC50 of 95 nM (Fig 3.12), in agreement with a high potency at a7 nAChRs. Consistent with data 
produced for the a7 nAChR agonist choline (Alkondon et al., 1997), De Filippi et al., (2002) 
reported compound A to be more potent in desensitising (IC50 = 0.58 ± 0.3 nM; oocytes) than 
activating a7 nAChRs; here we were able to measure [3H]D-aspartate release at concentrations 
as low as 10' 16 M compound A (Fig 3.13). This low concentration of compound A evoked 
[3H]D-aspartate at a similar magnitude to that seen following 10 pM nicotine application. The 
lack of measurable [3H]D-aspartate release evoked by lower concentrations is probably due to 
the compound A causing the a l  nAChR to be stabilised in it desensitised conformation (Section 
1.3.1). [3H]D-aspartate release was evoked by concentrations of compound A up to 10-4 M. The 
absence of [3H] D-aspartate release at higher concentrations of compound A can be explained by 
high concentrations mediating a l  nAChR desensitisation (Section 1.3.1). The propensity of 
compound A to cause desensitisation of the a l  nAChR may also explain the absence of activity 
in certain in vivo studies with the differing route of administration perhaps resulting in 
dissimilar concentrations of compound A reaching the brain, resulting in an altered balance of 
activation versus desensitisation (O'Neill et al., 2002; Cilia et al., 2005).
The concentration-response curve produced following application of compound A is 
very broad and flat, showing the concentrations stretching four orders of magnitude can elicit 
the same quantity of [3H]D-aspartate release. The overall magnitude of release is not 
significantly different with increasing compound A. However, as at all concentrations 
compound A-evoked release was collected in one fraction, it is possible that the kinetic profiles 
of release may differ across the curve, with low concentrations causing slow Ca2+ influx and a 
more sustained, but lower level of [3H]D-aspartate release and higher concentrations eliciting a 
more rapid influx of Ca2+ and a fast, large, bolus of [3H]D-aspartate release. Due to the relatively 
large fraction collections and agonist application time it is not possible to conclude from these 
experiments whether this is the case. [3H]D-aspartate release evoked by two concentration of 
compound A: 10 nM, which evoked maximal [3H]D-aspartate release, and 1 pM, which was the 
highest concentration to significantly elicit [3H]D-aspartate release were both sensitive to 
mecamylamine and aBgt, confirming that this compound mediates [3H]D-aspartate release via
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highly selective activation of a7 nAChRs.
This work was carried out in parallel to measurements of intracellular Ca2+ in the PC 12 
cell line using the a l  nAChR positive allosteric modulator PNU 120596 (section 5.2.3). PNU 
120596 is a positive allosteric modulator that is highly selective for a l  nAChRs (Section 1.3.2; 
Hurst et al., 2005). Previous data have shown that whilst this modulator has no effect when 
added alone in the presence of acetylcholine it enhances Ca2+ entry though a l  nAChRs 
expressed in SH-EP1 cells and peak current through a l  nAChRs both in oocytes and 
hippocampal cultures, without modifying the ion selectivity of the a l  nAChR but causing the 
receptor to remain in an open state for an increased length of time (Hurst et al., 2005). 
Noteworthy is the ability of PNU 120596 to activate desensitised a l  nAChRs in the presence of 
nAChR agonist and improve D-amphetamine-induced auditory gating deficits in rats (Hurst et 
al., 2005). As expected the addition of PNU 120596 (10 pM) markedly increased compound A- 
mediated release in an aBgt-sensitive manner. [3H] D-aspartate release evoked by compound A 
was sustained over an extra fraction following the addition of PNU 120596 (Fig 3.15), 
consistent with this modulator causing the a l  nAChR to remain in an open conformation and 
therefore preventing the desensitisation of this receptor in the presence of compound A. As 
compound A alone consistently evoked a l  nAChR-mediated [3H]D-aspartate release all further 
experiments were carried out with this agonist in the absence of PNU 120596.
J$2*nflCh^ine(£iate(£excitatory amino acidreCease
P2* nAChRs have been implicated in excitatory amino acid release from frontal cortex 
(Gioanni et al., 1999; Rousseau et al., 2005). The differential sensitivity of 10 and 300 pM 
nicotine-evoked [3H] D-aspartate from PFC synaptosomes to aBgt is consistent with a 
heterogeneous population of nAChRs mediating nicotine-evoked excitatory amino acid release 
in this region. To further confirm the presence of functional presynaptic non-a7 nAChRs in the 
PFC we took advantage of 5-I-A-85380 (Mukhin et al., 2000; Mogg et al., 2004), a selective 
p2* nAChR agonist.
Consistent with previous data, showing 5-I-A-85380 to be less potent at a l  than (32 
nAChRs (Mogg et al., 2004), 5-I-A-85380 was approximately 300 times less potent than 
compound A in displacing [125I]aBgt binding to PFC membranes. In accordance with 5-I-A- 
85380 acting at non-a7 nAChRs [3H]D-aspartate release evoked by 10 nM 5-1-85380 was 
insensitive to aBgt. Confirmation of the involvement of (32* nAChRs was obtained by the 
ablation of this response in the presence of DHPE. DHJ3E predominantly inhibits a4p2 nAChR,
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(Alkondon et al 1994) with varying potencies at p2* and a4* nAChRs expressed in 
heterologous systems (Alkondon et al 1994). Importantly this antagonist is two orders of 
magnitude less potent at a7 nAChRs (Harvey et al., 1996; Chavez-Noriega et al., 1997) 
enabling it to easily distinguish between a l  and non-a7 nAChRs when used in the low 
micromolar range. Although 5-I-A-85380 can not be described as an a402 selective agonist due 
to its ability to activate a6p2 nAChRs in striatum (Mogg et al., 2004) the lack of a6  and other p 
nAChR subunits in the PFC, combined with the prominence of the a4p2 nAChR in this region 
(Table 3.2) makes it possible to conclude that this agonist is acting at primarily at the a4p2 
nAChR.
Whilst [3H]D-aspartate release evoked by 10 nM 5-I-A-85380 was insensitive to aBgt, 
10 pM 5-I-A-85380-evoked [3H]D-aspartate release was decreased by aBgt. This higher 
concentration of 5-I-A-85380 was also less sensitive to DHPE. These release data combined 
with the [,25I]aBgt inhibition binding data, are in accordance with previous data (Mogg et al., 
2004) in suggesting that at higher concentrations 5-I-A-85380 becomes less selective for p2* 
nAChRs.
From this work we have determined that [3H]D-aspartate is a suitable surrogate in 
release studies and P2 synaptosomes are an acceptable fraction for studying presynaptic 
nAChR-mediated release. We have characterised the novel nAChR agonist compound A, 
showing it to be a highly potent and selective agonist at a l  nAChRs and that compound A and 
5-I-A-85380 elicit [3H]D-aspartate release from rat PFC synaptosomes via a l  and p2* nAChRs, 
respectively. Therefore these two compounds provide suitable tools for dissecting the nAChR- 
subtype selective pathways mediating [3H]D-aspartate release in rat PFC synaptosomes, and this 
is described in Chapter 4.
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4.1 Introduction
4.1.1 frims o f  this chapter
The work described in this Chapter was carried out on the ‘anterior PFC’, dissected as 
described in Section 2.4.2.1. In Chapter three we demonstrated that compound A and 5-1-A- 
85380 evoked [3H]D-aspartate release via a7 and p2* nAChRs respectively. Here we investigate 
the Ca2+ dependence of these release mechanisms.
Investigate the role o f VOCCs in oc7- andfi2* nfiCh^mediated pH](D-aspartate release from PTC 
synaptosomes
In Section 3.2.3 we confirmed that both [3H]D-aspartate and [3H]L-glutamate were 
taken up into a vesicular pool in an analogous manner (Fleck et al., 2001). Here, using 
superfusion (Section 1.6.3), we have addressed whether nAChR-mediated [3H]D-aspartate 
release happens via a Ca2+-dependent mechanism or via EAAT reversal (Section 1.6.2). By 
adding the EAAT inhibitor TBOA (Waagepetersen et al., 2001) to the superfusion buffer, or 
removing extracellular Ca2+ we have investigated the route of [3H]D-aspartate following nAChR 
stimulation or KCl-mediated depolarisation As discussed in Section 1.4.1 following nAChR 
activation extracellular Ca2+ can enter the neurone either directly, by permeation of the intrinsic 
ion channel of the receptor, or indirectly through voltage-operated Ca2+ channels (VOCC) 
activated by depolarisation in response to Na+ influx through nAChR channels. In studies of 
[3H] dopamine release from striatal synaptosomes, P2* nAChR activation facilitates exocytosis 
by activation of VOCC (Soliakov and Wonnacott, 1996; Kulak et al., 2001). Here we have used 
a variety of VOCC inhibitors to investigate the relationship between a7-, p2* nAChR- and KCl- 
mediated [3H]D-aspartate release from PFC synaptosomes.
(Determine the role o f CIQK in cc7~, j$2* nJLChPc and %Cl-mediated pUJo-aspartate release from 
PTC synaptosomes
Following nAChR activation Ca2+ entry via the intrinsic ion channel or VOCCs can be 
further augmented via CICR (Dajas-Bailador and Wonnacott, 2004), the role of intracellular 
Ca2+ stores and their involvement in neurotransmitter release was discussed in Section 1.4.1. 
nAChRs have been linked to CICR in many different preparations (Section 1.4.3), with the 
majority of studies using the pan-acting nAChR agonists nicotine or ACh. Here we have used 
selective agonists combined with modulators of intracellular Ca2+ dynamics to investigate the 
involvement of CICR in nAChR-mediated [3H]D-aspartate release.
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Explore the invoCvement ofTTfrJ/2 in cc7- andft2* nft.CfoRjmediated pTC]<D-aspartate release from 
(PTC synaptosomes.
One candidate for translating CICR into more sustained changes in presynaptic 
function is the extracellular signal-regulated /mitogen activated kinase (ERK/MAP) pathway 
(Section 1.5). Nicotine can promote the activation of ERK1/2 in neurones in an aBgt-sensitive 
manner, consistent with the selective involvement of a7 nAChR (Dajas-Bailador and 
Wonnacott, 2004). However, this relationship has not been examined in nerve terminals in 
relation to nAChR-mediated neurotransmitter release. Here we have investigated the effect of 
upstream MEK inhibitors PD 98059 and U0 126 (Alessi et al., 1995; Favata et al., 1998), on a7, 
(32* nAChR- and KCl-mediated [3H]D-aspartate release. We have further characterised the 
relationship between presynaptic nAChR activation and ERK1/2 phosphorylation using western 
blotting.
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4.1 (RgsuCts
4.2.1 Ca2+ dependency o f  [3Jd](D-aspartate reCease
To determine the Ca2+ dependency of [3H]D-aspartate release, PFC synaptosomes were 
perfused throughout the release experiment with Ca2+-free KB (see Methods 2.4.5). To 
investigate the contribution of EAAT reversal (Nicholls and Attwell, 1990) in [3H]D-aspartate 
release we used the EAAT inhibitor TBOA (Waagepetersen et al., 2001), which we showed to 
inhibit [3H]D-aspartate uptake in Section 3.2.6. Responses mediated by 8  mM KCI, which elicits 
[3H]D-aspartate at a similar magnitude to that evoked by compound A and 5-I-A-85380 (both at 
10 nM; Section 3.2.6) and 12 mM KCI (Rousseau et al., 2005) were investigated.
[3H]D-aspartate release evoked by both 8  and 12 mM KCI was significantly reduced in 
the absence of Ca2+ (Fig 4.1). However, whilst 8  mM KCl-evoked release was totally abolished 
12 mM KCl-evoked release was reduced to a lesser extent (51.1 ± 3.0 % reduction; Fig 4.1). 
The addition of TBOA did not significantly alter 8  mM KCl-evoked release (28.2 ±3 . 5  % 
inhibition, p  > 0.05, one-way ANOVA with post-hoc Dunnett’s test, n = 4; Fig 4.1B). In 
contrast [3H]D-aspartate release evoked by 12 mM KCI was significantly reduced in the 
presence of TBOA (48.4 ± 8.0 % inhibition, Fig 4. ID), and to a not significantly different level 
to that seen in the absence of Ca2+ (51.1 ± 3.0 % inhibition, Fig 4 .ID). These data are consistent 
with lower concentrations of KCI evoking [3H] D-aspartate release via Ca2+-dependent 
exocytosis, whereas higher concentrations elicit release by both Ca2+-dependent exocytosis and 
EAAT reversal.
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Figure 4.1: C a2+ dependence of 8 and 12 mM KCl-evoked |3H |D-aspartate release
from PFC synaptosomes
PFC synaptosomes were loaded with 0.2 pM [ H]D-aspartate, superfused and stimulated 
with a 90 s pulse of A, B: 8 mM or C, D: 12 mM KCI. A, C: Representative profiles 
following KCI application in the presence (blue) or absence (grey) of Ca2+, points represent 
the mean ± SEM of triplicates from one experiment. B, D: KCl-mediated [3H]D-aspartate 
release in the absence of Ca2+ (2.4 mM MgCl2, 2 mM EGTA) or presence of TBOA (10 
pM, added 10 min prior to stimulation) data are shown as fractional release, adjusted for 
buffer-evoked release, points represent the mean ± SEM from at least 3 separate 
experiments. Significantly different to corresponding KCI concentration alone; **p <0.01; 
one-way ANOVA with post-hoc Dunnett’s test.
In Section 3.2.5 compound A (10 nM) and 5-I-A-85380 (10 nM) were shown to evoke 
[3H]D-aspartate release by selectively activating a7 nAChRs and p2* nAChRs, respectively. 
Investigations were carried out to determine the effect of removing Ca2+ from the KB or the 
addition of TBOA (10 pM) on compound A- and 5-I-A-85380-mediated release. As seen with 8 
mM KCl-evoked [3H]D-aspartate release, both compound A- and 5-I-A-8538-mediated release 
were highly Ca2+-dependent (89.5 ± 4.2 and 79.9 ± 8.4 % inhibition in the absence of Ca2+,
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respectively; Fig 4.2). The EAAT inhibitor TBOA did not significantly alter compound A- or 5- 
I-A-85380-evoked release (23.6 ± 10.1 and 8.8 ± 6.5 % inhibition respectively, Fig 4.2). These 
data are consistent with compound A, 5-I-A-85380 and lower concentrations o f KCI eliciting 
[3H]D-aspartate release via Ca2+-dependent exocytosis, rather than release by transporter 
reversal.
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Figure 4.2: Ca2+ dependence of compound A and 5-I-A-85380-mediated J3H|D- 
aspartate release from PFC synaptosomes
PFC synaptosomes were loaded with 0.2 pM [3H]D-aspartate and stimulated with a 90 s 
pulse o f  A: 10 nM compound A or B: 10 nM 5-I-A -85380 in the absence o f  Ca2+ or 
presence o f  TBO A (10 pM, added 10 min prior to stimulation) data are shown as fractional 
release, adjusted for buffer, points represent the mean ±  SEM from at least 3 separate 
experiments. Significantly different to appropriate control, **p <  0.01; one-w ay ANO VA  
with post-hoc Dunnett’s test
4.2.2 ^Effect ofVOCC indi6itors on pfC](D-aspartate reCease
Following nAChR stimulation Ca2+ can enter the neurone either directly through the 
intrinsic ion channel or indirectly via VOCCs (Section 1.4). To determine the involvement o f 
VOCCs the effect o f selective VOCC inhibitors (Table 4.1) was analysed as described in the 
Methods (Section 2.4.5).
Cd2+ is a general VOCC inhibitor (see Table 4.1) that is often used to investigate the 
contribution o f VOCCs. A low (50 pM) and high a (200 pM) concentration o f Cd2+ were used 
to block VOCCs. Neither concentration significantly altered basal [3H]D-aspartate release 
(Table 4.1).
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Table 4.1: Concentrations and effects of VOCC inhibitors used
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To confirm that 200 pM Cd2+ did not have non-specific toxic effects in this system we 
carried out initial experiments using a double pulse of nicotine (10 pM) in the presence and 
absence of 200 pM Cd2+ (Fig 4.1). Cd2+ was present 10 min prior to and during the first nicotine 
stimulation (90 s); the synaptosomes were then washed for 6  min before a second nicotine pulse 
(90 s; Fig 4.3). In the presence of 200 pM Cd2+ the first nicotine response was greatly 
diminished, however, following the removal of Cd2+ the synaptosomes responded to the second 
nicotine response at a level not significantly different to the control (Fig 4.3) confirming that the 
synaptosomes were functioning normally.
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Figure 4.3: Effect of cadmium (200 pM ) treatm ent on nicotine (10 pM)-evoked [3H)D- 
aspartate release from ra t PFC synaptosomes
Rat PFC synaptosomes, loaded with 0.2 pM [3H]D-aspartate were superfused in the 
presence (dark pink) or absence (dark blue) of CdCl2 (200 pM) and stimulated with nicotine 
(nic, 10 pM). Following a further perfusion (6 min) in the absence of CdCl2 a second 
stimulation of nicotine (nic, 10 pM) was administered. Control chambers (grey) were 
stimulated with KB alone, firstly in the presence, and then in the absence of CdCl2. Results 
are the mean ± SEM of triplicate determinations from one experiment (n = 2).____________
In the presence o f 50 pM Cd2+ compound A-evoked [3H]D-aspartate release was not 
statistically different to control (20.8 ± 2.5 % inhibition p  > 0.05, one-way ANOVA with post- 
hoc Dunnett’s test n = 4, Fig 4.4A, B). However, this concentration o f Cd2+ produced a marked 
inhibition o f both 5-I-A-85380- and KCl-evoked release (71.5 ± 14.0 and 73.4 ± 8.8 % 
inhibition, respectively; Fig 4.4C, E).
A near total block o f compound A-mediated [3H]D-aspartate release was seen in the 
presence o f 200 pM Cd2+ (87.7 ±  9.2 % inhibition). The higher concentration o f Cd2+ abolished 
both 5-I-A-85380- and KCl-evoked release (101.6 ± 5.4 and 103.3 ±  10.2 % inhibition, 
respectively; Fig 4.4C, E). The inhibition o f 5-I-A-85380- or KCl-evoked release in the 
presence o f 50 or 200 pM  Cd2+ was not significantly different (one-way ANOVA with post-hoc 
Tukey’s test, n >  3).
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Figure 4.4: Effect of 50 and 200 pM Cd2 on compound A, 5-I-A-85380 and KCI- 
mediated [3H|D-aspartate release from PFC synaptosomes
PFC synaptosomes were loaded with 0.2 fiM [3H]D-aspartate, superfused and stimulated 
with a 90 s pulse of A, B: 10 nM compound A, C, D: 10 nM 5-I-A-85380 or E, F: KCI, in 
the absence or presence of 50 or 200 pM Cd2+, added 10 min prior to stimulation. A, C, E: 
representative profiles in the presence or absence of 50 pM Cd2+, points represent the mean 
± SEM of triplicate determinations from one experiment. B, D, F: release in the presence or 
absence of 50 or 200 pM Cd2+, data are shown as fractional release, adjusted for buffer, 
points represent the mean ± SEM from at least 3 separate experiments. Significantly 
different to appropriate control; **p <0.01; one-way ANOVA with post-hoc Dunnetf s test.
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To further investigate the possible differential coupling of nAChRs to VOCC subtypes, 
specific inhibitors of N-type, N-, P-/Q-type and L-type VOCCs: co-conotoxin GVIA, co- 
conotoxin MVHC and verapamil at concentrations previously shown to fully block specific 
VOCC (Table 4.1) were used. None of these inhibitors altered basal [3H]D-aspartate release 
(data not shown; Table 4.1). Compound A-evoked [3H]D-aspartate release was not significantly 
altered in the presence of N-P-/Q-type inhibitors co-conotoxin GVIA and co-conotoxin MVHC 
(84.9 ± 12.6 and 120.5 ± 3.0 % of control, respectively; Fig 4.5) or the L-type VOCC inhibitor 
verapamil (104.4 ± 3.2 % of control, respectively; Fig 4.5). These data are consistent with the 
insensitivity to 50 pm Cd2+ and confirm the lack of VOCC involvement in a7 nAChR-mediated 
[3H]D-aspartate release (Fig 4.5).
In contrast, 5-I-A-85380-evoked [3H]D-aspartate release was sensitive to the VOCC 
inhibitors oo-conotoxin GVIA and co-conotoxin MVnC (67.0 ± 7.7 and 46.7 ± 7.4 % inhibition, 
respectively; Fig 4.5), consistent with previous observations linking non-a7 nAChR stimulation 
with VOCC activation (Kulak et al., 2001; Soliakov and Wonnacott 1996). KCl-evoked [3H]D- 
aspartate release was also partially inhibited in the presence of co-conotoxin GVIA and co- 
conotoxin MVHC by 60.1 ± 4.5 and 71.8 ± 10.9 %, respectively (Fig 4.2F). Neither 5-I-A- 
85380- nor KCl-evoked [3H]D-aspartate release was altered in the presence of L-type VOCC 
inhibitor verapamil (87.2 ±1 . 6  and 96.8 ± 15.9 % of control, respectively; Fig 4.5); consistent 
with a lack of L-type VOCC in presynaptic regions (Westenbroek et al., 1990). Statistical 
analysis using one-way ANOVA with post-hoc tukey’s test to compare different treatments 
demonstrated that there was no significant difference between the co-conotoxin GVIA or co- 
conotoxin MVHC treated synaptosomes for any of the stimulations (Fig 4.5B-D). Because of 
the overlapping selectivity of co-conotoxin GVIA or co-conotoxin MVHC (N- and N-,P-/Q-type 
VOCCs, respectively) data from experiments with co-application of both inhibitors would be 
ambiguous and such experiments were not performed for this reason.
The insensitivity of compound A-evoked [3H]D-aspartate release to VOCC inhibitors 
and 50 pM Cd2+, in contrast to both 5-I-A-85380- and KCl-evoked release, suggests that the 
predominant route of Ca2+ entry into PFC synaptosomes in response to compound A stimulation 
is via the a l  nAChR channel itself.
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Figure 4.5: Sensitivity of Compound A, 5-I-A-85380 and KCI-mediated | 3H | d - 
aspartate release from PFC synaptosomes to VOCC inhibitors
Rat PFC synaptosomes were loaded with 0.2 pM [3H]D-aspartate, superfused and 
stimulated for 90 s with A, B: 10 nM compound A, C: 10 nM 5-I-A-85380 or D: 8 mM KCI 
in the presence of absence of co-conotoxin GVIA (GVIA, 1 pM), co-conotoxin MVIIC 
(MVIIC, 1 pM) or verapamil (ver, 10 pM). Inhibitors were introduced into the perfusing 
buffer 10 min before stimulation and remained throughout the experiment as described in 
the Methods. (A) Representative profiles of compound A alone (dark green) or in the 
presence of co-conotoxin GVIA (GVIA, 1 pM, light green) or co-conotoxin MVIIC (MVIIC, 
1 pM, red) points represent the mean ± SEM of triplicate determinates from a single 
experiment. (B, C, D) Release of radioactivity was calculated as fractional release and is 
expressed as a percentage of control responses. Bars represent the mean ± SEM of at least 
three independent experiments. Significantly different from control, *p < 0.05, **p < 0.01; 
one-way ANOVA, with post hoc Dunnetf s analysis
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4.2.3 Effect o f  modulators o f  intracellular Ca2+ on [37f](D-aspartate retease
To explore the possibility the nAChRs are coupled to CICR in PFC synaptosomes we 
examined the effects of ryanodine, dantrolene, xestospongin-C, thapsigargin and caffeine (Table 
4.2) on a7- (compound A), p2* nAChR- (5-I-A-85380) and KCl-evoked [3H]D-aspartate 
release. In all cases modulators were added to the perfusion 10 min before agonist stimulation. 
Ryanodine, dantrolene and xestospongin-C did not alter basal [3H]D-aspartate release (Fig 
4.6A), whereas addition of caffeine or thapsigargin resulted in a slight increase in the baseline, 
but this effect was not present at the point of stimulation and was not significantly different to 
buffer alone.
Table 4.2: Concentrations and effects of intracellular Ca2+ modulators used
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Compound A-evoked [3H]D-aspartate release was significantly reduced in the presence 
of both RyR inhibitors, ryanodine and dantrolene (85.8 ± 7.5 and 83.4 ± 4.8 % inhibition, 
respectively; Fig 4.6). Compound A-evoked release was also significantly reduced in the 
presence of the IP3R inhibitor xestospongin-C (74.2 ± 8.3 % inhibition, Fig 4.6) and the general 
modulators of intracellular Ca2+ stores thapsigargin and caffeine (104.6 ± 17.3 and 90.9 ± 3.9 % 
inhibition, respectively; Fig 4.6).
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Figure 4.6: Sensitivity of Compound A -mediated [3H|D-aspartate release from PFC 
synaptosomes to modulators of intracellular Ca2+ stores 
Rat PFC synaptosomes were loaded with 0.2 pM [3H]D-aspartate, superfused with KB and 
stimulated for 90 s with 10 nM compound A. Modulators: ryanodine (Rya, 30 pM), 
dantrolene (Dan, 10 pM), xestospongin-C (XeC, 1 pM), thapsigargin (Tha, 1 pM) and 
caffeine (30 mM) were introduced into the perfusing buffer 10 min before applying the 90 s 
stimulus and remained throughout the experiment as described in the Methods. A: 
Representative profiles of compound A alone (dark green) or in the presence of ryanodine 
(Rya, 30 pM, blue) or dantrolene (Dan, 10 pM, red), points represent the mean ± SEM of 
triplicate determinates from one experiment. B: Compound A-mediated [’H]D-aspartate 
release in the presence or absence of modulators, release of radioactivity was calculated as 
fractional release and is expressed as a percentage of control responses. Bars represent the 
mean ± SEM of at least three independent experiments. Significantly different from control, 
**p <0.01; one-way ANOVA, with post hoc Dunnett’s analysis
In contrast, ryanodine and dantrolene were without effect on [3H]D-aspartate release 
evoked by 10 nM 5-I-A-85380 (22.0 ± 9.6 and 17.2 ± 6.6 % inhibition respectively; Fig 4.7) or 
8 mM KCI (1.45 ± 12.4 and 10.0 ± 4.0 % inhibition, respectively; Fig 4.7). 5-I-A-85380- and 
KCl-evoked [3H]D-aspartate release was also insensitive to xestospongin-C (9.5 ± 5.4 and 10.7 
± 13.3 % inhibition, respectively; Fig 4.7), thapsigargin (7.1 ± 10.5 and 9.3 ± 6.9 % inhibition, 
respectively; Fig 4.7) and caffeine (24.8 ± 1.5 and 8.23 ± 18.6 % inhibition, respectively; Fig 
4.7). These data support the hypothesis that compound A-evoked [3H]D-aspartate release is 
dependent upon CICR triggered through Ca2+ influx via a7 nAChR and that a7 and (32* nAChR 
differentially mediate [3H]D-aspartate release through distinct Ca2 -dependent pathways
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Figure 4.7: Sensitivity of 5-I-A-85380 and KCI-mediated |JH]D-aspartate release from 
PFC synaptosomes to modulators of intracellular Ca + stores
Rat PFC synaptosomes were loaded with [3H]D-aspartate, superfused with KB and 
stimulated for 90 s with A: 10 nM 5-I-A-85380 or B: 8 mM KCI. Modulators, ryanodine 
(Rya, 30 pM), dantrolene (Dan, 10 pM), xestospongin-C (XeC, 1 pM), thapsigargin (Tha, 1 
pM) and caffeine (30 mM) were introduced into the perfusing buffer 10 min before 
applying the 90 s stimulus and remained throughout the experiment as described in the 
Methods. Release of radioactivity was calculated as fractional release and is expressed as a 
percentage of control responses. Bars represent the mean ± SEM of at least three 
independent experiments.
4.2.4 Identification o f  ryanodine receptor isoforms in <FFC synaptosomes
Although the presence o f RyRs within the presynaptic bouton is well documented 
(Section 1.3.4.1), the RyR isoforms present within glutamatergic terminals o f the PFC has not 
been documented. Here immunocytochemistry was carried out using an antibody that recognises 
RyR isoforms 1-3: 2149 (Zissimopoulos and Lai, 2005); and a RyR 2 selective antibody: 1093 
(Zissimopoulos and Lai, 2005).
Synaptosomes were labelled with VGluTl and VGluT2, to enable identification o f 
glutamatergic terminals (Section 3.2.2.2) and ryanodineRyR 2149 or 1093 as described in 
Section 2.4.10.1. As both anti-RyR antibodies are raised in rabbit they could not be used to 
double label the synaptosomes. In Section 3.2.2.2 we have shown that the majority o f 
synaptophysin-positive structure to be positive for V GluTl/2. Here we show that a large 
proportion o f these glutamatergic terminals are positive for either RyR 2149 or 1093 (Fig 4.8). 
There was not a noticeable difference in the labelling pattern produced by either the general 
RyR antibody, 2149, or that specific for RyR isoform 2, 1093 (Fig 4.8). Therefore it is 
reasonable to assume that the predominant RyR isoform in PFC synaptosomes is RyR2.
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Figure 4.8: Presence of RyR-positive structure in PFC synaptosomes
PFC P2 synaptosomes were layered onto poIy-D-lysine slides and labelled with anti- 
VGluTl/2 (secondary: anti-guinea-pig-546) and anti-RyR (secondary: anti-rabbit-488). A: 
general RyR antibody 2149 or B: RyR2 specific antibody 1083 and visualised using 
confocal microscopy. Representative pictures shown (n = 2); scale bar = 10 pm.
4.2.5 ‘Effect ofM E% l inhibitors on [3ttf]D-aspartate release
To examine the putative downstream signals activated by nAChR stimulation 
mediating [3H]D-aspartate release from PFC synaptosomes we examined the effect of two 
structurally distinct MEK1 inhibitors, PD 98059 (Alessi et al., 1995; Dudley et al., 1995) and 
U0126 (Favata et al., 1998).
Compound A-evoked [3H]D-aspartate release was significantly decreased in the 
presence of 10 pM PD 98059 and 10 pM U0126 (81.3 ± 20.1 and 79.2 ± 8.9 % 
inhibition, respectively; Fig 4.9). In contrast, [3H]D-aspartate release evoked by 10 nM 
5-I-A-85380 or 8  mM KCI was not significantly altered in the presence of these 
inhibitors (Fig 4.9). PD 98059 and U0126 decreased 10 nM 5-I-A-85380-evoked [3H]d- 
aspartate release by 32.3 ±21 . 5  and 51.5 ± 18.4% and 8  mM KCl-evoked release by
34.1 ± 13.3 and 51.5 ±7.1 %, respectively (Fig 4.9). These rather variable effects that 
may reflect non-specific actions of these inhibitors at other targets (Davies et al., 2000), 
potentially including VOCCs (Pereira et al., 2002b), which are involved in 5-1-A- 
85380- and KCl-evoked [3H]D-aspartate release (Fig 4.4); but do not contribute to a l  
nAChR-mediated release.
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Figure 4.9: Sensitivity of Compound A -mediated |3H|D-aspartate release from PFC 
synaptosomes to MEK1 inhibitors
Rat PFC synaptosomes were loaded with [3H]D-aspartate, superfused with KB and 
stimulated for 90 s with A, B: 10 nM compound A, C: 10 nM 5-I-A-85380 or D: 8 mM 
KCI. MEK1 inhibitors, PD 98059 (PD, 10 pM) and U0 126 (U0, 10 pM), were introduced 
into the perfusing buffer 10 min before applying the 90 s stimulus and remained throughout 
the experiment as described in the Methods A: Representative profiles o f  compound A 
alone (dark green) or in the presence o f  PD 098059 (PD, 10 pM, grey) or U0126 (U0, 10 
pM, teal), points represent the mean ± SEM o f triplicate determinates from one experiment. 
B -  D: [3H]D-aspartate release in the presence or absence o f MEK1 inhibitors, release o f  
radioactivity was calculated as fractional release and is expressed as a percentage o f  control 
responses. Bars represent the mean ± SEM o f at least three independent experiments. 
Significantly different from control, *p < 0.05; one-way ANOVA, with post hoc Dunnetf s 
analysis
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4.2.6 J46iRty ofpresynaptic nj4Ch<Ry to mediate (E(RJ<J/2phosphorylation
Whilst the sensitivity o f the compound A-mediated response to MEK1 inhibitors 
clearly demonstrates the involvement o f ERK1/2 in a l  nAChR-mediated [3H]D-aspartate 
release, the picture for both |32* nAChR- and KCl-mediated release is less clear due to the 
variation between experiments (Fig 4.8). To determine if the 90 s stimulus results in 
phosphorylation o f ERK1/2 we carried out western blotting using antibodies for either the 
phosphorylated form o f ERK1/2 or total ERK1/2 was carried out as described in Section 2.4.11.
Both 10 nM compound A and 8 mM KCI significantly increased ERK2 
phosphoiylation in PFC P2 synaptosomes (Mw 42 kDa; Fig 4.10; 150 ± 5 and 175 ± 14 % 
increase compared to buffer control). Although total levels o f ERK1 and ERK2 were veiy 
comparable (bottom blot, Fig 4.10), the phosphorylated ERK1 levels were very low (top blot, 
Mw 44 kDa, Fig 4.10) and no detectable change was seen in phosho-ERKl levels following any 
o f the stimuli. 5-I-A-85380 (10 nM, 90 s) did not significantly alter phospho-ERKl/2 levels 




Figure 4.10:Phosphorylation of ERK1/2 in response to nAChR agonists and KCI
stimulation
Synaptosomes were incubated with 10 nM compound A, 10 nM 5-I-A-85380 or 8 mM KCI 
for 90 s prior to western blot analysis. Top panel: P-ERK2 (Mw 42 kDa) levels, bottom 
panel: total ERK1/2 (Mw 44 and 42 kDa respectively) levels; representative blots shown. 
ERK2-phosphorylation was quantified by densitometry as described in the Methods and 
expressed as a percentage of the basal levels of ERK2-phosphorylation as determined in 
parallel (buffer response). Significantly different from basal; **p < 0.01; one-way ANOVA, 
with post hoc Dunnett’s analysis
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The lack o f effect o f  5-I-A-85380 (10 nM) was confirmed over the time-course o f  0-10 
min (Fig 4.11). In contrast compound A increased ERK2 phosphorylation in a time-dependent 
manner, with maximum increases seen following 90 sec and 3 min incubation o f compound A 
(Fig 4.11).
A B
5-I-A-85380 10 nM C o m p o u n d  A 10 nM
Figure 4.1 l:Tim e course of ERK1/2 phosphorylation in response to compound A and
5-I-A-85380 of stimulation
Synaptosomes were incubated with A: 10 nM 5-I-A-85380 or B: 10 nM compound A for 10 
sec -  10 min prior to western blot analysis. Top panel: representative blots of P-ERK2 (Mw 
42 kDa) levels, ERK2-phosphorylation was quantified by densitometry as described in the 
Methods and expressed as a percentage of the basal levels of ERK2-phosphorylation as 
determined in parallel (buffer: — ). Bars represent the mean ± SEM of at least four 
independent experiments. Significantly different from basal *p < 0.05; **p < 0.01; one-way 
ANOVA, with post hoc Dunnetf s analysis.
The specificity o f ERK2 phosphorylation was examined in response to 90 s stimulation 
(Methods, Section 2.4.1); as this is the stimulation time used in the superfusion experiments. 
Both mecamylamine and aBgt decreased compound A-evoked ERK2 phosphorylation (88.6 ± 
5.8 and 93.6 ± 5.7 % inhibition o f compound A-evoked increase, respectively; Fig 4.12) but 
DHpE was without effect (100.1 ± 10.3 % compound A control; Fig 4.12); confirming the 
compound A-mediated increase in ERK2 phosphorylation was mediated by a7 nAChR.
Both MEK1 inhibitors, PD 98059 (10 pM ) and U0126 (10 pM), significantly 
decreased the compound A-evoked increases in ERK2 phosphorylation (68.3 ± 6.0 and 106 ± 
6.7 % inhibition o f compound A-evoked increase, respectively; Fig 4.12), consistent with the 
involvement o f the MAPK pathway. Previous studies have shown a7 nAChR-mediated 
activation o f ERK to be Ca2+-dependent (Dineley et al., 2001; Dajas-Bailador et al., 2002a; Bell 
et al., 2004). To determine if  CICR is required, compound A-mediated activation o f ERK2 was
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determined in the presence o f ryanodine. Under conditions that block [3H]D-aspartate release 
(30 pM ryanodine, 10 min pre-incubation, Fig 4.3A,B) there was a significant attenuation o f 
ERK2 phosphorylation (56.5 ± 6.4 % decrease; Fig 4.12B), consistent with CICR mediating at 
least a major proportion o f this response.
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Figure 4.12: Pharmacological specificity of compound A-evoked increases in phospho-
ERK2
Synaptosomes were stimulated with a 90 s application of 10 nM compound A in the 
presence or absence of A: DH|3E (1 pM), mecamylamine (Mec, 20 pM), or aBgt (40 nM); 
B: PD 980569 (PD, 10 pM), U0 126 (U0, 10 pM) or ryanodine (Rya 30 pM). When present 
antagonists were introduced 10 min (30 min aBgt) prior to agonist application and were 
present during stimulation. Representative blots of P-ERK2 (Mw 42 kDa) shown. ERK2- 
phosphorylation was quantified by densitometry as described in the Methods and expressed 
as a percentage of the basal levels of ERK-phosphorylation as determined in parallel. Bars 
represent the mean ± SEM of at least five independent experiments. Significantly different 
from agonist control *p < 0.05; **p < 0.01; one-way ANOVA, with post hoc Dunnett’s 
analysis.
These data are consistent with a7, but not p2* nAChR activation causing ERK2- 
phosphorylation via the MAPK pathway following CICR.
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4.3 (Discussion
4.3.1 Summary
Having determined that compound A and 5-I-A-85380 evoke [3H]D-aspartate release 
from PFC synaptosomes via a7 and p2* nAChRs respectively (Chapter 3), we characterised the 
pathways o f a7- and (32* nAChR-mediated release reporting:
• Both a7 and p2* nAChR-mediated release occurs via a Ca2+-dependent pathway, that 
does not involve EAATs. However, the route o f  Ca2+ influx into the synaptosomes 
following a l  and (32* nAChR activation are different: a l  nAChR stimulation causes 
sufficient Ca2+ influx through the intrinsic ion channel to elicit [3H]D-aspartate release 
whereas both (32* nAChR- and KCl-mediated [3H]D-aspartate release require the 




Figure 4.13: Model illustrating pathways of presynaptic a7 and (32* nAChR-mediated 
(3H ]D -aspartate release in PFC synaptosomes
(32* nAChR and KCI stimulation evokes [3H]D-aspartate release by activating VOCCs. 
Activation of al nAChRs leads to [3H]D-aspartate release by initiating CICR, without the 
participation of VOCCs, and subsequently causes an increase in ERK1/2 phosphorylation 
enabling neurotransmitter release. It is not known if the al  and P2* nAChRs reside on the 
same terminal.
•  Whilst neither KCl-evoked nor p2* nAChR-mediated [3H]D-aspartate release require 
Ca2+ release from intracellular Ca2+ stores, conversely CICR is essential for a l  
nAChR-mediated [3H]D-aspartate release from PFC synaptosomes (Fig 4.13).
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• Stimulation of a7 nAChRs and subsequent initiation of CICR causes increases in 
ERK1/2 phosphorylation. Activation of this kinase was shown to be essential for a7 
nAChR-mediated [3H]D-aspartate release (Fig 4.13). Although KCI application to 
synaptosomes elicited increases in ERK1/2 phosphorylation, inhibition of the ERK1/2 
pathway did not significantly alter KCl-mediated [3H]D-aspartate release. In 
comparison stimulation of p2* nAChRs did not cause any change to ERK1/2 
phosphorylation levels.
4.3.2 Ca2+-dependent aticf <EJLjlcT reversaC-mediatecf [37£]<D-aspartate reCease from
<3*FC synaptosomes.
The use of [3H]D-aspartate as a surrogate for L-glutamate has previously received 
criticism (Nicholls, 1989; Nicholls and Attwell, 1990) due to conflicting views on its ability to 
be incorporated into synaptic vesicles and subsequently be released via Ca2+-dependent 
exocytosis. In Chapter 3 we addressed the issue of [3H]D-aspartate uptake into a crude vesicular 
preparation and showed [3H]D-aspartate to be taken up into this fraction in an analogous way to 
[3H]L-glutamate. Here we have used our three stimuli, characterised in Chapter 3: compound A 
(a7 nAChR), 5-I-A-85380 (P2* nAChR) and KCI, to explore the roles of Ca2+ in [3H]D- 
aspartate release.
Both compound A- and 5-I-A-85380-evoked [3H]D-aspartate was undetectable in the 
absence of extracellular Ca2+, consistent with a l  and p2* nAChRs modulating neurotransmitter 
release via Ca2+-dependent exocytosis. Comparable responses evoked by 8  mM KCI were also 
abolished in the absence of Ca2+. As discussed in Section 1.6.1, whilst glutamatergic 
neurotransmission is thought to be regulated by Ca2+-dependent exocytosis, glutamate can also 
be release via EAAT reversal, a process commonly associated in neurotoxic insults such as 
ischemia. EAAT reversal has been shown to play an important role in KCl-evoked excitatory 
amino acid release, indeed in frontal cortex synaptosomes [3H]D-aspartate release evoked by 12 
mM KCI occurs by both a Ca2+-dependent process and EAAT reversal (Rousseau et al., 2005). 
Whilst the insensitivity of compound A, 5-I-A-85380 and 8  mM KCl-evoked [3H]D-aspartate to 
EAAT inhibitor TBOA suggests these agents do not elicit release via EAAT reversal, [3H]D- 
aspartate release evoked by 12 mM KCI was equally reduced in the presence of TBOA or 
absence of Ca2+. These data confirm that [3H]D-aspartate can be released in a Ca2+-dependent 
manner (Simonato et al., 1993; Palmer and Reiter, 1994; Muzzolini et al., 1997; Savage et al., 
2001; Rousseau et al., 2005) but also highlight that higher levels of depolarisation can result in 
Ca2+-independent release, due to EAAT reversal (Nicholls and Attwell, 1990; Szatkowski et al., 
1990; Phillis et al., 2000; Rousseau et al., 2005). These data add credence to the use of [3H]D-
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aspartate as a surrogate for L-glutamate in release studies (Section 3.3.4).
4.3.3 Mechanisms o f  Ca2+-dependent [3fC]<D-aspartate reCease
f2* , 6ut not oc7 nfl.Ch<Rj are coupCedto voCtage operatedC&2+ channels
Here we have shown that whilst KCI- and (32* nAChR-mediated [3H]D-aspartate 
release was dependent upon VOCCs; a7 nAChR-mediated release was insensitive to inhibitors 
of VOCCs (Fig 4.13). The lack of L-type VOCC involvement in (32* nAChR- or KCi-mediated 
[3H]D-aspartate release is not unexpected due to the absence of this VOCC subtype at the 
presynaptic terminal (Westenbroek et al., 1990). As discussed in Section 1.4.3 N- and P-/Q- 
type VOCCs are commonly associated with presynaptic increases in intracellular Ca2+.
[3H]D-aspartate release evoked by either KCI or 5-I-A-85380 application was equally 
reduced in the presence of co-conotoxin GVIA or co-conotoxin MVHC. Previous 
pharmacological characterisation of these co-conotoxins has shown that these two antagonists 
have overlapping effects at VOCCs subtypes. Hillyard et al., (1992) reported that in rat 
hippocampal neurones perfusion of co-conotoxin MVHC significantly attenuated Ca2+ currents 
and that this decrease was not furthered following subsequent application of co-conotoxin 
GVIA, consistent with co-conotoxin MVIIC inhibiting co-conotoxin GVIA-sensitive VOCCs. 
However, addition of co-conotoxin MVIIC to this preparation caused a greater inhibition of 
response than co-conotoxin GVIA alone (Hillyard et al., 1992). These data have subsequently 
been interpreted such that co-conotoxin GVIA acts solely at N-type VOCCs whereas co- 
conotoxin MVHC has a broader specificity, inhibiting N- and P-/Q-type VOCCs (Section 1.4.3). 
[3H]D-aspartate release evoked by either KCI or 5-I-A-85380 was equally blocked in the 
presence of both co-conotoxin GVIA and co-conotoxin MVIIC, due to the overlapping VOCC 
pharmacologies of these to co-conotoxins their additive effect was not addressed in the system as 
little more information would have been gained. As discussed in Section 1.4.3 both N- and P- 
/Q- type VOCCs are located at the presynaptic terminal in tight association with SNARE 
proteins. From the data obtained it is possible to conclude that, in accordance with KCl-evoked 
excitatory amino acid release from spinal chord (Martire et al., 2000) and striatal synaptosomes 
(Hill and Brotchie, 1999) the primary VOCC responsible for KCI- and 5-I-A-85380-evoked 
[3H]D-aspartate release from PFC synaptosomes is the N-type channel.
The lack of detectable VOCC involvement in a7 nAChR-mediated [3H]D-aspartate 
release from PFC synaptosomes, determined by the insensitivity of these responses to co- 
conotoxin GVIA, co-conotoxin MVIIC and verapamil, suggests that extracellular Ca2+ entry via 
the a l  nAChR’s intrinsic ion channel is sufficient to trigger the cascade of events that results in
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Ca2+-dependent [3H]D-aspartate release, independent of Ca2+ entry through VOCC. This is 
perhaps not surprising given the relatively high Ca2+ permeability of the a7 vs. p2* nAChR (Pf 
= 8.8-11.4 and 2.6-2.9 % respectively; (Fucile, 2004).
C&+ as a VOCC inHi6itor
Whilst the [3H]D-aspartate release data produced following the application selective 
VOCC inhibitors is clear cut, there was varying sensitivity to general VOCC Cd2+. Cd2+ has 
been widely employed to investigate the role of VOCCs in nAChR-mediated responses, at 
concentrations ranging from 50 -  200 pM (Gray et al., 1996; Grassi et al., 1999; Kulak et al., 
2001; Sharma and Vijayaraghavan, 2001). In accordance with the investigation of Grassi et al., 
(1999), who reported Cd2+ concentrations >10 pM Cd2+ significantly block VOCCs, 50 pM Cd2+ 
abolished KCI- and (32* nAChR-mediated responses. However, whilst 50 pM Cd2+ was without 
effect on a7 nAChR-mediated responses 200 pM Cd2+ significantly reduced a l  nAChR 
responses.
Cd2+ is also well documented as being highly toxic to humans (Satoh et al., 2002), 
animals (Martelli et al., 2006) and plants (Deckert, 2005), as well as being used to induce cell 
death in in vitro systems, with LD50 ranging from 12 pM (PC 12 cells; Hinkle and Osborne, 
1994) to 350 pM (human lymphoblastoid cell line Boleth; Coutant et al., 2006). Here we 
controlled for toxicity of Cd2+ by showing that nicotine (10 pM) was still able to elicit [3H]D- 
aspartate release from PFC synaptosomes that had previously been incubated with Cd2+ (200 
pM; Fig 4.3). The lack of toxicity is probably due to the relatively short incubation period of 10 
min; however, these data do not confirm that Cd2+ is acting solely at VOCCs. Studies using 
selective VOCC antagonists have revealed that even in the presence of extracellular Ca2+ 
VOCCs are able to transport Cd2+ into the neurone (Hinkle et al., 1987; Usai et al., 1999). Once 
in the neurone Cd2+ is able to interact with a plethora of proteins, of particular relevance to this 
investigation is its ability to inhibit Ca2+ ATPases (Kiss and Osipenko, 1994).
The first evidence that Cd2+ could decrease the function of Ca2+ ATPases was shown 
by Sugawara and Sugawara (1975), who reported that concentrations of Cd2+ as low as 1 pM 
could reduce the function of intestinal brush border Ca2+ ATPases to 65 % of control. 
Subsequent studies have shown that thapsigargin can significantly reduce Cd2+-induced 
increases in intracellular Ca2+, consistent with this cation acting at the ER Ca2+ ATPase (Benters 
et al., 1997; Faurskov and Bjerregaard, 2002). Indeed Cd2+ has been shown to inhibit 
extracellular Ca2+-indendent GABA-activated chloride currents via a ruthenium red-sensitive 
process in snail neurones (Molnar et al., 2004). In this chapter we have reported a critical role
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for intracellular Ca2+ stores in a7 nAChR-elicited [3H]D-aspartate release from PFC 
synaptosomes. As such the differential sensitivity of the a l  nAChR-mediated responses to 50 
and 200 pM Cd2+ may reflect the lack of VOCC involvement whilst providing further evidence 
for the pivotal role for intracellular Ca2+ stores in a7 nAChR-mediated [3H]D-aspartate release.
Another potential target for Cd2+ is SOCCs. As discussed in Section 1.4.1 capacitive 
Ca2+ entry through SOCCs is a secondary pathway of Ca2+ influx following Ca2+ release from 
internal stores, thereby playing an important role in shaping the Ca2+ signal within the cell. 
Whilst the mechanism of SOCC activation remains a unclear (Lewis, 2007), the ability heavy 
metals, such as Cd2+, to block SOCCs is viewed as a hallmark of this Ca2+ channel (Gore et al.,
2004). Although it was originally proposed that SOCCs had the sole task of refilling 
intracellular Ca2+ stores it is now widely recognised that they can play a role in generating Ca2+ 
signals that are associated with multiple cellular processes including: exocytosis, muscle 
contraction, gene transcription and apoptosis (Parekh and Putney, 2005). Whilst the SOCC 
remains elusive recent work has revealed the protein STIM1 to be the Ca2+ sensor for store- 
operated Ca2+ entry (Liou et al., 2005; Roos et al., 2005) and Orail to act as a pore forming 
subunit in the SOCC (Feske et al., 2006). These proteins have subseqently been associated with 
TRP channels and release (Liao et al., 2007). Whilst the majority of studies on SOCCs have 
concentrated on the trp gene family, which are present in synaptosomes (TRPC1 and TRPC3- 
TRPC6 ; Goel et al., 2002) there is still some doubt over the definition of the TRP channel as a 
true SOCC, as they can be activated by processes other than store depletion (Lewis, 2007).
In a recent elegant study Feng et al., (2006) determined that TRPC channels were 
essential for nicotine-induced psychomotor stimulation, tolerance, withdrawl and sensitisation 
in C. elegans. These authers concluded by speculating that TRP channels may be paramount to 
nicotine mediated responses in other organisms. Whilst this is the only evidence of nAChR 
interactions with SOCCs, an in depth study using a variety of techiniques Singh et al., (2004) 
showed the TRPC3 to interact with the multiple SNARE proteins, including VAMP2 and 
aSNAP in cultured rat hippocampal neurones, placing the TRP channel in an ideal location to 
facilitate exocytosis. TRPC4 has also implicated with exocytosis in PC 12 and mouse chromaffin 
cells (Obukhov and Nowycky, 2002) and a recent study by Topolnik et al., (2006) documented 
that blocking the TRP channels in hippocampal slices prevents the induction of LTP. However, 
due to the non-specific effects of TRP-antagonists these data should be treated with caution 
(Halaszovich et al., 2000).
Of course it must not be overlooked that higher concentrations of Cd2+ may also be 
acting at the nAChR itself. Several papers have reported nAChR-mediated currents to be 
insensitive to Cd2+ (Gray et al., 1996; Khiroug et al., 1997; Seddik et al., 2006). However, Cd2+
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has also been shown to potentiate a4p4 nAChR-mediated currents in oocytes with an EC50 of 24 
pM (Hsiao et al., 2001) as well as decreasing a3, a5, 04 nAChR subunit-mediated currents in 
the presence of high Ca2+ (Rathouz and Berg, 1994). Cd2+ also blocks both the L247T and 
S240T/L247T (non-desensitising) a l  nAChRs at millimolar concentrations (Eddins et al., 2002). 
Indeed investigations carried out at GlaxoSmithKline (Psychiatry CEDD; Harlow) during this 
project determined that 200 pM Cd2+ substantially blocked aBgt-sensitive currents in 
hippocampal cultures (Mok and Kew, unpublished observation).
In conclusion it is unlikely that VOCCs are involved in compound A-evoked [3H]d- 
aspartate release, in agreement with the lack of effect of selective VOCC inhibitors.
cc7, Sut notfl2* are cowpCedto Ca2+-inducedCa2+ release
Previous studies using Ca2+ fluorimetry and electrophysiological techniques have 
demonstrated a link between a l  nAChR and CICR (Section 1.4.4; Sharma and Vijayaraghavan, 
2001; Dajas-Bailador et al., 2002a). The release of presynaptic Ca2+ from internal stores can 
initiate signalling cascades leading to post-translational events and/or neurotransmitter release 
(for review see Collin et al., 2005). Preliminary electron microscopy studies, carried out in 
Section 3.2.2.1 identified a sub-cellular organelle which was similar in size and shape to 
previous documentation of ER in synaptosomes (Fig 1.20; McGraw et al., 1980) in both the P2 
and Percoll™ synaptosomes (Fig 3.2). Immunocytological labelling of PFC P2 synaptosomes 
confirmed the presence of RyRs in this fraction, consistent with previous reports for mammalian 
brain that RyR2 is the predominant isoform in this region (Bouchard et al., 2003).
The five modulators of intracellular Ca2+ stores used in this project have provided 
evidence that a l  nAChRs are coupled to CICR in PFC synaptosomes. These modulators: 
ryanodine, dantrolene, xestospongin-C, thapsigargin and caffeine are discussed below. 
Unfortunately, like many pharmacological tools, the specificity of these modulators has 
previously been questioned (Collin et al., 2005).
• Ryanodine', is generally regarded to be selective for RyRs and has been used to study 
CICR in skeletal and cardiac muscle for nearly 40 years (Jenden and Fairhurst, 1969). 
Ryanodine has multiple actions at RyRs, with low concentrations sensitising the 
channels response to Ca2+ and higher concentrations, in the same range as used in this 
study, inhibiting Ca2+ release from the RyR (Zucchi and Ronca-Testoni, 1997).
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• Dantrolene: since its original synthesis in 1967 (Snyder et al., 1967) dantrolene has 
reduced the mortality of malignant hyperthermia (a genetic-based side effect of 
general anaesthetic) from 80 % to < 10 % (Krause et al., 2004). Although dantrolene 
displaces [3H]ryanodine binding (Fruen et al., 1997) and is often used to study CICR, 
its molecular targets have yet to be fully characterised (Krause et al., 2004).
• Xestospongin-C: is a more recent addition to the list of intracellular Ca2+ modulators, 
having been isolated from an Australian sponge Xestospongia species (Verkhratsky,
2005). Whilst xestospongin-C was originally portrayed as a selective blocker of IP3RS 
(Gafhi et al., 1997) subsequent work revealed this compound to be equally potent at 
inhibiting the ER Ca2+ ATPase (Smet et al., 1999), therefore blockade of response in 
the presence of this compound is not definitive of the involvement of IP3RS.
• Thapsigargin: is commonly used as a Ca2+ ATPase inhibitor (Verkhratsky, 2005). 
Blocking the ER Ca2+ ATPase results in the ER loosing ~ 22% of its Ca2+ store per 
minute, however, the mechanism of this Teak’ remains unknown (Camello et al., 
2002). Thapsigargin has also been shown inhibit (L-type) VOCCs (Rossier et al., 
1993; Shmigol etal., 1995).
•  Caffeine: at millimolar concentrations acts as an agonist at RyRs, causing this receptor 
to remain in its open conformation (Verkhratsky, 2005), however, it also has multiple 
other targets within the cell including antagonising potassium channels (Mathie et al.,
1998), adenosine receptors and a multitude of enzymes (Fisone et al., 2004).
With the exception of ryanodine, the lack of truly selective modulators of RyRs or 
IP3Rs means the data produced in the presence of these compounds must be treated with a 
certain level of caution. This issue is further confounded by the ability of these modulators to 
alter resting Ca2+ levels. Here was have reported that both thapsigargin and caffeine evoked 
[3H]D-aspartate release from PFC synaptosomes. These data are not surprising as both of these 
compounds act by directly or indirectly releasing Ca2+ from the intracellular stores 
(Verkhratsky, 2005). By employing all five modulators in this project we have been able to 
offset concerns about their disparate non-specific actions.
The insensitivity of [3H]D-aspartate release evoked by either KCI or 5-I-A-85380 to all 
five of these modulators, supports the lack of a role for CICR in non-a7 nAChR-mediated 
[3H]D-aspartate release. From these data it is possible to conclude that consistent with previous 
experiments (Dajas-Bailador et al., 2002a) non-a7 nAChRs are not preferentially linked to
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CICR (Fig 4.13). In contrast a7 nAChR-mediated [3H]D-aspartate release was significantly 
decreased in the presence of all five modulators, showing a clear link between a7 nAChR 
stimulation and CICR (Fig 4.13). The strong correlation between the data produced in the 
presence of all five modulators corroborates previous reports that have indirectly shown a l  
nAChRs to elicit CICR using nicotine or acetylcholine in the presence of nAChR antagonists 
(Dajas-Bailador et al., 2002a; Ren et al., 2005; Campusano et al. 2007).
4.3.4 oc7 and  nflChtits segregate to distinct Ca2+ pathways: physioCogicaC 
significance?
Here we have shown that at the presynaptic terminal a l  and (32* nAChRs differentially 
couple to CICR and VOCC respectively. These findings raise interesting questions as to the 
location of these nAChR subtypes and their functional coupling to Ca2+ channels, as well as to 
the different signalling cascades that they might initiate.
As discussed in Chapter 1 nicotine, acting at nAChRs in the PFC, has been shown to 
enhance aspects of working memory (Section 1.3.3; Granon et al., 1995; Jones, 2002). Here we 
have demonstrated that presynaptic a l  and (32* nAChRs in this region are capable of enhancing 
glutamatergic transmission in a Ca2+-dependent manner. These data are consistent with a recent 
report where nicotine was shown to increase the frequency and amplitude of spontaneous 
EPSCs in pyramidal neurones and intemeurones in mouse PFC, consistent with the facilitation 
of glutamate release by presynaptic nAChR associated with glutamatergic afferents (Couey et 
al, 2007).
The ability of nicotine to enhance cognitive processes in this region may arise from the 
ability of presynaptic nAChR activation to alter synaptic plasticity by increasing or altering 
excitatory amino acid release (Section 1.4.4.1; Radcliffe and Dani, 1998; Mansvelder and 
McGehee, 2000). Investigations into synaptic plasticity events have traditionally concentrated 
upon the postsynaptic component with multiple studies determining the importance of post- 
synaptic Ca2+, however, there is a growing body of evidence for the importance of presynaptic 
Ca2+ and subsequent initiation of molecular events (Reyes and Stanton, 1996).
The use of intracellular modulators of Ca2+ has shown that ryanodine-sensitive stores 
may play a pivotal role in miniature postsynaptic currents and forms of short-term synaptic 
plasticity such as paired-pulse facilitation (Llano et al, 2000; Emptage et al, 2001; Galante and 
Marty, 2003). Indeed stimulation of presynaptic kainate receptors initiates the facilitation of 
presynaptic CICR, resulting in a rapid facilitation of neurotransmitter release which
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subsequently forms the bases of LTP (Lauri et al., 2003). There are multiple ways in which 
presynaptic CICR can lead to potentiated synaptic transmission, the resulting increase in 
intracellular Ca2+ can serve to increase action-potential, or stimulation-induced extracellular 
Ca2+ entry. CICR could also serve to sensitise the response to subsequent stimuli by increasing 
the basal Ca2+ level. In this latter scenario CICR may serve to alter the vesicle population 
available for fusion via activation of presynaptic synaptic-plasticity signalling cascades, 
including ERK1/2 and CAMKII, which can ultimately result in synapsin-1 phosphorylation, see 
Section 4.3.5 (for review see Lynch, 2004).
Although evidence for nAChR-mediated LTP in the PFC has yet to be provided as 
discussed in Section 1.4.4.3 nAChRs have been shown to enhance LTP in both the VTA and the 
hippocampus (Mansvelder and McGehee, 2000; Ji et al., 2001; Ge and Dani, 2005). Although it 
is apparent that the location of the nAChRs and the ancillary stimulation is paramount to the 
resulting synaptic plasticity (Ji et al., 2001; Ge and Dani, 2005) presynaptic nAChRs have been 
implicated. In the VTA the action of nicotine on presynaptic a7 nAChRs located on 
glutamatergic neurones results in LTP and subsequent increases in dopamine release in the 
nucleus accumbens (Mansvelder and McGehee, 2000). Indeed presynaptic a7 nAChR-mediated 
glutamate release in the hippocampus has also been shown underlie certain mechanisms of 
synaptic plasticity (Gray et al., 1996; Radcliffe and Dani, 1998). As such our findings that the 
a7 nAChR can enhance glutamate release via CICR provides a plausible mechanism by which 
this receptor can modulate synaptic plasticity in the PFC.
Using confocal microscopy we have shown in the present study that a sub-population 
of PFC synaptosomes contain RyR-positive structures. Interestingly current research in our 
laboratory using aBgt-488 to label a7 nAChRs and mAb270 to identify 02* nAChRs suggests 
that the majority of aBgt-488-positive structures, but not mAb270-postitive structures, is co­
localised with RyR labelling. Autoradiography experiments, using [125I]aBgt and [3H]nicotine, 
show a7 and a402 nAChRs binding sites are differentially localised to cortical layers V/VI and 
I/ni, respectively (Section 1.3.3; Clarke et al., 1985; Gioanni et al., 1999). These observations 
suggest that the [3H]D-aspartate release measured following a7 or 02* nAChR stimulation in 
our PFC preparation may arise from distinct populations of synaptosomes. If the a7 nAChR is 
solely confined to presynaptic terminals containing RyRs this poses an interesting question as to 
whether these two proteins are functionally linked, or whether they are juxtaposed in such a way 
that enables the Ca2+ influx through the a7 nAChR to form a Ca2+ microdomain that initiates 
CICR. The possibility that the a l  nAChR is physically linked to the RyR is not inconceivable, 
indeed only recently this large, rather promiscuous protein was found to be physically tethered 
to the SNARE-protein snapin (Zissimopoulos et al., 2006) highlighting the functional role of 
RyRs in neurotransmitter release. Indeed the direct coupling of RyRs to SNARE proteins is in
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accordance with the contribution of presynaptic intracellular Ca2+ stores to modulation of both 
spontaneous and evoked synaptic transmission (Emptage et al., 2001; Bardo et al., 2006). The 
role of RyRs in altering spontaneous presynaptic firing is of particular interest in relation to 
nAChR activation as these latter receptors have been shown to enhance basal release in the 
resting/hyperpolarised neurone (Mulle et al., 1992), perhaps suggesting that nicotine, acting at 
a7 nAChRs in the PFC can modulate cognitive function by enhancing RyR-mediated basal 
release thereby altering synaptic plasticity (Sharma and Vijayaraghavan, 2003).
Whilst the lack of involvement of intracellular Ca2+ stores in (32* nAChR-mediated 
neurotransmitter release has not previously been reported, the requirement for Ca2+ influx 
through VOCCs in heteromeric nAChR-mediated [3H]D-aspartate release is consistent with the 
previously reported for this receptor subtype in neurotransmitter release from the striatum and 
hippocampus (Soliakov and Wonnacott, 1996; Kulak et al., 2001), suggesting that this is a 
common coupling. It has previously been suggested that nAChR stimulation will result in a 
uniform depolarisation of the entire synaptosome (Kulak et al., 2001); in this scenario the (32* 
nAChR and VOCC would reside on the same terminal, but not, necessarily, in close proximity. 
However, it also remains possible that the (32* nAChR and VOCC may be in close proximity, 
enabling the (32* nAChR to act as a sensor for the VOCC. As described in Section 1.4.3, 
VOCCs are physically attached to multiple SNARE proteins (Fig 1.27; Catterall, 1999) and are 
well defined as being able to mediate exocytosis, therefore a direct link between (32* nAChR 
activation to VOCC opening could mediate exocytosis of excitatory amino acids, without the 
requirement for CICR.
4.3.5 oc7, 6ut not fi2* nfLCh^ ctre coupfecf to t/2: a. roCe in synaptic plasticity?
One potential downstream target of CICR following a l  nAChR stimulation is the 
MAPK pathway (Kemmerling et al., 2007). ERK1/2 activation is traditionally associated with 
altering gene expression via activation of transcription factors such as CREB (Dineley et al., 
2001; Hu et al., 2002) and ELK (Nuutinen et al., 2007), both of which have been associated 
with nAChR activation and gene-expression in long term synaptic plasticity changes (Davis et 
al., 2000). However, interest in this pathway at the presynaptic terminal has recently gained 
momentum following reports that its activation may be essential for synaptic plasticity (Section 
1.5.1). Although other investigations have documented that a l  nAChR stimulation can initiate 
increases in ERK1/2 phosphorylation (Dineley et al., 2001; Dajas-Bailador et al., 2002b; 
Brunzell et al., 2003; Bell et al., 2004) here we have reported for the first time the ability of 
presynaptic a l  (but not (32*) nAChRs to cause increases in presynaptic ERK1/2 
phosphorylation.
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In the presynaptic terminal activation of ERK1/2 can lead to phosphorylation of 
multiple targets that can subsequently assist in exocytosis. In this project we have shown using 
MEK-1 inhibitors that this pathway is required for a7 nAChR-mediated [3H]D-aspartate release 
from PFC synaptosomes. The data for both |32* nAChR- and KCl-evoked [3H]D-aspartate are 
less clear-cut with both MEK-1 inhibitors decreasing [3H]D-aspartate release, but not to a 
statistically significant extent. As we directly showed using western blotting that stimulation of 
P2* nAChRs did not increase levels of ERK1/2 phosphorylation it is unlikely that the decrease 
seen in (32* nAChR-mediated [3H]D-aspartate release in the presence of MEK-1 inhibitors 
correlates with a contribution of ERK1/2 in this pathway. Whilst both MEK-1 inhibitors used 
are considered relatively selective for the MAPK pathway (Davies et al., 2000), they have also 
both been shown to inhibit KCl-mediated glutamate release from hippocampal synaptosomes by 
non-specific effects on VOCCs (Pereira et al., 2002b). This latter non-specific interaction is 
particularly pertinent, given the necessity of VOCCs in both p2* nAChR- and KCl-evoked 
release.
The involvement of ERK1/2 in a7, but not (32* nAChR-mediated [3H]D-aspartate 
release once again highlights the different pathways activated following stimulation of these two 
nAChR subtypes. Further investigation into a7 nAChR-generated increases in ERK1/2 
phosphorylation showed this response to be sensitive to aBgt and MEK-1 inhibitors as well as 
ryanodine. These data are consistent with the model shown in Fig 4.13 where a7 nAChR 
stimulation leads to CICR which subsequently initiates the MAPK cascade resulting in ERK1/2 
phosphorylation.
Infusion of MEK-1 inhibitors has been shown to attenuate KCl-evoked dopamine 
release in PC12 cells (Bloch-Shilderman et al., 2001) and bovine chromaffin cells (Cox and 
Parsons, 1997) as well and growth factor-evoked glutamate release from hippocampal cultures 
(Numakawa et al., 2002) and synaptosomes (Pereira et al., 2002). Of more relevance to this 
thesis is the previous documentation that MEK-1 (and PKC) inhibitors block nAChR-mediated 
noradrenaline release from bovine chromaffin cells (Cox and Parsons, 1997). Whilst the 
downstream target of ERK1/2 remains unknown there are multiple possibilities, including 
Muncl3, SNAP-25 and synapsin-1 (Leenders and Sheng, 2005). Phosphorylation of this latter 
protein has been proposed as one possible mechanism by which ERK1/2 enhances synaptic 
plasticity (Section 1.6.2; Kushner et al., 2005). The role of synapsin-1 has been most 
extensively studied in BDNF-modulated glutamate release. Jovanovic et al., (2000) reported that 
BDNF-evoked glutamate and GAB A release from hippocampal synaptosomes was greatly 
reduced in synapsin-1 knock out mice. This group showed that MEK-1 inhibitors also reduce 
release, western blot analysis revealed that BDNF initiated a cascade of events resulting in 
ERK1/2 activation and subsequent synapsin-1 phosphorylation leading to the facilitation of
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neurotransmitter release. BDNF- and nAChR-evoked neurotransmitter release is similar in that 
both are thought to serve a modulatory function. Therefore, by causing the release of synapsin- 
tethered vesicles ERK1/2 can influence synaptic plasticity. As discussed in Section 1.5.1 
ERK1/2 has an essential role in learning with studies showing increases in ERK1/2 
phosphorylation levels during behavioural learning tasks and extinction of the ability to learn 
certain memory-based tasks following infusion of MEK-1 inhibitors, interestingly synapsin-1 is 
also phosphorylated in learning tasks (Gomez-Pinilla et al., 2001).
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5.1 Introduction
Measuring [3H]D-aspartate release from PFC synaptosomes we have shown differential 
coupling of presynaptic nAChR subtypes to distinct Ca2+ sources (Chapter 4). Here we have 
expanded this work to investigate this coupling in the broader cellular context using the PC 12 
cell line.
5.1.1 JLims o f  this chapter.
Investigate the presence ofn fl.Ch<R$ in (PC12 ceds
As a prerequisite to using the PC 12 cells to study nAChR coupling to Ca2+, it was first 
necessary to define the nAChR subtypes present. Although multiple investigations have been 
carried out to identify the nAChR subunits present in the PC 12 cell line (Section 5.1.2) these 
studies have highlighted the variability between PC 12 cell lines. Here we have used in situ 
[125I]aBgt and [3H]epibatidine binding to confirm the presence of homomeric a7 and 
heteromeric [32* nAChRs. We have also taken advantage of aBgt-488 to visualise the surface a7 
nAChRs using confocal microscopy.
Vse selective nJ^Ch^su6type tooCs to investigate oc7 and non-oc7 mediated increases in intracedufar 
Ca2+ in the <PC12 ceds
Section 3.2.5-6 showed that compound A and PNU 120596 act at a7 nAChRs to evoke 
[3H]D-aspartate release from PFC synaptosomes, whereas 5-I-A-85380 acts at non-a7 nAChRs. 
Here we have used the same compounds to measure increases in intracellular Ca2+ in PC 12 cells 
using the Ca2+ indicator dye fluo-3 AM.
Investigate differential coupling ofoc7 andnon-oc7 nA.Ch<R§ to ClOP^and VOCC
Following the results in Section 4.2.2-4 indicating that nAChR subtypes are 
differentially coupled to VOCCs and CICR we sought to investigate this relationship in a 
different system. As such here we have used our selective nAChR subtype tools to mediate 
increases in intracellular Ca2+ using fluo-3 AM in the PC 12 cell line in the presence or absence 
of modulators of Ca2+ channels.
5.1.2 The (PCI 2 ceCC Cine
PC 12 cells are an immortal secondary cell line, derived from a rat pheochromocytoma 
that are often used as a in vitro neuronal model system (Adler, 2006). Pheochromocytomas are 
neuroendocrine tumours, originating from the chromaffin cells within the medulla of the adrenal 
gland. The devastating effects of these tumours in humans, primarily resulting from increased
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adrenaline and noradrenaline release, spurred the quest to produce a model of this disease. In 
1972 Warren and Chute reported the identification and isolation of a rat pheochromocytoma, 
which, when transplanted into New England Deaconess Hospital (NEDH) rats resulted in a 
weight gain, followed by weight loss and subsequent death, providing a suitable experimental 
model for the human disease (Warren and Chute, 1972). This transplantable pheochromocytoma 
was then further characterised in vitro (DeLellis et al., 1973), revealing these cells to be 
catecholinergic in nature. However, unlike previously cultured cells from neuroblastomas these 
pheochromocytoma cells failed to exhibit evidence of neuronal differentiation in the form of 
branching cell processes. Subsequent investigation into this cell line by Tischler and Greene, 
(1975), demonstrated that upon addition of nerve growth factor (NGF) these cells ceased 
proliferation and differentiated to produce processes in a manner analogous to that seen with 
primary cultures of sympathetic neurones treated with NGF. These findings lead to the 
conclusion that rat pheochromocytoma, which is part of the neural crest lineage, has kept its 
pluripotency, enabling it to exhibit both pheochromocytoma and neuronal properties. A clonal 
cell line that was NGF responsive and catecholinergic in nature was subsequently produced and 
designated ‘PC12’ (Greene and Tischler, 1976).
5.1.3 (PCI 2 cell Cine an(C nJiCdPj
Initial experiments carried out by Dichter et al., (1977) revealed that acetylcholine 
could produce d-tubocurarine-sensitive ‘action potentials’ in this cell line, consistent with a 
nAChR mechanism. These data complemented reports from the same group showing that 
nicotine and DMPP produced Ca2+-dependent, mecamylamine-sensitive [3H]noradrenaline 
release from PC 12 cells (Greene and Rein, 1977). Further work investigating acetylcholine- 
induced single channel currents subsequently revealed that there was a heterogeneous 
population of nAChR present on the PC 12 cells (Bormann and Matthaei, 1983).
Since these initial experiments there have been a plethora of investigations into the 
presence of nAChRs within the PC 12 cell line. These studies have detected a3, a5, a7, 02 and 
04 nAChR subunit mRNA (Boulter et al., 1990; Rogers et al., 1992; Henderson et al., 1994; 
Blumenthal et al., 1997; Takahashi et al., 1999), with a consistent lack of a2, a4 and a6  subunit 
mRNA (Boulter et al., 1990; Rogers et al., 1992; Henderson et al., 1994). Rogers et al., (1992) 
also detected 03 subunit mRNA, however, this has not been replicated. These subunits have 
been shown to form a302(a5)t, a304(a5) and a7 nAChRs (Rogers et al., 1992; Blumenthal et 
al., 1997; Avila et al, 2003).
* Brackets signify that the nAChR can exist with, or without the a5 nAChR subunit.
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The effect of NGF on the expression of nAChR subunit mRNA and protein has also 
been reported, although the data produced have been inconsistent. Whilst in some studies there 
has been a robust increase nAChR mRNA (Henderson et al., 1994; Hu et al., 1994; Takahashi et 
al., 1999) as well as nAChR-mediated catecholamine release (Greene and Rein, 1977; Baizer 
and Weiner, 1985), ion flux (Amy and Bennett, 1983), and whole cell currents (Ifune and 
Steinbach, 1990; Henderson et al., 1994) there are also been reports of no change in nicotine 
mediated responses and an actual decrease in subunit mRNA (Rogers et al., 1992; Blumenthal et 
al., 1997). These variations highlight the wide variety of PC 12 lines now used, each distinct 
from that originally isolated by Greene and Tischler (1976). The PC 12 cells used in this project 
were a generous gift from Dr D. Berg, who has previously reported the nAChR composition to 
be unaffected by NGF (PC12C; Blumenthal et al., 1997), therefore non-differentiated PC 12 
cells were used throughout this project.
5.1.4 (PCI2 ceCC Cine andvoCtage-operatedCa2+ channels
The importance, structure and function of voltage-operated Ca2+ channels (VOCCs) 
have already been described in depth (Section 1.4.3). Investigations into the VOCC subtypes 
present in the PC 12 cell line have confirmed that it does contain a heterogenous array of 
VOCCs (Sher et al., 1991). Although initial pharmacological studies only revealed the presence 
of L- and N-type VOCCs in undifferentiated PC 12 cells (Janigro et al., 1989; Plummer et al., 
1989; Reber and Reuter, 1991), three aj subunit genes: aiA, aiB and aiC were subsequently 
demonstrated using RT-PCR (Liu et al., 1996). Further evidence for the expression of three 
distinct functional VOCCs: L-type (alc), N-type (<XiB), and P/Q-type (a!A) was obtained using 
pharmacological tools combined with patch clamping of the PC12 cell line (Liu et al., 1996). In 
addition, this cell line contains the mRNA of pi_3; with the latter being the most prominent. 
Immunoprecipitation experiments revealed both p3 and p2 proteins to be associated with the N- 
type VOCC (Liu et al., 1996).
Contrary to mRNA and protein expression studies of nAChR subunits (Section 5.1.3) 
the effect of NGF and subsequent cellular differentiation on VOCCs has produced consistent 
results. Three min - 12 days NGF treatment increases both L- and N-type VOCC number and 
subsequent Ca2+ conductance (Plummer et al., 1989; Reber and Reuter, 1991; Bouron et al.,
1999). This increase has been mirrored with the expression of aJB subunit mRNA in proportion 
to increases of p3 and p2, consistent with their relationship remaining unaltered following PC 12 
differentiation (Liu et al., 1996).
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5. 1.5 (PCI2 ceCCCine andintraceCCuCar Ca2+ stores
The PC 12 cell line is well defined as containing multiple IP3- and ryanodine/caffeine- 
sensitive intracellular Ca2+ stores (Fasolato et al., 1991; Zacchetti et al., 1991). Pharmacological 
tools have defined different Ca2+ stores in PC 12 cells: solely rP3R-sensitive, caffeine and 
ryanodine sensitive, H^R/ryanodine sensitive and thapsigargin sensitive stores, all of which are 
capable of inducing capacitive Ca2+ entry (Bennett et al., 1998). There has been some confusion 
as to whether the PC 12 IP3 and ryanodine receptors are expressed on separate compartments 
(Reber et al., 1993); or together (Zacchetti et al., 1991). Whichever may be the case it is clear 
that these two receptors are capable of working in synergy (Barry and Cheek, 1994).
Using the techniques of western blotting and confocal microscopy Johenning et al., 
(2002) investigated IP3R and RyR composition in NGF-treated PC 12 cells. IP3R type I and in  
were found to be present, however, their localisation varied, with the latter being localized 
primarily to the nucleus and the former stretching into the neurites. Their different cellular 
location suggests these different isoforms may have different roles within the cell. The RyR2 
(and to a lesser extent RyR3) were also detected, with confocal microscopy revealing labelling 
throughout the cell. Investigations into the presence of IP3R and RyR in undifferentiated PC 12 
cells have revealed equal abundances of EP3R type I and III (Newton et al., 1994) and the 
presence of type 1,11 (Bennett et al., 1998) and HI (Chan et al., 2000); RyR isoforms. Although 
the cellular localisation of IP3R and RyR in undifferentiated PC 12 cells has not been studied, it 
is interesting to note that (Bennett et al., 1996) who reported the presence of type I and II RyRs 
in undifferentiated PC 12 cells, could only detect type I in NGF-treated cells.
5.1.6 Ccl2+ measurements in ceCCCines
The importance of Ca2+ as a pivotal cell signalling molecule (Section 1.4) has led to the 
development of indicator dyes based on the Ca2+ chelators EGTA or BAPTA, which fluoresce 
upon Ca2+ binding. These Ca2+ indicators, which can be divided into two groups, ratiometric and 
non-ratiometric (Tsien, 1988), have been widely used for investigating intracellular Ca2+ fluxes.
Ratiometric dyes fluoresce in the absence of Ca2+, binding of Ca2+ results in a shift in 
the fluorescence wavelength emitted. The ability to measure both wavelengths of fluorescence 
allows the user to gain a quantitative insight into exact concentration of cytosolic Ca2+ prior to 
and following stimulation in the system studied. The most commonly used ratiometric Ca2+ 
indicators are fura-2 and indo-1, based on the structures of EGTA and BAPTA, respectively. 
Due to the detection system available for this project we have used the non-ratiometric Ca2+ 
indicator fluo-3 (Dajas-Bailador et al., 2002a). Non-ratiometric indicators display very low 
levels of fluorescence in the absence of Ca2+, but show a 40 -  100 fold increase in fluorescence
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when bound to Ca2+. Fluo-3 has been used here in its acetoxymethyl ester form (fluo-3 AM), 
this makes the dye uncharged and enables it to pass across the lipid membrane without the 
requirement for cell permeabilisation. Fluo-3 displays a Kd value of 400 nM, allowing detection 
of Ca2+ accurately into the micro-molar range.
CKJKFTE^S: n C f t  3C media te d  increases in intracellular Ca2+ in <PC12 cells
5.2 (RjsuCts
5.2.1 (Determination o f  nftCh^suStypes expressed in <PC12 cells
Single concentration in situ binding analyses were carried out (Section 2.4.8) using 2 
nM [3H]epibatidine, to quantitate a3* nAChR or 10 nM [125I]aBgt, to quantitate a7 nAChR. 
Binding experiments were carried out in parallel with Ca2+ assays to determine nAChRs levels 
in samples used for functional assays at time o f assay. Substantial specific binding o f both 
radioligands to the PC 12 cells was demonstrated (261 ± 49 fmol [3H]epibatidine/mg protein; 
and 420 ± 46 fmol [!25I]aBgt binding sites/mg protein; Fig 5.1).
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Figure 5.1: [3H|Epibatidine and | l25IlaBgt binding to PC12 cells
[3H]Epibatidine (2 nM) or [ 25I]aBgt (10 nM) were incubated with PC 12 cells, as described 
in the Methods, to determine total binding. Non-specific binding was determined in the 
presence of 1 mM nicotine. Specific binding was calculated by subtraction of non-specific 
binding from total binding. Data represent the mean ± SEM of 3 independent experiments, 
carried out on cells at passage 7 - 1 1 ;  each carried out in triplicate. This work was carried 
out in collaboration with Katharine Hanrott.
To confirm the presence o f surface a7 nAChRs we carried out alexafluor-488 tagged 
aBgt (aBgt-488; 200 nM) labelling on non-permeabilised PC 12 cells. aBgt-488 labelling was 
detected in approximately 70 % o f the cells and was present at varying densities (Fig 5.2A). All 
o f  the aBgt-488 labelling was eliminated in the presence o f 1 mM nicotine (Fig 5.2B), 
consistent with the selective labelling o f a7 nAChRs by aBgt-488.
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Figure 5.2: aBgt-488 labelling of PC 12 cells
Unfixed, non-permeabilised PC 12 cells were labelled with 200 nM aBgt-488 in the A: 
absence or B: presence of 1 mM nicotine as described in the Methods and visualised using 
confocal microscopy. Representative pictures shown (n = 2); scale bar = 10 pm. This work 
was carried out in collaboration with Neal Innocent.
5 2 2  a.7 andnon-oc7 nSiCfdR^mediatedincreases in intraceffufar Ccf+ in PC12 cefls
To investigate the coupling between specific nAChR subtype activation and increases 
in intracellular Ca2+ we monitored changes in intracellular Ca2+ in populations o f PC 12 cells 
loaded with fluo-3 AM. Responses to application of selective nAChR agonists, in the presence 
or absence of antagonists and modulators were measured. Basal fluorescence levels were 
measured for 5 s before the addition of agonist and subsequently as a continual measurement for 
20 s (see Fig 5.3). In all cases increases in fluorescence reached a maximum within 5 s and this 
response was maintained over the remainder of the time course of the experiment. The addition 
of Triton-XlOO and subsequently manganese to each well determined Fmax and Fmin, 
respectively, facilitating the normalisation of fluorescence in each well.
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Consistent with previous studies in PC 12 cells (Sabban and Gueorguiev, 2002) 
nicotine evoked a concentration-dependent increase in intracellular Ca2+, with an EC50 value o f 
23.5 ± 6.6 pM  (Fig 5.3). The maximum increases in intracellular Ca2+ was seen following 
application o f  100 pM nicotine.
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Figure 5.3: Nicotine-evoked elevation of intracellular Ca2+ in PC12 cells
Cells were loaded with fluo-3 AM and changes in fluorescence monitored in response to 20 
s stimulation with nicotine. A: Representative traces of nicotine 10 and 100 pM-evoked 
changes in fluorescence. B: Changes in fluorescence following stimulation with nicotine 
(1-300 pM). Data are expressed as the percentage of Fmax-Fmin (mean ± SEM), from at 
least 3 independent experiments, each carried out with 4 replicates. Data points were fitted 
to the Hill equation, as described in Section 2.4.6.1, giving as EC50 = 23.5 ± 6.6 pM. This 
work was carried out in collaboration with Katharine Hanrott.
nAChR subtype-selective antagonists were employed to characterise the receptors 
mediating the response to 100 pM  nicotine-evoked response. The general nAChR antagonist 
mecamylamine decreased nicotine-evoked increases in intracellular Ca2+ to a level comparable 
to buffer alone responses (87.6 ± 1.8 % inhibition; Fig 5.4), confirming that nicotine was indeed 
acting at nAChRs. aBgt failed to significantly decrease nicotine-evoked increases in 
intracellular Ca2+ (19.8 ± 2.2 % inhibition). In contrast the non-a7 nAChR antagonists, DHpE 
(p2* nAChR antagonist), a-conotoxin M il (a3p2 nAChR antagonist) and a-conotoxin AUIB 
(a3p4 nAChR antagonist) all significantly reduced the nicotine-evoked increase in intracellular 
Ca2+ (39.1 ± 7.8 %, 33.6 ± 4.5%, and 40.2 ± 4.8 % inhibition, respectively; Fig 5.4). The ability 
o f these three nAChR antagonists to significantly decrease the nicotine-evoked increases in 
intracellular Ca2+ is consistent with multiple non-a7 nAChRs contributing to the response. None 
o f the nAChR antagonists, at the concentrations, used significantly altered basal fluorescence 
readings.
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Figure 5.4: The contribution of nAChR subtypes to nicotine-evoked increases in 
intracellular Ca2+ in PC12 cells
Cells were loaded with fluo-3 AM and stimulated with 100 |iM nicotine in the presence or 
absence of mecamylamine (Mec; 20 pM), aBgt ( l00 nM), DH0E (1 pM), a-conotoxin Mil 
(Mil; 200 nM) or a-conotoxin AUIB (AUIB; 1 pM). Antagonists were pre-incubated with 
the cells for 10 min (20 min for aBgt), before stimulation with nicotine. Changes in 
fluorescence were monitored for 20 s following the addition of nicotine. Data are expressed 
as a percentage of nicotine (100 pM) control response, monitored in parallel. A: 
Representative traces are shown of nicotine-evoked changes in fluorescence in the presence 
and absence of mecamylamine (mec; 20 pM), aBgt (100 nM). B: Bars represent the mean ± 
SEM of at least 3 independent experiments, each carried out with 4 replicates. 
(Significantly different from nicotine (100 pM) alone; **p < 0.01, one-way ANOVA and 
post hoc Dunnetf s test. This work was carried out in collaboration with Katharine Hanrott.
The presence o f functional a l  nAChRs was further examined using lower 
concentrations o f nicotine. Under these conditions aBgt significantly reduce both 10 and 30 pM 
nicotine-evoked increases in intracellular Ca2+ (68.8 ± 5.0 % and 55.6 ± 3.5 % inhibition, 
respectively; Fig 5.5), consistent with the presence o f  functional a l  nAChRs on this cell line. 
However, the responses mediated by these lower concentrations o f nicotine were relatively 
small, which hampers the ability to investigate the pharmacology mediating the response.
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Figure 5.5: Contribution of a l  nAChRs to nicotine-evoked elevation of intracellular
C a2+ in PC 12 cells
Cells loaded with fluo-3 AM were stimulated for 20 s with 10, 30 or 100 pM nicotine in the 
presence or absence aBgt (100 nM, 20 min pre-incubation) or mecamylamine (mec; 20 pM, 
10 min pre-incubation). Data are expressed as a percentage of the respective control 
responses measured in parallel. Bars represent the mean ± SEM of at least 3 independent 
experiments, each carried out with 4 replicates. Significantly different from control 
stimulation, **p < 0.01; one-way ANOVA and post hoc Dunnetfs test. This work was 
carried out in collaboration with Katharine Hanrott.
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5.2.3 oc7- and non-oc7 nACh^evo^ed increases in Ca2+: studies with su6type 
selective agonists
To investigate the ability o f a l  nAChR to increase Ca2+ levels in the absence o f other 
nAChR activation we applied the a l  nAChR-selective agonist compound A (De Filippi, 2002; 
O’Neill, 2002; Cilia et al., 2005; Visanji et al., 2006). Despite the high potency o f this agonist in 
the superfusion system (Section 3.2.5.2, Fig 3.13), over the concentration range 0.1 nM -  10 
pM, compound A failed to elicit any detectable increase in intracellular Ca2+ over buffer alone 
(Fig 5.6A, B).
To facilitate the generation o f measurable a l  nAChR-mediated responses we took 
advantage o f PNU 120596, a selective positive allosteric modulator o f the a l  nAChR (Hurst et 
al., 2005). Based on conditions used to give a maximal response o f Ca2+ flux through an 
engineered variant o f the human a l  response using a FLIPR assay (Hurst et al., 2005) we 
incubated the PC 12 cells with 10 pM PNU 120596 for 2 min before addition o f agonist. This 
did not alter the initial basal fluorescence reading compared to control (Fig 5.6A, D).
Initial PNU 120596 experiments were carried out using 100 pM nicotine, which gave a 
robust increase in intracellular Ca2+, but did not contain a significant a l  nAChR component (Fig
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5.4). Following a 2 min preincubation of 10 pM PNU 120596 100 pM nicotine-evoked 
increases in fluorescence were significantly enhanced (33.6 ± 6 .8 % increase; Fig 5.6). These 
responses were markedly attenuated in the presence of mecamylamine (80.4 ±3.1 % inhibition 
of nicotine plus PNU 120596 control, Fig 5.6B). In the presence of aBgt (100 nM), responses to 
nicotine plus PNU 120596 were reduced to a similar level as responses to nicotine alone in the 
presence of aBgt (Fig 5.6B), suggesting that PNU 120596 selectively enhanced the a7 nAChR- 
mediated component of nicotine-induced increases in intracellular Ca2+.
We reported in Section 3.2.5.2 that compound A evoked [3H]D-aspartate release via a l  
nAChRs. Although this compound did not produce a measurable effect on Ca2+ levels in PC 12 
cells (Fig 5.6A, B) in the presence of 10 pM PNU 120596 (2 min pre-incubation), compound A 
elicited responses over a range of concentrations (0.1 nM -  1 pM, Fig 5.6A). As seen with 
compound A-mediated [3H]D-aspartate release from synaptosomes (Fig 3.13) this response was 
bell-shaped, with no significant difference in the increase seen between application of 0.1 nM - 
1 pM compound A (Fig 5.6C). Using the fixed concentration of 10 nM compound A we 
investigated the effects of varying concentration of PNU 120596 (0.1 -  300 pM; Fig 5.6D). 
PNU 120596 potentiated compound A-mediated responses with a bell-shaped concentration- 
response profile (Fig 5.6D), with maximum potentiation observed at 10 pM PNU 120596. The 
attenuation of responses at higher concentrations of PNU 120596 could signify desensitisation 
or channel block, or may reflect its limited solubility.
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Figure 5.6: The effect of PNU 120596 on nicotine evoked elevation of intracellular
Ca2+ in PC 12 cells
PC 12 cells were loaded with fluo-3-AM and fluorescence was monitored at F538. A: 
Representative traces from PC 12 cells, loaded with fluo-3 AM and stimulated with nicotine 
alone (100 pM); nicotine after a 2 min pre-incubation with PNU 120596 (PNU, 10 pM) in 
the absence or presence of aBgt (100 nM, 20 min pre-incubation). B: Cells were stimulated 
with 100 pM nicotine, either alone or following a 2 min incubation with 10 pM PNU 
120589 (PNU), in the presence or absence of mecamylamine (Mec, 20 pM, 10 min pre­
incubation) or aBgt (100 nM, 20 min pre-incubation). Maximum fluorescence responses 
were calculated as a percentage of Fmax-Fmin. Data are expressed as a percentage of 
nicotine alone; bars are the mean ± SEM from at least four independent experiments. 
Significantly different from nicotine alone *p < 0.05, ** p < 0.01; Significantly different 
from nicotine plus PNU 120596 t1p  <0.01; one-way ANOVA with post-hoc Dunnett’s test. 
C: PC 12 cells were stimulated with varying concentrations of compound A alone (light 
green bars) or following a 2 min pre-incubation with PNU 120596 (PNU, 10 pM; dark 
green bars). The dashed line shows the mean fluorescence in response to buffer. D: Cells 
were pre-incubated with varying concentrations of PNU 120596 (PNU; 0.1 nM -  300 pM) 
for 2 min before stimulation with compound A (Cpd A, 10 nM); controls were pre- 
incubated and stimulated with buffer only (black bar), treated with 10 pM PNU 120596 in 
the absence of agonist (red bar) or stimulated with 10 nM compound A alone (light green 
bar). Data are expressed as a percentage of Fmax-Fmin; bars are the mean ± SEM from at 
least four independent experiments. Significantly different from 10 nM compound A alone 
**p <0.01, one-way ANOVA with post-hoc Dunnetf s test
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To confirm that the rapid increase in fluorescence in response to addition o f 10 nM 
compound A in the presence o f 10 pM PNU 120596 was selectively mediated by a7 nAChR the 
effect o f nAChR antagonists was investigated (Fig 5.7).
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Figure 5.7: The effect of nAChR antagonists on increases in intracellular C a2+ evoked 
by compound A plus PNU 120596
PC 12 cells were loaded with fluo-3 AM and fluorescence was monitored at F538. A: 
Representative traces from PC 12 cells, loaded with Fluo-3 AM and stimulated with 
compound A alone (Cpd A; 10 nM light green line); compound A after a 2 min pre­
incubation with PNU 120596 (PNU, 10 pM) in the absence (dark green line) or presence of 
aBgt (100 nM, 20 min pre-incubation, grey line). B: Cells were incubated with 10 pM PNU 
120596 for 2 min and then stimulated with 10 nM compound A, in the presence or absence 
of mecamylamine (Mec 20 pM, 10 min pre-incubation), dihydro-P-erythroidine (DHPE, 1 
pM, 10 min pre-incubation) or aBgt (100 nM, 20 min pre-incubation). Bars show the mean 
± SEM from at least five independent experiments. Data are presented as a percentage of 
control as determined in parallel in the absence of inhibitors. Significantly different from 
compound A plus PNU control **p < 0.01; one-way ANOVA with post-hoc Dunnetf s test.
The response elicited by compound A plus PNU 120596 was inhibited by 78.6 ± 7.0% 
and 85.9 ± 1.4% in the presence o f 20 pM mecamylamine or 100 nM aBgt, respectively, but 
was insensitive to 1 pM DHpE (97.5 ± 13.1% o f control, Fig 5.7). This confirmed that only a7 
nAChRs were activated by application o f 10 nM compound A in the presence o f 10 pM PNU 
120596. Therefore this stimulation procedure was used to selectivity elicit a7 nAChR-mediated 
responses in subsequent experiments.
To examine non-a7 nAChR-mediated increases in intracellular Ca2+ 5-I-A-85380 
(Mukhin et al., 2000; Mogg et al., 2004) was utilised. 5-I-A-85380 elicited increases in 
fluorescence with an EC5o o f 11.2 ± 1.1 pM  (Fig 5.8A). The maximum response was achieved 
with 30 pM 5-I-A-85380 (Fig 5.8A); this response was similar in magnitude to the produced by 
10 nM compound A in the presence o f 10 pM PNU 120596 (23 ± 2.3 versus 34.2 ± 4.1 %
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Fmax-Fmin). The nAChR pharmacology mediating the response to 30 pM 5-I-A-85380 was 
investigated. 5-I-A-85380-evoked increases in intracellular Ca2+ were inhibited by 78.2 ± 5.1 % 
in the presence o f mecamylamine (Fig 5.8B). Responses were also significantly inhibited by 
DHpE (1 pM; 61.5 ± 15.5 % inhibition, Fig 5.8B), a-conotoxin M il (200 nM; 66.0 ± 5.45 
inhibition Fig 5.8B). Inhibition by DHpE and a-conotoxin M il was not additive (Fig 5.8B), 
suggesting that this concentration o f 5-I-A-85380, which produced a similar level o f 
fluorescence to that seen following compound A plus PNU 120596 application (Fig 5.10), is 
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Figure 5.8: 5-I-A-85380-mediated increases in intracellular C a2+ levels in PC12 cells
PC 12 cells, loaded with fluo-3 AM were stimulated with A: varying concentrations of 5-1- 
A-85380. Data are presented as a percentage of Fmax-Fmin; data points are fitted to the 
Hill equation; EC50 = 11.2 ± 1.1 pM. Values are the mean ± SEM from at least four 
independent experiments. B: Cells were stimulated with 5-I-A-85380 (30 pM) in the 
presence or absence of aBgt (100 nM), DHpE (1 pM), mecamylamine (mec; 20 pM), a- 
conotoxin Mil (Mil; 200 nM) or a-conotoxin Mil and DHPE together. Antagonists were 
added 10 min before agonist (aBgt, 20 min). Data are presented as a percentage of control 
as determined in parallel in the absence of inhibitors. Bars show the mean ± SEM from at 
least five independent experiments. Significantly different to control *p < 0.05, **p <0.01; 
one-way ANOVA with post-hoc Dunnett’s test.
Although this relatively high concentration o f 5-I-A-85380 inhibited [125I]aBgt to PFC 
P2 membranes (Section 3.2.5.3; Fig 3.16), in PC12 cells responses to 30 pM 5-I-A-85380 were 
insensitive to aBgt (100 nM, 100.7 ± 3.3% o f control, Fig 5.8B). To confirm the lack o f a7 
nAChR involvement in the 30 pM 5-I-A-85380-mediated increases in intracellular Ca2+ we 
examined the effect o f  PNU 120596 on this response. PNU 120596 (10 pM; 2 min pre- 
incubation) did not significantly alter the 5-I-A-85380 evoked increases in intracellular Ca2+ 
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Figure 5.9: The effect of PNU 120596 on 5-I-A-85380-mediated increases in 
intracellular Ca2+ levels in PC12 cells
PC12 cells, loaded with fluo-3 were stimulated with 30 pM 5-I-A-85380 alone, or 
following a 2 min preincubation with 10 pM PNU 120596. A: Representative traces of 
increases in fluorescence B: Data are presented as a percentage of 5-I-A-85380 alone, 
carried out in parallel, values are the mean ± SEM from five independent experiments.
In Chapter 4, when comparing nAChR-mediated [3H]D-aspartate responses we 
examined the effect o f a KC1 stimulation in parallel, revealing that KC1 application elicits 
[3H]D-aspartate via a similar pathway to p2* nAChR mediated release (Section 4.2.2-3). To 
determine a suitable concentration o f KC1 to use for comparison o f depolarisation-evoked 
increases in intracellular Ca2+ we first examined a range o f KC1 concentrations. KC1 evoked a 
concentration-dependent increase in intracellular Ca2+ (Fig 5.10), with 60 mM KC1 producing a 
comparable increase in fluorescence to that achieved by compound A plus PNU 120596 (Fig
5.10). KCl-evoked increases in fluorescence were unaffected by 10 pM PNU 120596 (97.4 ± 
4.7% o f response to 60 mM KC1 alone, data not shown). Therefore 60 mM KC1 was used 
throughout the rest o f this project.
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Figure 5.10: The effect of KCI on intracellular Ca2+ levels in PC12 cells
PC 12 cells, loaded with fluo-3 AM were stimulated with A: varying concentrations of KCI. 
Data are presented as a percentage of Fmax-Fmin. Values are the mean ± SEM from at least 
three independent experiments, carried out with four replicates. B Representative traces 
from PC 12 cells stimulated with compound A (following 2 min pre-incubation with 10 pM 
PNU 120596); KCI (60 mM); 5-I-A-85380 (30 pM).
S.2.4 (Rputes ofCa2+ injTu^foHowing cc7- or non-oc7 nJLC^stimulation
nAChR stimulation can result in direct Ca2+ entry through the intrinsic ion channel, or 
indirectly through activation o f VOCC (Section 1.4). In Section 4.2.2 we revealed that 
presynaptic a l-  and non-a.7 nAChR-mediated [3H]D-aspartate release is entirely dependent 
upon extracellular Ca2+, but the route o f  Ca2+ entry varies depending upon the nAChR subtype 
activated. Following a l  nAChR activation, the primary route o f  Ca2+ entry was via the ion 
channel itself, in comparison following non-a7 nAChR stimulation there was subsequent 
activation o f VOCCs. Here we have used the selective a l-  and non-a7 nAChR methods o f 
stimulation to determine if the same model operates in the broader context o f  the PC 12 cell.
In PC12 cells increases in intracellular Ca2+ mediated by a l -, non-a7 nAChR or KCI 
were all significantly reduced in the absence o f extracellular Ca2+ (Fig 5.11), however, their 
sensitivity to VOCC inhibitors varied. A low concentration o f Cd2+ (50 pM), a general VOCC 
inhibitor, significantly reduced 5-I-A85380- and KCl-evoked responses by 70.8 ± 12.7% and 
71.3 ± 3.4%, respectively (Fig 5.11), but did not significantly affect responses to compound A 
plus PNU 120596 (12.8 ± 14.5% inhibition, Fig 5.11). Compound A plus PNU 120596-evoked 
increases in intracellular Ca2+ were, however, sensitive to 200 pM Cd2+. Cd2+ has previously 
been reported to result in a steady increase in basal fluoresce in this system (Dajas-Bailador et 
al., 2002a). Basal levels o f  Ca2+ were unaltered by the low concentration o f Cd2+ (50 pM; Fig
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5.11); however, preincubation with 200 pM resulted in a substantial, consistent increase in basal 
fluorescence levels (Fig 5.11; Table 5.1).
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L-Type X
To explore the possible differential coupling of nAChRs to VOCC subtypes, specific 
inhibitors of N-type, N-, P-/Q-type and L-type VOCCs (co-conotoxin GVIA, 1 pM; co-conotoxin 
MVIIC, 1 pM; verapamil, 10 pM and nifedipine, 5 pM; see table 5.1) at subtype selective 
concentrations were used. None of these inhibitors altered basal fluorescence levels (data not 
shown; Table 5.1). Responses to compound A plus PNU 120596 were not significantly altered 
in the presence of N-, P-/Q-type inhibitors co-conotoxin GVIA and co-conotoxin MVIIC (81.7 ± 
7.0 and 98.5 ± 10.4 % of control, respectively; Fig 5.12); or the L-type VOCC inhibitor 
nifedipine (88.3 ± 14.5 % of control, respectively; Fig 5.12). Although the L-type VOCC 
inhibitors verapamil decreased the compound A-evoked increase in intracellular Ca2+ (67.5 ± 
13.5 % of control) this decrease was not statistically significant (one-way ANOVA, with post- 
hoc Dunnett’s test, n = 8 ). These data are consistant with the lack of inhibition seen in the 
presence of 50 pm Cd2+ and confirm the lack of VOCC involvement in a7 nAChR-mediated 
increase in fluorescence (Fig 5.12).
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Figure 5.11: Effect of extracellular Ca2+ on a l -  and non-a7 nAChR-mediated 
increases in intracellular Ca2+ in PC12 cells
PC 12 cells were loaded with fluo-3 AM and fluorescence was monitored at F538. A: 
Representative traces from PC 12 cells, loaded with Fluo-3 AM and stimulated with 
Compound A (10 nM) plus PNU 102596 '! ? r I ~ in the presence or absence of Cd2+ 50 or 
200 pM. B: Compound A (Cpd A; 10 nM) plus PNU 120596 (PNU; 10 pM), C 30 pM 5-1- 
A-85380, or D: 60 mM KCI; in the absence of Ca2+ or in the presence of Cd2+ (50 pM or 
100 pM). Data were calculated as a percentage of Fmax - Fmin and are shown as a 
percentage of control, carried out in parallel. Bars are the mean ± SEM from five 
independent experiments. Significantly different from control, *p < 0.05, **p <0.01; one­
way ANOVA with post-hoc Dunnett’s test.
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Figure 5.12: Effect of selective VOCC inhibitors on a7- and non-a7 nAChR-mediated 
increases in intracellular Ca2* in PC12 cells
PC 12 cells were loaded with fluo-3 AM and fluorescence was monitored at F538. Cells 
were stimulated with A, B: Compound A (10 nM) plus PNU 120596 (10 pM), C, D: 30 pM 
5-I-A-85380, or E, F: 60 mM KCI, in the presence of co-conotoxin GVIA (GVIA, 1 pM; N- 
type), co-conotoxin MVIIC (MVIIC, 1 pM; N-, P-, Q-type), nifedipine (Nif, 5 pM; L-type) 
or verapmil (Ver, 10 pM; L-type). A, C, E: Representative traces in response to A: 
Compound A plus PNU 120596 (Cpd A & PNU 10 nM; 10 pM), C: 30 pM 5-I-A-85380 or 
E: 60 mM KCI in the absence or presence of co-conotoxin MVIIC (MVIIC, 1 pM) or co- 
conotoxin MVIIC (MVIIC, 1 pM). B, D, F: Data were calculated as a percentage of Fmax 
-  Fmin and are shown as a percentage of control. Bars are the mean ± SEM from at least 
five independent experiments. Significantly different from control, **p < 0.01; one-way 
ANOVA with post-hoc Dunnett’s test.
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In contrast to the a7-mediated responses, 5-I-A-85380- and KCl-evoked increases in 
intracellular Ca2+ were sensitive to VOCC inhibitors, co-conotoxin GVIA and co-conotoxin 
MVIIC, both produced small, non-significant, decreases in responses to 5-I-A-85380 (26.7 ± 
14.9% and 28.9 ± 14.5% inhibition, respectively; Fig 5.12) and KCI (22.8 ± 5.4% and 19.8 ± 
7.7% block, respectively; Fig 5.12). However, 5-I-A-85380- and KCl-evoked responses were 
significantly blocked by two chemically distinct inhibitors of L-type VOCCs (Fig 5.12). This 
decrease in response was comparable: verapamil and nifedipine inhibited 5-I-A85380-induced 
increases in fluorescence by 79.6 ± 6.0% and 80.9 ± 0.4%, respectively, whereas responses to 
KCI were decreased by 64.2 ± 6.3 % and 52.2 ± 5.9 %, respectively. These data are consistent 
with previous reports (Plummer et al., 1989) that L-type VOCCs are the predominant subtype 
mediating Ca2+ influx in PC 12 cells.
5.2.5 InvoCvement o f  C&2+-induced Ca2+ release following <x7- or non-oc7 nflChGL 
stimulation
In section 4.2.4, we showed that a7, but not p2* nAChR-mediated [3H]D-aspartate 
release from PFC synaptosomes required CICR. Previous investigations have shown a link 
between a7 nAChRs and CICR in diverse preparations (Section 1.4.3). Here, using our selective 
a7 and non-a7 nAChR stimulation in PC 12 cells we have investigated whether this relationship 
is present in the PC 12 cell line.
To confirm the presence of ryanodine receptors in our PC 12 line we carried out 
immunocytochemistry using an antibody for all three ryanodine receptor isoforms (2149; and a 
ryanodine receptor 2 selective antibody (1093 Zissimopoulos and Lai, 2005; Fig 5.13). Both 
antibodies gave clear staining around the nuclei of the PC 12 cells, with a similar pattern to that 
expected for endoplasmic reticulum labelling. The level of labelling was similar with both 
antibodies, consistent with the ryanodine receptor 2  being the predominant isoform within the 
PC 12 cells. No fluorescence was seen when either the primary or secondary antibody was 
omitted from the experiment (data not shown).
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Figure 5.13: Presence of RyR-positive structure in PC12 cells
PC 12 cells were permeabilised and labelled with anti-a-tubulin, Topro-3 and anti-RyR A: 
2149 or B: 1093 as described in the M ethods and visualised using confocal m icroscopy. 
Representative pictures shown (n = 2); scale bar = 10 pm
Increases in intracellular Ca2+ evoked by compound A plus PNU 120596, 5-I-A-85380 
and KCI were measured in the presence of five modulators of intracellular Ca2+ levels (Table 
5.2). The modulators were all incubated with the PC 12 cells for 10 min prior to stimulation. 
Ryanodine, dantrolene and xestospongin-C were all without effect on the basal fluorescence (5 s 
measurement prior to agonist application) at the concentrations used. In comparison, the 10 min 
preincubation with either thapsigargin or caffeine resulted in a consistent increase in the basal 
level of fluorescence (Fig 5.15; Table 5.2). However, this did not compromise the analysis of 
results as neither the Fmax nor Fmin values were altered in either case.
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Fluorescence increases following compound A plus PNU 120596 application were 
greatly reduced in the presence of ryanodine (6 6 . 6  ± 7.6% decrease; Fig 5.14). This 
concentration of ryanodine has no effect on a7 nAChR-mediated whole-cell currents in 
hippocampal neurones (Mok and Kew, unpublished observation), supporting the interpretation 
that the effect seen was due to the block of Ca2+ release from intracellular stores, not a l  nAChR 
inhibition. The involvement of ryanodine receptors in compound A plus PNU 120596-evoked 
responses was further supported by partial blockade following application of 10 pM dantrolene 
(39.62 ± 6.0 % inhibition of control; Fig 5.14). Xestospongin-C, which acts at IP3R, and 
thapsigargin and caffeine also inhibited the a l  nAChR-evoked responses (Fig 5.14). The 
selectivity of these latter modulators has been questioned (Collin et al., 2005) therefore, the data 
using these compounds must be interpreted with caution.
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Figure 5.14: Effect of drugs that act at intracellular Ca2+ stores on increases in 
intracellular Ca2+ levels mediated by a7 nAChRs
PC 12 cells were loaded with fluo-3 AM and fluorescence was monitored at F538. A: 
Representative traces from PC 12 cells stimulated with compound A (Cpd A; 10 nM) 
following 2 min pre-incubation with PNU 120596 (PNU; 10 pM) in the absence (green 
line) or presence (blue line) of ryanodine (30 pM) B: Cells were stimulated with 10 nM 
compound A (following 2 min pre-incubation with PNU 120596 10 pM) in the presence or 
absence of ryanodine (Rya, 30 pM), dantrolene (Dan, 10 pM), xestospongin-C (XeC, 1 
pM); , thapsigargin (Tha, 1 pM) or caffeine (Caf; 30 mM). All modulators of intracellular 
Ca2+ stores were incubated with the cells for 10 min before stimulation. Responses were 
calculated as a percentage of Fmax-Fmin and are shown as a percentage of agonist in the 
absence of inhibitor carried out in parallel. Bars are the mean ± SEM from at least five 
independent experiments. Significantly different to control, **p <0.01; one-way ANOVA 
with post-hoc Dunnetf s test.
In contrast 5-I-A-85380 and KCl-evoked increases in fluorescence in the PC 12 cells 
were not significantly altered in the presence o f ryanodine or dantrolene (Fig 5.15), consistent 
with a lack o f ryanodine receptor involvement. Xestospongin-C also failed to significantly alter 
5-I-A-85380 or KCl-evoked increases in fluorescence (Fig 5.15). However, both responses were 
significantly reduced in the presence o f thapsigargin and caffeine (Fig 5.15). However, as 
previously mentioned the selectivity o f these compounds is questionable (Collin et al., 2005) 
and both o f these modulators altered the basal fluorescence reading (Fig 5.15; Table 5.2), 
therefore, the significance o f these effect is unclear.
These data suggest that in PC 12 cells stimulation o f a7 nAChR results in CICR. In 
contrast, intracellular Ca2+ stores do not contribute to non-a7 nAChR-mediated or KCl-evoked 
increases in intracellular Ca2+ in PC 12 cells.
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Figure 5.15: Effect of drugs that act at intracellular Ca2+ stores on increases in 
intracellular Ca2+ levels mediated by non-a7 nAChRs or KCI
PC 12 cells were loaded with fluo-3 AM and fluorescence was monitored at F538. Cells 
were stimulated with A, B: 30 pM 5-I-A-85380 or C, D 60 mM KCI in the presence or 
absence of ryanodine (Rya, 30 pM), dantrolene (Dan, 10 pM), xestospongin-C (XeC, 1 
pM); thapsigargin (Tha, 1 pM) or caffeine (Caf; 30 mM). All modulators of intracellular 
Ca2+ stores were incubated with the cells for 10 min before stimulation. A, C: 
Representative traces from PC 12 cells stimulated with A: 30 pM 5-I-A-85380 or C: 60 mM 
KCI in the presence of modulators of intracellular Ca2+ B, D: Data were calculated as a 
percentage of Fmax-Fmin and are shown as a percentage of agonist in the absence of 
inhibitor carried out in parallel. Bars are the mean ± SEM from at least five independent 
experiments. Significantly different to control, **p <0.01; one-way ANOVA with post-hoc 
Dunnetf s test.
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5.3 (Discussion
5.3.1 Summary
This chapter reports studies measuring changes in intracellular Ca2+ using fluo-3 AM 
in PC 12 cells. The data have:
•  Confirmed the presence o f both a7 and non-a7 nAChRs on PC 12 cells using [125I]aBgt
and [3H]epibatidine in situ b inding. U sing selective nAChR antagonists, it was 
demonstrated that multiple nAChR subtypes contribute to increases in intracellular Ca2+ 
following application o f the pan-acting agonist nicotine.
•  Characterised nAChR-mediated increases in intracellular Ca2+ in the presence o f the
novel a7 nAChR positive allosteric modulator PNU 120596. The use o f  nAChR
subtype-selective pharmacological tools has shown that a7 and non-a7 nAChRs 
increase cytoplasmic Ca2+ in PC 12 cells via distinct routes. Stimulation o f p2* nAChRs, 
and KCI depolarisation, elevates intracellular Ca2+ predominantly via L-type VOCC 
activation, without involvement o f CICR (Fig 5.16). In contrast a7 nAChR stimulation 
results in increased intracellular Ca2+ through CICR, independently o f VOCC activation 
(Fig 5.16).
n l nAChR V0CC
a3p2* nAChR
Figure 5.16: Model illustrating the coupling of a7 and 02* nAChRs to distinct routes
of Ca2+ entry and mobilisation.
|32* nAChR and KCI stimulation of PC12 cells results in an increase in cytoplasmic Ca2+ 
primarily through the opening of L-type VOCCs with no involvement of intracellular Ca2+ 
stores. Activation of a7 nAChRs leads to an increase in intracellular Ca2+ by coupling the 
nAChR to CICR from intracellular stores, typically endoplasmic reticulum bearing RyRs. 
The response to a7 nAChR stimulation is independent of VOCC activation, but may result 
in capacitive Ca2+ entry via SOCCs.
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5.3.2 n ftCfi^expression in the <PC12 ceCCCine
As discussed in Section 5.1.3, previous investigations using the PC 12 cell line have 
detected multiple nAChR subunits (a3, a5, a7, 02, and 04), which can form a range of nAChR 
subtypes (Boulter et al., 1990; Rogers et al., 1992; Henderson et al., 1994; Blumenthal et al., 
1997; Takahashi et al., 1999; Avila et al., 2003). Although the PC 12 cell line was originally 
clonal in nature (Section 5.1.2) there are now several distinct subclones, which can vary in the 
expression of multiple proteins, including nAChR subunits (Blumenthal et al., 1997). The PC 12 
cell line used in this project was provided by D. Berg (University of Calfomia, USA) and 
corresponds to the PC12C clonal line reported by (Blumenthal et al., 1997). In this report 
[125I]aBgt and [3H]epibatidine binding was carried out to determine the levels of a7 and non-a7 
nAChR protein, respectively. The PC12C line had the highest level of nAChRs of those PC 12 
cells used, containing total binding sites corresponding to approximately 600 fmol 
[3H]epibatidine/mg protein and 950 fmol [,25I]aBgt/mg protein; surface [125I]aBgt binding sites 
were reported to be approximately 275 foml/mg protein. This group reported no alteration in 
either [125I]aBgt and [3H]epibatidine binding in the PC12C cells following application of NGF, 
therefore undifferentiated PC 12 cells were used throughout this project.
Confirmation of the levels a7 and non-a7 nAChRs in our cell line was determined 
using in situ [125I]aBgt and [3H]epibatidine binding (Ridley et al., 2002) and aBgt-488 labelling. 
Consistent with the previous findings (Blumenthal et al., 1997), the PC 12 cells contained 
significant levels of specific [125I]aBgt and [3H]epibatidine binding sites, as well as substantial 
aBgt-488 labelling. However, our values of 261 fmol [3H]epibatidine/mg protein and 420 fmol 
[125I]aBgt binding sites/mg protein are not entirely in accordance with the previous report. The 
overall changes in [,25I]aBgt and [3H]epibatidine binding sites highlights how sensitive this cell 
line is to change, and may be particularly apparent as the cells used in the study were of a later 
passage number than those used by (Blumenthal et al., 1997). We reported the levels of 
[,25I]aBgt binding sites to be approximately half-way between the surface and total [125I]aBgt 
levels reported by (Blumenthal et al., 1997). This disparity could also be explained by 
differences in the methodology, here we used a 4 hr [125I]aBgt period (Davies et al., 1999) as 
opposed to 1 hr in the previous report. It is possible that the longer incubation period maximised 
[l25I]aBgt, as well as this longer incubation period possibly resulting in an increase in [,25I]aBgt 
binding sites due to internalisation of this receptor.
Blumenthal et al., (1997) used electrophsiological experiments, with acetylcholine as 
the agonist, to identify the presence of two distinct functional nAChR subtypes. As previously 
reported by Gueorguiev et al., (1999) and consistent with the presence of functional nAChRs in 
the PC 12 cell line used in the present studies, application of nicotine resulted in concentration-
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dependent increase in intracellular Ca2+ in populations of PC 12 cells, as determined by increase 
fluo-3 AM fluorescence. As the most robust increase in intracellular Ca2+ was evoked by 100 
pM nicotine, nAChR subtype-selective antagonists were used to investigate the nAChR 
pharmacology mediating this response. Whilst statistical analysis determined that aBgt did not 
significantly reduce this response there was a 20 % decrease in the presence of aBgt, suggesting 
a possible involvement of a7 nAChRs. The use of nAChR antagonists, selective for heteromeric 
nAChR subtypes: a-conotoxin Mil (a3(32*), a-conotoxin AUIB (a304*) and DHpE (p2*) all 
significantly decreased nicotine (100 pM)-evoked increases in intracellular Ca2+. These data 
suggest that a heterogeneous population of heteromeric nAChRs assembled from different 
combinations of nAChR subunits, with a3p2 and/or a3p4, and to a lesser extent a7 nAChR 
subunit interfaces providing the agonist binding sites (Luetje and Patrick, 1991; Le Novere et 
al., 2002a) are activated by nicotine and subsequently cause increases in intracellular Ca2+ in 
PC12 cells.
5.3.3 (Pathways o f  cc7 andnon-oc7 nJAChPcmecCiatecfincreases in intraceCCuCar Ca2+ 
oc7 nJlCh(Rjmedtatedincreases in intraceCCuCar Ca2+
Whilst the [125I]aBgt binding and aBgt-488 labelling data support the presence of a7 
nAChRs, aBgt inhibition of increases in intracellular Ca2+ elicited by nicotine were only 
statistically significant at low nicotine concentrations, probably reflecting the rapid 
desensitisation of the a7 nAChR. The low level of these responses made them unsuitable for 
further characterisation; therefore to further explore the a7 nAChR-component we employed the 
novel a l  nAChR-selective agonist compound A. The properties of this agonist were previously 
described in Section 3.5.5, in brief this compound has been shown to a highly selective agonist 
at human a l  nAChRs expressed in GH4 cells and oocytes (EC50 = 14 ± 2 nM and 950 ± 850 
nM, respectively; De Filippi et al., 2002). Indeed in Chapter 3 we reported compound A to be a 
highly potent agonist at presynaptic a l  nAChRs, with no cross-reactivity at (32* nAChRs.
Although there was an a l  nAChR component to increases in intracellular Ca2+ evoked 
by low concentrations of nicotine, compound A could not elicit a significant increase in 
intracellular Ca2+ over a range of concentrations (100 pM -  1 fiM; Fig 5.6). The lack of 
detectable response to compound A alone is probably due to the rapid desensitisation of a l  
nAChRs resulting in insufficient elevation of intracellular Ca2+ for detection using the 
fluorescence assay. To overcome this we used PNU 120596 (Hurst et al., 2005). As described in 
Section 3.5.5 PNU 120596 is a positive allosteric modulator that is highly selective for a l  
nAChRs, displaying a EC50 of 216 nM at a l  nAChRs expressed in SH-EP-1 cells and maximal 
efficacy at -  3 pM (Hurst et al., 2005). Of particular interest to this section is the ability of PNU
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120596 to activate desensitised a7 nAChRs, without modifying the ion selectivity of the a l  
nAChR (Hurst et al., 2005).
PNU 120596 (10 pM) significantly enhanced nicotine-elicited increases in intracellular 
Ca2+. In the presence of aBgt responses to nicotine plus PNU 120596 were reduced to the same 
magnitude as responses to nicotine alone in the presence of aBgt, consistent with PNU 120596 
acting selectively at a l  nAChRs. In the presence of PNU 120596, compound A now evoked a 
robust, consistent increase in intracellular Ca2+. PNU 120596 caused a similar level of change in 
fluorescence at all concentrations of compound A tested (100 pM -  1 pM; Fig 5.6), consistent 
with it attenuating desensitisation of a l  nAChRs. The enhancement of compound A-elicited 
responses by PNU 120596 was concentration-dependent. Whilst Hurst et al., (2005) reported an 
increase in fluorescence at a concentration of 0.3 pM PNU 120596, here 3 pM was the lowest 
concentration to significantly increase compound A-elicited increases in fluorescence. The 
differences between these two studies is probably due to the detection system used, Hurst and 
colleagues used the Ca2+ indicator Calcium Green-1AM combined with the highly sensitive 
fluorometric imaging plate reader (FLIPR), which will have facilitated the measurement of 
small changes in Ca2+ that may have not been detectable in our system (Section 2.4.9). It should 
also be noted that this original characterisation used the pan-acting nAChR agonist 
acetylcholine, whereas here we have used the a l  nAChR selective agonist compound A. The 
decreased compound A-evoked response in the presence of higher ( > 100 pM) PNU 120596 
reflects the insolubility of this compound, which was dissolved in DMSO but started to 
precipitate out of buffer at ~ 100 pM.
The insensitivity of the maximal compound A/PNU 120596 response (10 nM 
compound A in the presence of 10 pM PNU 120596) to DH0E, combined with the total ablation 
of this response in the presence of aBgt, is consistent with a l  nAChRs mediating this response. 
These data, in addition to the lack of significant effect of PNU 120596 on either 5-I-A-85380- 
or KCl-evoked responses, confirms that this modulator is specific for a l  nAChRs, and 
highlights its utility as a suitable compound for unmasking a l  nAChR-mediated responses.
Non-cc7 nJLChtRjniecCiatecf increases in intraceCCuCar C&2+
Responses to nicotine indicated the presence of multiple functional nAChR subtypes in 
our PC12 cell line. To selectively activate non-a7 (02*) nAChRs we used the 02* nAChR 
agonist 5-I-A-85380 (see Section 3.5.5). 5-I-A-85380 elicited a robust concentration-dependent 
increase in fluorescence, with 30 pM 5-I-A-85380-evoking a response that was similar in speed 
of increase and magnitude to that seen following compound A application in the presence of
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PNU 120596. 5-I-A-8530 (30 pM)-mediated responses were blocked in the presence of 
mecamylamine, but insensitive to aBgt and PNU 120596, consistent with a non-a7 nAChR- 
mediated response. The 5-I-A-85380-mediated responses were blocked equally in the presence 
of DH|3E (1 pM) or a-conotoxin-MH (200 nM), the effect of these two nAChR antagonists was 
not additive. At the concentration used DHpE will preferentially compete for (32* nAChR 
agonist binding sites (Harvey and Luetje 1996) and a-conotoxin-MH will selectively bind to the 
a3p2 interface (Harvey et al., 1997 Kulak et al., 1997). Therefore one a302 pair of nAChR 
subunits may be sufficient to produce the inhibition exhibited and the presence of additional 
subunits can not be excluded (Kaiser et al., 1998). Consequently it is possible to conclude that 
the non-a7, 5-I-A-85380-evoked responses measured in this project are mediated via a3p2* 
nAChRs.
5.3.4 cc7 and non-oc7 nJ^Ch^mediated increases in intracefduCar Ca.2+: Ca2+ 
pathways
Consistent with previous measurements of nicotine-evoked increases in intracellular 
Ca2+ in SHSY-5Y cells (Dajas-Bailador et al., 2002b), PC12 cells (Gueorguiev et al., 1999), 
hippocampal cultures (Barrantes et al., 1995) and chick ciliary ganglia (Rathouz and Berg, 
1994; Shoop et al., 2001), responses to compound A plus PNU 120596 (a l nAChR-mediated), 
5-I-A-85380 (a3p2* nAChR-mediated) and KC1 were all dependent upon extracellular Ca2+. 
The routes of extracellular Ca2+ influx following nAChR stimulation have already been 
discussed (Section 1.4.2); in brief Ca2+ can enter directly, via the intrinsic ion channel, or 
indirectly, via VOCCs, in both cases there is scope for further augmentation via CICR from 
intracellular Ca2+ stores.
fi2*, Sut not cc7 nJLCh<R§ are coupkdto voCtage-operatedCa2+ channels
Previous studies using the pan-acting nAChR agonists nicotine or acetylcholine have 
shown nAChRs to mediate increases in intracellular Ca2+ via activation of VOCCs (Dajas- 
Bailador and Wonnacott, 2004). Two concentrations of Cd2+, 50 pM (Grassi et al., 1999; Kulak 
et al., 2001) and 200 pM (Sharma and Vijayaraghavan, 2001) were used to non-selectively 
inhibit Ca2+ entry through all VOCCs. Compound A plus PNU 120596-, 5-I-A-85380- and KC1- 
mediated increases in intracellular Ca2+ were all significantly attenuated in the presence of 200 
pM Cd2+. However, as previously reported in SHSY-5Y cells (Dajas-Bailador et al., 2002a), this 
concentration of Cd2+ consistently caused significant increases in basal fluorescence levels 
(Table 5.1 and 5.3). As reported in Chapter 4 for KCl-evoked [3H]D-aspartate release, Cd2+ (50 
pM) significantly inhibited increases in intracellular Ca2+ elicited by KC1. The ability of this 
lower concentration of Cd2+ to decrease KCl-mediated increases in Ca2+ further substantiates
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this as a suitable concentration to inhibit VOCCs as discussed in Section 4.3.3. 5-I-A-85380- 
evoked increases in intracellular Ca2+ were also significantly reduced in the presence of 50 or 
200 pM Cd2+, indicating that a3p2* nAChRs increase levels of intracellular Ca2+ via VOCC 
activation.
The sensitivity of KC1- and 5-I-A-85380-mediated increases in intracellular Ca2+ to 
Cd2+ is consistent with previous studies of heteromeric nAChRs in PC 12 cells (Gueorguiev et 
al., 1999) and in other preparations (Soliakov and Wonnacott 1996; Tsuneki et al., 2000), 
including PFC synaptosomes as documented in Chapter 4. The use of selective VOCC 
inhibitors (Table 5.3) further revealed the predominant route of KC1 and 5-I-A-85380-mediated 
Ca2+ influx is the L-type channel, consistent with this subtype being the abundant in PC 12 cells 
(Plummer et al., 1989). These data linking non-a7 nAChRs with VOCCs are in agreement to 
that seen with [3H]D-aspartate release from PFC synaptosomes (Chapter 4) suggesting that non- 
a7 nAChR mediated VOCC activation may be a common phenomenon.
Mirroring the sensitivity of a7 nAChR-mediated [3H]D-aspartate release from PFC 
synaptosomes (Chapter 4), increases in intracellular Ca2+ mediated by compound A plus PNU 
120596 were not significantly altered in the presence of the selective VOCC inhibitors or 50 pM 
Cd2+, but were substantially reduced in the presence of 200 pM Cd2+. The insensitivity of 
compound A plus PNU 120596-mediated responses to lower concentrations of Cd2+ suggests 
that VOCCs are unlikely to have a major role in a l  nAChR-mediated increases in intracellular 
Ca2+. As discussed in Section 4.3.3 Cd2+ has a multitude of non-selective effects, including 
inhibiting Ca2+ ATPases and SOCCs. The dependence of caffeine-evoked catecholamine release 
from PC 12 cells on extracellular Ca2+ provided the first evidence for the presence of non-VOCC 
on the cell membrane (Taylor and Peers 1999) and subsequent RT-PCR analysis has revealed 
the presence of TRPC1-6 mRNA (Tesfai et al., 2001; Ohta et al., 2004). As a l  nAChR are 
linked to intracellular Ca2+ stores in this (and other) systems (see below), it is possible that there 
is a further amplification of the a l  nAChR-mediated response by capacitive Ca2+ flux through 
SOCC that is blocked by this higher concentration of Cd2+. The use of selective VOCC 
inhibitors confirmed the lack of VOCC involvement in the compound A plus PNU response 
(Table 5.3).
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Table 5.3: Summary of extracellular Ca2+ channel involvement in a7 versus $2* nAChR-mediated
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X ^  -not statistically 
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cc7, 6ut not J$2* n^CC^are coupCedto intraceCCuCar Ca2+ stores
As described in Section 1.4.1, the ability of a cell to tightly regulate its intracellular 
Ca2+ concentration is paramount for the correct functioning of most signally pathways. 
Following Ca2+ entry through plasma membrane Ca2+ permeable channels, Ca2+ levels can be 
augmented by Ca2+ release from intracellular stores (CICR) and subsequent influx of 
extracellular Ca2+ through SOCCs. PC 12 cells express both ryanodine and DP3 receptors, both of 
which are capable of increasing cytoplasmic Ca2+ levels (Section 5.1.5).
Previous studies using Ca2+ fluorimetry and electrophysiological techniques have 
demonstrated a link between a7 nAChR and CICR (Section 1.4.4; Sharma and Vijayaraghavan, 
2001; Dajas-Bailador et al., 2002a). Indeed in Chapter 4 we have shown that this differential 
coupling of a7 and p* nAChRs to VOCCs and CICR is also apparent in rat PFC synaptosomes 
(Chapter 4).
Having established compound A plus PNU 120596 and 5-I-A-85380 as selective 
agonists at a7 and p* nAChRs, respectively, in the PC 12 cell line, we investigated whether the 
coupling of a7 nAChRs to CICR was also apparent at the cell soma using this model. Five
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modulators of intracellular Ca2+: ryanodine, dantrolene, xestospongin-C, thapsigargin and 
caffeine were employed. The targets of these modulators are discussed in Section 4.3.3.
Both modulators of ryanodine-sensitive stores used, namely ryanodine and dantrolene, 
and the IP3R inhibitor xestospongin-C were without effect on the intracellular Ca2+ responses to 
5-I-A-85380 and KC1, yet both responses were sensitive to thapsigargin and caffeine. Although 
these data appear disparate, as discussed in Section 4.3.3, the specificity of both thapsigargin 
and caffeine is relatively poor, with non-specific targets including L-type VOCCs (Rossier et 
al., 1993; Shmigol et al., 1995). As L-type VOCCs are essential for both 5-I-A-85380- and KC1- 
mediated increases in intracellular Ca2+ in this PC 12 clone, thapsigargin would be expected to 
decrease these responses. Both thapsigargin and caffeine consistently increased basal 
fluorescence levels (Fig 5.11), therefore it is possible that the reduced increase in intracellular 
Ca2+ produced by 5-I-A-85380 or KC1 in the presence of these compounds is as a direct result of 
the increase in basal fluorescence. These factors, combined with the lack of effect of ryanodine 
and dantrolene, suggest that 5-I-A-85380 and KC1 application does not result in CICR in PC 12 
cells (Table 5.4). This is consistent with the previous observation of Tully and Treistman (2004) 
who reported that Ca2+ entering through the L-type VOCCs is not coupled to CICR in PC 12 
cells (Fig 5.16).
Table 5.4: Summary of intracellular Ca2+ stores involvement in a7 versus p2* nAChR-mediated














^  -but basal 
affected
^  -but basal 
affected
S  -but basal 
affected
Caffeine sensitive
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Ca2+ stores involved? YES No (possible) No (possible)
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In contrast to the (32* nAChR-mediated responses, compound A plus PNU 120596 
generated increases in intracellular Ca2+ that were sensitive to all of the modulators of 
intracellular Ca2+ used. Although the response to thapsigargin and caffeine must be treated with 
caution due to their altering of basal fluorescence (Table 5.4), the significant decrease in the 
presence of ryanodine or dantrolene provides strong evidence for a link between Ca2+ entry 
through the a7 nAChR’s intrinsic ion channel and CICR (Table 5.4; Fig 5.16). This work 
furthers our previous observations in PFC synaptosomes that a7 and non-a7 nAChR have 
distinct signalling pathways that appear to be conserved both at the presynaptic terminal and the 
cell soma (Fig 4.13 and 5.16).
5.3.5 cc7 and fl2* n jlC h ^  segregate to disparate C&2+ pathways: physioCogicaC 
significance?
Here we have shown that in PC 12 cells a7 and (32* nAChRs differentially couple to 
CICR and VOCCs, respectively. These findings are in accordance with the data shown in 
Chapter 4 identifying this same coupling at the presynaptic terminal. However, whereas at the 
presynaptic terminal Ca2+ microdomains will be involved in post-translational modifications 
(Section 4.3.4) at the cell soma discrete Ca2+ pathways are likely to activate distinct signalling 
pathways that will not only serve to facilitate post-translational modifications but also regulate 
transcription.
Nicotine is well documented as being able to modulate the activity of different 
transcription factors, and to subsequently alter gene expression. The best characterised example 
being via CREB activation. CREB, which can be activated by ERK1/2 (Section 1.5.1) causes an 
increase in the expression of early genes including c-fos and c-jun, both of which in turn act as 
transcription factors (Shaywitz and Greenberg, 1999). In PC 12 cells nicotine application has 
been reported to increase CREB phosphorylation via Ca2+ entry through L-type VOCCs 
following non-a7 nAChRs stimulation (Nakayama et al., 2001). This would serve as an example 
of how different nAChRs can segregate to separate signalling pathways based on the route of 
Ca2+ entry into the cell, although it should be noted that in hippocampal cultures (Hu et al., 
2002) reported that nicotine acted at a l  nAChRs to promote CREB phosphorylation following 
CICR from internal stores.
Unfortunately the lack of nAChR subtype-selective agonists has meant studies into 
nAChR-mediated changes in gene transcription have used the pan-acting agonists nicotine and 
acetylcholine. However, the commercial availability of the relatively new (32* nAChR agonist 
5-I-A-85380 and a l  nAChR selective agonist PNU 120596 will enable future investigations to
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determine whether a7 and non-a7 nAChRs cause differential regulation of gene expression. 
Interestingly using PC 12 cells, Gueorguiev and colleagues have demonstrated the nicotine can 
induce tyrosine hydroxylase expression, with both a fast component and a slower, more 
sustained component. Using a variety of antagonists and modulators they have shown that the 
initial increase is due to VOCC activation (Gueorguiev et al., 2000), whereas the later, sustained 
response is mediated via a l  nAChR activation and subsequent CICR (Gueorguiev et al., 1999). 
The data described here are in accordance with this model and indicate how specific nAChR 
subtype/Ca2+ pathways can segregate to have separate effects, even at the same protein.
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6.1: ConcCusions
Here we set out to characterise nAChR subtype selective agonists and subsequently 
exploit these ligands to investigate the presynaptic cellular mechanisms that couple a7 and p2* 
nAChRs to excitatory amino acid release in the PFC. Activation of both a7 and 02* nAChRs 
has been reported to enhance working memory and attention (Mansvelder et al., 2006), which 
are both associated with the PFC (Dailey et al., 2004; Chudasama and Robbins, 2006) and may 
underlie the cognitive enhancing activity of nicotine (Levin et al., 2006). However the cellular 
mechanisms underpinning nAChR-mediated modulation of these processes have not been 
elucidated.
The present studies show that both a7 and p2* presynaptic nAChRs in the rat PFC 
mediate excitatory amino acid release in a Ca2+-dependent manner, but via different 
mechanisms. Whilst stimulation of the a7 nAChR leads to CICR and subsequent ERK2 
phosphorylation, stimulation of 02* nAChRs causes activation of VOCCs. Using Ca2+ assays in 
PC 12 cells we were able to show that this coupling of a7 and 02* nAChRs to different sources 
of Ca2+ is also present in a broader context when measuring responses from a population of 
cells, suggesting this dichotomy may be a common phenomenon.
[37C](D-aspartate as an L-gCutamate surrogate
[3H]D-aspartate has been used throughout this investigation as an excitatory amino acid 
analogue of glutamate due to its limited involvement in metabolic processes. In Chapter 3, 
evidence was provided for the use of [3H]D-aspartate as a surrogate for [3H]L-glutamate. 
Consistent with previous data (Fleck et al., 2001) both of these amino acids were taken up into 
PFC synaptosomes via EAATs and subsequently into vesicles. nAChR-mediated [3H]D- 
aspartate release has been shown to be analogous to that of endogenous L-glutamate (Patti et al., 
2006; Patti et al., 2007). The data in Chapter 3 have shown that the profiles for depolarisation- 
mediated [3H]D-aspartate and [3H]L-glutamate release were indeed similar. Although the results 
obtained for nAChR-mediated [3H] L-glutamate were variable, the level of release was similar to 
that seen for [3H]D-aspartate. The Ca2+-dependency of nAChR- and KCl-elicited [3H]D-aspartate 
is also consistent with exocytosis-mediated neurotransmitter release. These data are consistent 
with previous KC1- and electrically-evoked excitatory amino acid release experiments which 
have concluded [3H]D-aspartate release to be analogous to that of endogenous L-glutamate and 
further substantiate the use of this amino acid as a suitable alternative for measuring excitatory 
amino acid release.
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cc7 and fi2* nfl.Ch<R§ coupCe to different ceCCuCar pathways
This study has characterised three nAChR ligands: compound A, PNU 120596 and 5-1- 
A-85380, in both the [3H]D-aspartate release assay in PFC synaptosomes and Ca2+ 
measurements in PC 12 cells. Compound A was shown to be a highly potent and selective 
agonist at the a7 nAChR in PFC synaptosomes, consistent with previous data (De Filippi et al., 
2002). However, in PC 12 cells the presence of PNU 120596 was required to detect an a7 
nAChR-mediated increase in intracellular Ca2+, probably reflecting different detection methods 
and the rapid desensitisation of this receptor. PNU 120596 did not have any cross reactivity with 
other nAChRs in either the PFC synaptosomes or the PC 12 cells. These data demonstrate that 
compound A and PNU 120596 provide selective means of a7 nAChR stimulation that can be 
used in future to investigations of this nAChR subtype. 5-I-A-85380 activated (32* nAChRs in 
both of the systems used here, although its ability to inhibit [125I]aBgt binding to PFC 
membranes at high concentrations highlights the limitations with regard to its selectivity.
[3H]D-aspartate release from PFC synaptosomes and increases in intracellular Ca2+ in 
PC 12 cells, induced by a7 nAChR activation were both mediated via CICR. The latter system 
showed that approximately 50 % of the a7 nAChR-mediated increases in intracellular Ca2+ were 
insensitive to inhibition of CICR, consistent with Ca2+ entry via the a l  nAChR’s intrinsic ion 
channel, or via a secondary mechanism of depolarisation-mediated VOCC activation. However, 
a l  nAChR-mediated [3H]D-aspartate release was entirely dependent upon CICR, indicating that 
even though Ca2+ enters the synaptosomes through the a l  nAChR, this does not provide a 
sufficient signal to initiate detectable transmitter release. As described in Section 1.4.4 a link 
between activation of a l  nAChRs and CICR has been reported for diverse cellular systems, 
including mEPSCs recorded in hippocampal CA3 pyramidal neurones (Sharma and 
Vijayaraghavan, 2003) and Ca2+ responses in substantia nigra dopaminergic neurones (Tsuneki 
et al., 2000), astrocytes (Sharma and Vijayaraghavan, 2001), Drosophila (Campusano et al., 
2007), SH-SY5Y cells (Dajas-Bailador et al., 2002a) and PC12 cells (Gueorguiev et al., 2004) 
However, these investigations have primarily used the pan-acting nAChR agonists acetylcholine 
or nicotine in the presence of nAChR antagonists. The use of the a l  nAChR selective ligands, 
compound A and PNU 120596, in this project has provided direct evidence that the a l  nAChR 
is coupled to ryanodine-sensitive Ca2+ stores. These previous reports, in concert with the data 
described herein, are consistent with the hypothesis that the highly Ca2+ permeable a l  nAChR 
are localised to directly elicit CICR.
As discussed in Section 1.4.4 and 4.3.4 ryanodine-sensitive stores have been associated 
with synaptic plasticity (Collin et al., 2005). Indeed recent studies have shown that CICR is 
essential for enhancement of LTP in dentate gyrus (Welsby et al., 2006) and for nicotine-
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mediated modulation of evoked synaptic transmission in hippocampus (Le Magueresse and 
Cherubini, 2007). Interestingly, genetic ablation of RyR isoforms has also been reported to 
result in impaired LTP and learning (Balschun et al., 1999; Futatsugi et al., 1999), consistent 
with an important role for Ca2+ stores in learning and memory. The ability of presynaptic 
nAChRs to mediate excitatory amino acid release, which may subsequently alter synaptic 
efficacy in the PFC, could underlie the beneficial effects of nicotine on cognitive processes in 
this region. Indeed, in other regions a7 nAChR-mediated glutamate release has been shown to 
enhance both LTP and LTD (Aramakis and Metherate, 1998; Mansvelder and McGehee, 2000; 
Ge and Dani, 2005). Whilst reports of nAChR-mediated modulation of synaptic plasticity events 
in the PFC are scarce, Couey et al., (2007) recently reported the modulation of synaptic spike- 
timing dependent potentiation in layer V pyramidal neurones of the mouse PFC following 
nicotine application.
6.2: Future (Perspectives
The findings reported here, that a l  and (32* nAChRs are differentially coupled to CICR 
and VOCCs, raises some very interesting questions. These are discussed below in relation to 
future work on this project.
oc7 nACfi^mecfiatecf [3J{](D-aspartate retease: a rotefor SOCCs?
As discussed in Section 4.3.3 SOCCs can shape local Ca2+ microdomains, resulting in 
exocytosis, muscle contraction, gene transcription and apoptosis (Parekh and Putney, 2005). 
Putative SOCCs have recently been associated with LTP where they serve to augment CICR 
(Mellentin et al., 2007). SOCCs are blocked by heavy metals such as Cd2+ (Gore et al., 2004). It 
is possible to hypothesise that the differential sensitivity of a l  nAChR-mediated responses 
([3H]D-aspartate release, Chapter 4; increases in intracellular Ca2+, Chapter 5) to increasing 
concentrations of Cd2+ may indicate activation of SOCCs following a l  nAChR stimulation. 
Indeed, ERK1/2 phosphorylation has been shown to be a downstream effector of SOCC- 
mediated Ca2+ entry (Denys et al., 2004), consistent with a role for this channel in the 
ryanodine-sensitive a l  nAChR-mediated ERK2 phosphorylation, as reported in Chapter 4. It is 
impossible to deduce from the current studies that a l  nAChRs signal to SOCCs, however, this 
would be an avenue worth exploring if and when SOCC selective antagonists become available 
(Lewis, 2007).
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fire oc7 nftChtRf physically tinnedto ryanodine-sensitive stores?
The association between a7 nAChRs and ryanodine-sensitive stores in both PFC 
synaptosomes and PC 12 cells suggests a close coupling between the a7 nAChR and RyR. This 
raises the question of whether these two proteins are in close proximity or are physically 
tethered such that Ca2+ influx via the a7 nAChR initiates CICR. As discussed in Section 4.3.4, 
current work in our laboratory using confocal microscopy, has shown that a7 nAChRs 
(identified by aBgt alexa-fluo 488 labelling) preferentially localise with a subpopulation of 
synaptophysin-positive structures that are double labelled with a ryanodine antibody. These data 
suggest a co-localisation of a l  nAChRs and RyRs; however, a higher cellular resolution would 
be require to determine the exact spatial relationship of these two proteins. This could be 
obtained my employing electron microscopy, a technique that has previously been used to 
identify the presence of presynaptic a l  nAChRs on glutamatergic terminals (Jones and 
Wonnacott, 2004). A physical link between the presynaptic a l  nAChR and ryanodine receptor 
could be explored using immunoprecipitation experiments, or in the broader context, by yeast 
two hybrid analysis.
fire presynaptic cc7 and fl2* nfl.Ch<R$ present on the same terminals?
As discussed in Section 4.3.4, the coupling of a l  and 02* nAChRs to different 
signalling pathways may be indicative of these nAChR subtypes being present on distinct 
populations of terminals. The differences in [3H]nicotine and [125I]aBgt autoradiography shown 
in Fig 1.13 (Clarke et al., 1985), are consistent with these receptors residing on different 
neurones. These data are further substantiated by functional data revealing a402 nAChRs to be 
present on thalamocortical afferents in the in the PFC (Gioanni et al., 1999; Lambe et al., 2003), 
consistent with the high level of a4 and 02 nAChR subunit expression in thalamic nuclei 
(Clarke, 2004) that project to the PFC (Lavine et al., 1997). In contrast, a l  nAChR subunit 
expression in the thalamus is scarce, but is well documented in the cortex (Clarke et al., 1985; 
Seguela et al., 1993). As such it is likely that the PFC a l  nAChRs are located on intrinsic 
cortical neurones or projections from hippocampal neurones.
Indeed, a recent study using selective a l  and 02* nAChR agonist application directly 
to the PFC, has suggested that these nAChRs may have differential roles in working and 
reference memory (Chan et al., 2007). Whilst this investigation reported PFC stimulation of a l  
nAChRs to enhance both working and reference memory; 02* nAChRs activation enhances 
working memory, but was without effect on reference memory (Chan et al., 2007). These data 
are consistent with a l  and 02* nAChRs being situated on separate neurones where they will be 
coupled to different signalling pathways. The link between the a l  nAChR and CICR may 
provide a pathway by which this receptor can mediate a distinct signalling function relative to
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P2* nAChR activation in the PFC. Whilst some information could be obtained from confocal 
microscopy, electron microscopy would be best employed to determine the exact neuronal 
location of a7 and 02* nAChRs in the rat PFC. This work could also be furthered by carrying 
out electrophysiological recordings from different cortical layers in the PFC (Couey et al., 
2007).
Which 'proteins coupCe cc7 nflCh^m ediatetf (E(B!KJt/2 phosphorylation to [3Jf]<D- 
aspartate reCease?
a l  nAChR-mediated [3H]D-aspartate release reported in Chapter 4 was dependent upon 
ERK1/2 activation. Western blot analysis confirmed that stimulation of presynaptic a l  nAChRs 
resulted in CICR-dependent ERK1/2 phosphorylation. Multiple proteins are associated with 
nAChR-elicited ERK1/2 activation and nAChR-mediated neurotransmitter release, including 
PKA (Dajas-Bailador et al., 2002b), PKC (Cox and Parsons, 1997; Soliakov and Wonnacott, 
2001) and CAMK (Chang and Berg, 2001), all of which can promote ERK1/2 phosphorylation 
(Yoon and Seger, 2006). As specific inhibitors exist for all of these kinases, western blot 
analysis could be carried out to further explore the cellular pathway transducing a l  nAChR- 
mediated ERK1/2 phosphorylation. These data could be further extrapolated to the superfusion 
assay, where experiments could be carried out to determine which kinases are upstream of 
ERK1/2 in a l  nAChR-mediated [3H]D-aspartate release from PFC synaptosomes. Whilst it 
would be interesting to explore the upstream components of ERK1/2 activation it would, 
perhaps, be more pertinent to investigate the presynaptic downstream targets of ERK1/2.
Multiple exocytototic proteins can be phosphorylated by ERK1/2 (Turner et al., 1999; 
Takahashi et al., 2003). The involvement of ERK1/2 in the phosphorylation of these proteins, 
such as SNAP-25 and Munc-18, could be investigated using in situ phosphorylation assays with 
32P-orthophosphate in the presence or absence of MEK1 inhibitors (Fukunaga et al. 1992), and 
subsequent immunoprecipation using antibodies for the protein of interest. One particularly 
interesting target of presynaptic ERK1/2 activation is synapsin-1. As discussed in Section 1.6.3 
synapsin-1 tethers vesicles to actin, phosphorylation of synapsin-1 facilitates the translocation of 
vesicles to the presynaptic membrane (Greengard et al., 1993). Synapsin-1 has multiple 
phosphorylation sites, which are all regulated by different kinases (Leenders and Sheng, 2005): 
CAMKI, IV and PKA (site 1); CAMKII (sites 2 and 3) and ERK1/2 (sites 4,5 and 6). ERK- 
dependent phosphorylation of sites 4, 5 and 6 has been shown to mediate neurotrophin-evoked 
enhancement of glutamate release from cortical synaptosomes (Jovanovic et al., 1996; 
Matsubara et al., 1996; Jovanovic et al., 2000). Indeed, as discussed in Section 1.5.1 ERK1/2- 
mediated phosphorylation of synapsin-1 has been shown to be essential for hippocampus-
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dependent learning (Kushner et al., 2005) and accordingly synapsin-1 is phosphorylated in 
learning tasks (Gomez-Pinilla et al., 2001). Interestingly, synapsin-1 expression is also reduced 
concomitantly with the a7 nAChR in schizophrenic patients (Browning et al., 1993; Freedman 
et al., 2000; Vawter et al., 2002).
There has not yet been an investigation into the role of synapsin-1 in nAChR-mediated 
neurotransmitter release and synaptic plasticity, however, at the confocal level a l, a4 and p2 
nAChR subunits and synapsin-1 are juxtaposed on glutamatergic neurones within the mouse 
olfactory bulb (Barazangi and Role, 2001). Future work could involve using phospho-specific 
synapsin-1 antibodies (Matsubara et al., 1996), to determine if  this protein is downstream of 
presynaptic a l  nAChR activation, using western blot analysis.
nJLCH^Rjmediatecf neurotransmitter release: a mecHanism o f  synaptic plasticity?
The a l  nAChR-mediated CICR/ERK1/2-dependent excitatory amino acid release 
reported in this project may enhance synaptic activity and modulate synaptic plasticity. The 
involvement of presynaptic CICR and ERK1/2 in synaptic activity/plasticity was discussed in 
Section 1.4.4.1 and 1.5.1, respectively. In brief, presynaptic CICR has been reported to be an 
essential mediator of miniature GABAA-mediated currents (Savic and Sciancalepore, 1998); 
large-amplitude miniature inhibitory postsynaptic currents (Llano et al., 2000) and paired-pulse 
facilitation (Emptage et al., 2001). Nicotine is known to modulate synaptic efficacy in a Ca2+- 
dependent manner, indeed nicotine-mediated hippocampal LTP has recently been shown to 
require ryanodine (Welsby et al., 2006). In addition ERK1/2 inhibition abolishes BDNF- and 
electrically-induced LTP in the hippocampus, amygdala and cortex (English and Sweatt, 1996, 
1997; Davis et al., 2000; Cristo et al., 2001; Pandey et al., 2006). Behavioural studies have also 
shown an increase in ERK1/2 activation during memory tasks and an impairment of learning 
and memory following ERK1/2 inhibition (Atkins et al., 1998; Izquierdo et al., 1998; Walz et 
al., 1999; Quevedo et al., 2004; Igaz et al., 2006), including PFC-based memory retention 
(Runyan et al., 2004). Whilst the majority of studies investigating ERK1/2 have focused on its 
post-synaptic role, there is clear evidence for its involvement in presynaptic mechanisms 
relevant to LTP and memory formation (Kushner et al., 2005).
The hypothesis that a l  nAChRs can enhance synaptic plasticity through CICR and 
subsequent ERK1/2 activation could be tested by examining a l  nAChR-mediated glutamatergic 
transmission in PFC slices using the selective agonist characterised in this project, compound A. 
Presynaptic a l  nAChRs have previously been shown to increase mEPSCs via a VOCC- 
independent mechanism (Gray et al., 1996; Radcliffe and Dani, 1998) and CICR has been 
shown to underlie nAChR-mediated LTP (Welsby et al., 2006). Assuming that compound A
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evokes glutamatergic neurotransmission the involvement of VOCCs and CICR, as well as 
ERK1/2 and other kinases could be dissected by way of the inhibitors used in this project. These 
mechanisms could be studied using both a model of short-term plasticity, paired-pulse 
facilitation (Emptage et al., 2001) and/or LTP (Welsby et al., 2006).
In conclusion, this work has revealed that a l  and (52* in PC 12 cells mediate increases 
in intracellular Ca2+ via CICR and VOCCs, respectively. In the PFC, presynaptic nAChRs 
mediate excitatory amino acid release. As seen in PC 12 cells presynaptic a7 and p2* nAChRs 
elicit this release by CICR and VOCCs, respectively. Excitatory amino acid release evoked by 
a7 nAChRs also couples to ERK1/2 activation via CICR. The PFC is widely regarded as the 
executive centre of the brain and nicotine has been shown to enhance cognitive processes 
associated with this region. As such the findings here may provide a significant advance in 
understanding the cellular mechanisms that may couple nAChR activation to nicotine’s 
cognitive effects.
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